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 I 
Abstract 
The prevalence of obesity has illuminated the demand for safer and more efficacious anti-
obesity therapeutics. Gut hormones, such as PYY3-36, has been shown to play a role in the 
control of body energy homeostasis. However, in general gut hormones have poor 
metabolic stability and some have moderate selectivity, thus novel analogs needed.   
The present thesis describes the design, synthesis, and characterization of several novel 
PYY3-36 analogs. The ligand design was based on a recently presented hypothesis 
claiming that the PP-fold family of peptides (PYY, NPY and PP) associates with the 
membrane prior to receptor activation. Four different design strategies were chosen: i) 
Modifications of the C-terminal Tyr-36 of the receptor-recognizing pentapeptide of 
PYY3-36 to increase the selectivity towards the Y2 receptor. ii) Glyco-scan using human 
PYY3-36 as a model peptide - to investigate the impact of glycosylation on affinity, 
selectivity, and stability. iii) Branching the PYY3-36 sequence at the turn motif to create 
more selective agonists. iv) Introduction of an additional amphipathic α-helix either at the 
end of the N-terminus as a branch or instead of the N-terminal, to increase the affinity 
towards the membrane and thereby the Y receptor. 
The results demonstrate numerous novel PYY3-36 analogs with increased selectivity. 
Successfully, several ligands were found to improve or maintain sub-nanomolar affinity 
towards the Y2 receptor. Interesting analogs were further investigated in acute or chronic 
mouse models of obesity and showed to reduce body-weight and food intake in 
comparison to PYY3-36.  
The work conducted during this thesis has increased the understanding of the ligand-
receptor interaction as well as further confirmed the hypothesis that the PP-fold peptides 
recognizes their target-receptors via a membrane-bound intermediate.       
 
 II 
Resumé (In Danish) 
Den globale fedme epidemi understreger behovet for ikke mindst bedre forebyggelse, men 
også udviklingen af nye sikre og effektive lægemidler til behandlingen af overvægt. 
Tarmhormoner, såsom PYY3-36, har vist sig at spille en rolle i kontrollen af kropsvægt 
samt i energibalancen, men flere af tarmhormonerne er dårlige lægemidler pga. ringe 
metabolisk stabilitet og/eller moderat selektivitet overfor forskellige receptorer. Studier i 
både gnavere og mennesker har påvist, at PYY3-36 virker appetitnedsættende via Y2 
receptoren, og at denne receptor kan være et relevant farmaceutisk target. I den 
nærværende Ph.D.-afhandling beskrives designet, syntesen og karakteriseringen af 4 nye 
serier af PYY3-36 analoger. Designet af PYY3-36 analogerne blev inspireret af en nyligt 
frembragt hypotese, der erklærer, at ’PP-fold’ peptiderne (PYY, NPY og PP) binder til 
membranen, inden de interagerer med deres specifikke receptorer. Der blev fokuseret på 
fire forskellige designstrategier: i) Modificering af den C-terminal Tyr-36, som er en del af 
det receptorgenkendende pentapeptid af PYY3-36, for at øge selektiviteten mod Y2 
receptoren. ii) ’Glyco-scan’ med PYY3-36 som modelpeptid - for at undersøge 
indvirkningen af glykosylering på affiniteten, selektiviteten og stabiliteten. iii) Forgrening 
af PYY3-36 sekvensen i turn regionen for at skabe en mere selektiv agonist. iv) 
Introduktion af en ekstra amfipatisk α-helix; a) som en forgrening i enden eller b) i stedet 
for N-terminalen for at øge affiniteten til membranen, og derved også til Y receptorerne. 
Resultaterne viser adskillige nye PYY3-36 analoger med øget selektivitet. Flere ligander 
opretholder PYY3-36’s sub-nanomolære affinitet mod Y2 receptoren, og nogle udviser 
endda øget affinitet og aktivitet. De mest interessante af disse analoger blev endvidere 
undersøgt i musemodeller for fedme, både akut og kronisk, og det viste sig, at stofferne 
reducerede både kropsvægten og fødeindtaget i samme grad som PYY3-36.  
Arbejdet udført i løbet af dette projekt har ført til øget forståelse af interaktionen mellem 
ligand og receptor, samt understøttet den hypotese, at PP-fold peptiderne genkender deres 
receptor via et membranbundet intermediat.  
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Project aim and outline 
The aim of the present Ph.D. project is to use solid-phase peptide synthesis (SPPS) to make 
novel peptide analogs of the gut hormone peptide YY (PYY), that act as high affinity 
agonist towards the Y2 receptor. The project focus is on developing novel high-affinity Y2 
receptor agonists with improved selectivity (Y2 over Y1) and stability, when compared to 
the anorectic gut hormone PYY3-36. Recently published data obtained from NMR studies 
of PYY have shed new light on the binding mechanism and conformation of the PP-fold 
family of peptides;1-5 results that are being exploited in the design of new ligands with 
enhanced affinity for the Y2 receptor and better plasma stability. Finally, the Ph.D.-project 
aims at delivering lead peptide candidates for future clinical development. 
 
As a side-project the use of a new custom-made microwave-assisted peptide synthesizer 
has been conducted. The work has resulted in one peer-reviewed article (Appendix 6). The 
article describes the utilization of the custom-made semi-automated peptide synthesizer 
and describes a set of optimized protocols for this unique platform. Moreover, the 
optimized protocols have been used to synthesize long and ‘difficult’ sequences.      
 
Outline of thesis 
Part 1 ‘Introduction’: 
Chapter 1: Herein the control and regulation of food intake is described with special focus 
on the gut-brain axes. Moreover, the hormonal changes subsequent to a gastric bypass 
operation are described.  
Chapter 2: The PP-fold peptide structures interact with plasma membrane prior to receptor 
recognition, which are exploited in the design of the novel PYY analogs of this project. 
Besides the membrane compartment model ligand-receptor interactions are also described 
in this chapter.  
 
 
 
 XIII 
Part II ‘Methods’: 
Chapter 3: Here a brief presentation of solid-phase peptide synthesis, circular dichroism 
spectroscopy, binding and functional assays, and finally animal models of obesity are 
given. 
 
Part III ‘Results and discussion’:  
Chapter 4: The rationale for the different designs and the main results for each of the four 
projects of the thesis are described and discussed in this chapter. The work is moreover 
described thoroughly in the papers and manuscripts that are located in the appendices.      
Chapter 5: Overall conclusion and perspective. 
 
Part IV ‘References’  
 
Appendix 1-5: PYY papers - reprints of one published paper, one accepted article, as well 
as three papers in manuscript.   
Appendix 6: MW article. The manuscript of one paper is given (accepted for publication).  
Part I                                  
‘Introduction’
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Chapter 1. Obesity: Controlling of energy homeostasis 
Obesity (BMI > 30 kg/m2) is increasing with an alarming rate worldwide, hence intensive 
research have been invested in understanding the physiological mechanisms underlying 
human food intake and body-weight regulation. Although our knowledge of appetite and 
body-weight regulation has increased tremendously over past decades, still only few 
pharmacological therapies targeting obesity exist.  
The health consequences of obesity are many and serious: Insulin resistance and type II 
diabetes, cardiovascular disease, osteoarthritis and certain types of cancers are just a few of 
the many diseases strongly associated with obesity. It is generally agreed that today’s 
obesity epidemic is the result of both environment (i.e. increased consumption of 
energy-dense food combined with a sedentary life style) and inheritance.6 Several 
monogenic diseases as well as Mendelian disorders have been identified and characterized 
in the search for genes involved in the development of obesity. However, individuals 
affected by mutations causing these diseases only represent a minor fraction of the 
population and these genes are clearly not sufficient to explain the obesity prevalence of 
today.7 
In normal-weight individuals, the cumulative energy intake corresponds precisely to the 
energy expenditure. Most healthy humans maintain a steady body-weight, although, an 
increasing number of individuals worldwide, consume more calories than needed for their 
level of physical activity, leading to an enhanced storage of energy (fat). For several years 
it has been anticipated that homeostatic regulators, such as peptide hormones, control the 
energy balance.8 Despite an array of experiments distracted from the initial report, it took 
more than 25 years before energy homeostatic molecules were identified. The 
understanding of physiological processes that control food intake, has grown rapidly the 
latest two decades; consequently, we are now familiar with numerous circulating 
molecules to have considerable influence on the control of food intake and energy 
expenditure. Most of these compounds act on the hypothalamus, the brainstem, or afferent 
autonomic nerves and primarily come from fat cells, the endocrine pancreas and the 
gastrointestinal tract (Figure 1.1). 
Along with the growing obesity epidemic the past few years has seen a nearly exponential 
rise in obesity surgeries.9 One of the most dramatic and efficient types of obesity surgery is 
the Roux-en-Y gastric bypass whereby gastric volume is drastically reduced and food is 
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conveyed directly into the upper jejunum.10 Aside from marked weight-loss this type of 
gastric bypass surgery often leads to a rapid (usually within days) resolution of type II 
diabetes in more than 80% of obese type II diabetics.11 The mechanisms mediating the 
dramatic weight-loss and resolution of diabetes are unknown. However, changes in gut-
brain communication involving both hormones and neural pathways are thought to be the 
major candidates for these beneficial effects.12 Nevertheless, it is well known that Roux-
en-Y gastric bypass leads to a rise in plasma levels of a number of gut hormones with 
either anorectic and/or anti-diabetic effects (e.g. PYY3-36, GLP-1, PP).13  
 
Figure 1.1. The pathways in which gut hormones regulate energy homeostasis. 
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1.1 Gut-brain interactions 
The brain regions regulating energy homeostasis receives neural, metabolic and humoral 
signals from the stores of body-energy, thus determining the levels of intake and 
expenditure. Pivotal studies on the arcuate nucleus (ARC) of the hypothalamus have led to 
identification of the actual regions involved in energy homeostasis.14-18 The neurons of the 
ARC are anatomically placed in close proximity to capillaries at the base of the 
hypothalamus, giving them access to humoral signals that otherwise are restricted to the 
periphery due to the blood brain barrier.19,20 Two sets of neurons, with opposite effect on 
feeding, have been identified in the ARC. The neurons that express proopiomelanocortin 
(POMC) are anorexigenic, and the neuropeptide Y (NPY) and agouti gene related 
transcript (AgRP) are orexigenic (Figure 1.1 and 1.2).  
 
Figure 1.2. Schematic drawing of the ARC and the sites of various homeostatic 
receptors.20 Abbreviations: Lep-R, leptin receptor; insulin-R, insulin receptor; MC3-R, 
melanocortin-3 receptor; Y1-R, Y2-R, neuropeptide Y1 or Y2 receptors; MOP-R, 
m-opioid receptor. 
The cleavage products of the POMC precursor, α- and β-melanocyte stimulating hormones 
(α- and β-MSH), are the main reason for the anorexigenic effect of POMC, and act on the 
melanocortin receptor subtype 3 and 4 (MC3-R and MC4-R).21-23 NPY and AgRP potently 
stimulate food intake:24 NPY, via the Y1 receptor and AgRP, acts as a natural antagonist of 
the MC3 and MC4 receptors, thereby blocking for α- and β-MSH (Figure 1.2).24,25 
1.1.1 Neuropeptide Y 
Neuropeptide Y (NPY) is one of the most abundant and potent orexigenic26 peptides in the 
hypothalamus.27 The ARC of the hypothalamus is the major site of expression for NPY, 
and the most notable effect is the stimulation of feeding (Figure 1.2). NPY synthesis and 
secretion are up-regulated during energy deficiency and metabolic demand, such as 
starvation, insulin-dependent diabetes mellitus and exercise.28 Thus, the primarily 
physiological role of the ARC NPY neurons probably is to restore normal energy balance 
and body-fat stores under conditions of energy deficit. 
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1.1.2 Glucagon-like peptide-1 
Glucagon-like peptide-1 (GLP-1) is a product of the preproglucagon precursor molecule 
and is released postprandially. Besides GLP-1, preproglucagon is processed to glucagon-
like peptide-2 (GLP-2) and oxyntomodulin. GLP-1 is metabolized to several forms, but the 
most abundant circulating form is the N-terminal truncated analog which is cleaved 
between residue 6 and 7.29 Administration of GLP-1 as well as analogs thereof, stimulates 
insulin release and inhibits appetite.30-35  
1.1.3 Pancreatic polypeptide 
Pancreatic polypeptide (PP) is a member of the PP-fold family of peptides,36 and is 
secreted from F-cells in the pancreas (Figure 1.1).37 PP release reflects the calorie content 
of a meal and is a strong and selective agonist towards the Y4 receptor leading to a 
reduction in appetite. The anorectic effects may partly result from a delayed gastric 
emptying.38,39 Repeated peripheral administration of PP in rodents reduced food intake40,41 
and intravenous infusion of PP in normal weight human subjects resulted in a 25% 
reduction in food intake.38  
1.1.4 Peptide YY 
Peptide YY in full length (PYY1-36) is co-secreted with the preproglucagon derived 
hormones (GLP-1, GLP-2 and oxyntomodulin) from L-cells lining the gut.42 PYY1-36 is 
released postprandially, and subsequently processed by the ubiquitously expressed 
enzyme, dipeptidyl peptidase IV (DPP-IV) to yield PYY3-36.43,44 PYY3-36 is the major 
circulating form of PYY in both the fed and fasted state.45,46 Following a meal PYY3-36 
concentrations start to increase after 15 minutes and peaks after 1-2 hours and stay elevated 
for several hours thereafter.42 Peak concentrations reflect the calorific content of the 
meal.42,45,47 PYY3-36 is a potent agonist for the Y2 receptor, a member of the so-called Y 
receptors,48 which also bind NPY and PP. The Y2 receptor is located throughout the 
central nervous system (CNS),49-51 and substantial evidence suggests that PYY3-36 exerts 
its effects on feeding via the ARC of the hypothalamus (Figure 1.1 and 1.2).49,52 However, 
PYY3-36 may also indirectly influence hypothalamic control of feeding via the brainstem 
and vagal afferents.51 Radiolabled PYY3-36 has been reported to accumulate in around the 
brainstem and the hypothalamus.53 Vagotomy (removing some of the vagus nerve) has 
been shown to reduced the anorectic effects of PYY3-36.51,54 Moreover, PYY1-36 and 
PYY3-36 exert a number of actions on the gastrointestinal function, including inhibition of 
pancreatic exocrine secretion,55-58 inhibition of the gastrointestinal motility,59-62 inhibition 
of the gastric acid secretion,63,64 and stimulation of the gallbladder contraction65. 
Batterham et al. initially showed that peripheral administration of PYY3-36 reduced food 
intake in rodents.49 Although Tschop et al. questioned the initial findings of Batterham and 
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co-workers,66 subsequent reports from numerous independent groups have reproduced the 
initial results found by Batterham and co-workers and further confirmed the anorectic 
properties of PYY3-36,44,52,54,67-75 e.g. in male DIO C57BL/6J mice and DIO male 
Sprague-Dawley rats (Figure 1.3)75.  
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Figure 1.3. Body-weight in male DIO C57BL/6J mice (A) and male DIO Sprague-
Dawley rats (B) administrated subcutaneously by minipump.75  
PYY3-36 has also been reported to reduce feeding in obese and normal-weight humans at 
physiological concentrations.76-79 Intravenous administration of PYY3-36 for 90 minutes to 
healthy and obese humans has been shown to reduce appetite and caloric intake,76 further 
indicating a possible therapeutic role of PYY3-36 in appetite and weight control (Figure 
1.4).76,77 Given that obese retain their PYY3-36 sensitivity; PYY3-36 has potential as a 
therapeutic for the treatment of obesity.  
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Figure 1.4. Appetite scores for lean and obese humans.76 
Despite the anorectic properties of peripherally administrated PYY3-36, it suffers from low 
metabolic stability as well as being a non-selective Y receptor agonist engaging both the 
Y1 and Y2 receptor subtypes.80 The half-life of intravenous administration of PYY3-36 in 
mice81 and rabbits82 has been reported to 13 and 19 minutes, respectively. Thus, longer-
acting and metabolic stable as well as highly selective Y2 agonists are therefore on 
demand. 
1.1.5 The Y receptors 
The PP-fold family of peptides (PYY, NPY and PP)36 binds to Y receptors, a G-protein-
coupled receptor (GPCR) family that belong to the rhodopsin-like superfamily (class A) of 
receptors.48 Four Y receptor subtypes have been cloned from human tissue, the Y1, Y2, Y4 
and Y5 receptors,48 furthermore, an additional subtype, the y6 receptor, has been cloned, 
but is not expressed in mammal tissue.83 The receptors all couple to inhibitory G-proteins 
(Gi) thus mediating the inhibition of cyclic adenosine monophosphate synthesis.48 The Y 
receptor subtypes all differ in their potency from the PP-fold peptides (NPY, PP and 
PYY1-36 as well as PYY3-36) (Table 1.1).  
The N-terminal domain of the Y receptors (N-Y) is located in the extracellular space and is 
potential interaction sites for the ligands. It has recently been suggested that PP interacts 
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with the N-Y4 receptor84 and later studies has indicated that all the peptides of the PP-fold 
family interact with the N-terminal region the Y receptors, however, much weaker than PP 
to the N-Y4.85 These N-terminal interactions may help to guide and engage the ligands 
onto the rigid Y receptor prior to activation.84,85 
The Y1 receptor is mainly expressed in the hypothalamus,86 but also in adipose tissue87 and 
vascular smooth muscle cells88 leading to effects on food intake and vasoconstriction. Full 
length of NPY or PYY are essential for Y1 receptor activity, which has been shown by 
N-terminal truncated analogs of NPY or PYY that leads to 1000-fold decreases in 
affinity.80 
The Y2 receptor is predominantly expressed in the hypothalamus,49 but also in adipose 
tissue,89 and the digestive tract63 leading to effects primarily on food intake. The Y2 
receptor has high affinity for both NPY as well as PYY1-36 (Table 1.1), and, in contrast to 
the Y1 receptor, also to the N-terminal truncated analogs, such as NPY3-36, PYY3-36, 
NPY13-36, PYY13-36, and even NPY18-36 and NPY22-36 have resulted in nanomolar 
affinities towards the Y2 receptor.80  
Table 1.1. The PP-fold peptides affinity (Ki) towards the Y receptor subtypes. 
 Y1 [nM] Y2 [nM] Y4 [nM] Y5 [nM] 
PYY1-36 1.16 ± 0.26 0.012 ± 0.001 1.057 ± 0.068 0.62 ± 0.04 
NPY 0.81 ± 0.12 0.016 ± 0.001 1.900 ± 0.003 0.19 ± 0.05 
PP 48.9 ± 27.5 >1000 0.008 ± 0.001 7.25 ± 1.98 
Determined by radioligand competition binding assay.90 Tracers; Y1R and Y5R: 125I-NPY, Y2R: 
125I-PYY, and Y4R: 125I-PP. 
 
The Y4 receptor is primarily expressed in the gastrointestinal tract, but is also found in the 
heart and in the hypothalamus.91 The Y4 receptor has a high sequence homology with the 
Y1 receptor, 46%, and less with the Y2 and Y5 receptors, 33% and 23% respectively. The 
Y4 receptor is also referred to as the PP-preferring receptor due to high selectivity of PP 
over NPY and PYY (Table 1.1). The Y4 receptor is primarily involved in the regulation of 
food intake and motility of the gastrointestinal tract. 
The Y5 receptor is predominantly expressed in the CNS and rarely in the peripheral 
tissues.92,93 The Y5 receptor has a high affinity to NPY and PYY1-36, but not PP (Table 
1.1). In contrast to the Y1 receptor, the N-terminal truncated analogs, NPY2-36 and 
NPY3-36, maintained their high potency towards the Y5 receptor.91 
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Chapter 2. PP-fold family of peptides 
2.1 Sequences and secondary structures of PYY, NPY and PP 
There is a high degree of homology between the sequences of the PP-fold peptides.36 They 
all contain 36 amino acid residues, are C-terminally amidated, and have a high number of 
tyrosine, arginine and proline residues. The sequence identity between NPY and PYY is 
69% and between PP and PYY it is 50% (Table 2.1).36  
Table 2.1. Sequences of human PYY1-36, PYY3-36, NPY and PP. 
PYY1-36 H-YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
PYY3-36 H-IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
NPY H-YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
PP H-APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
Conserved residues are underlined.36 
 
In 1981, Blundell reported the crystal structure of avian pancreatic polypeptide (aPP),94 
and showed that PP consists of an amphipathic α-helical segment between residues 14-31, 
a N-terminal type II polyproline helix comprising residues 1-8, connected by a spacer and a 
β-turn, and finally, a flexible C-terminal pentapeptide. The amphipathic α-helix was shown 
to be back-folded onto the polyproline N-terminus to generate a stable well-packed 
hydrophobic core. It is this back-folded structure of PP that has led to the general term, the 
PP-fold. The X-ray structure also revealed that PP is able to form antiparallel dimers.94 
Both the PP-fold structure and the dimer-formation have subsequently been confirmed by 
NMR studies of PP in solution.95-98 The X-ray structure and mutational scanning 
experiments of PP have revealed three stabilizing interactions at the PP-PP dimer interface 
(Figure 2.1.A): i) An intermolecular π-stacking between each Tyr-7 side-chain (Figure 
2.1.B), ii) an intramolecular edge-to-face interaction with Phe-20 (Figure 2.1.B), and iii) an 
intermolecular π-stacking between each Tyr-21 (Figure 2.1.C).98  
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Figure 2.1. Ribbon diagram of the PP dimer.94 (A) Highlighting: Tyr-7 side chain pair: 
red and pink, Phe-20 side chain pair: teal and light teal, and Tyr-21 side chain pair: 
blue and light blue. (B) Close-up of the inter- and intramolecular interactions of Tyr-7 
and Phe-20. (C) Close-up on the intermolecular interaction of Tyr-21.98 
Unlike PP, PYY1-36 does not self-associate into dimers, however, NMR analysis has 
revealed that both PP and PYY1-36 have a hydrophobic core due to back-folding.4,99,100 
Initial reports also suggested that the PP-fold was found in human NPY.101 Today, 
however, we know that this is not correct, as NMR and FRET studies has shown that NPY 
is very flexible in the N-terminus.1,102 The solution structure predicted by Keire et al. 
indicate that the α-helical part of PYY1-36 is interrupted at residue 23-25, which was not 
observed by the other members of the PP-fold family of peptides.99 Nevertheless, Lerch et 
al. have later repeated the initial experiments and found the secondary structure of residue 
14-31 primarily to be of α-helical nature.4  
2.2 The membrane compartment model 
Despite the solution structures of PP, NPY and PYY1-36 shows major differences, Zerbe 
and co-workers reported that the PP-fold family of peptides most likely associate with the 
membrane prior to receptor recognition.1-5 
Several years ago Kaiser and Kezdy proposed the hypothesis that amphipathic ligands 
targeting membrane bound receptors recognize their targets from the membrane bound 
state.103,104 Moreover, they suggested that the active site of the receptor only occupies a 
few amino acid residues, and that the activation of the receptor is usually mediated by a 
few stereospecific interactions between ligand and receptor. The remainder of the 
amphipathic α-helix of the peptide hormone act as an anchor onto the membrane as well as 
a conformational guide for the receptor recognizing part of the peptide.103,104 Subsequently, 
Schwyzer et al. formulated the membrane compartment model: Prior to binding to the 
receptor, the ligand associates to the membrane surface and accumulates in the vicinity of 
the receptor. The residues of an amphipathic α-helix interact with the membrane in which 
the hydrophobic face of the α-helix penetrates into the space between the phospholipid 
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head groups allowing interaction with the long lipophilic chains of the phospholipids. The 
hydrophilic face of the helix is orientated towards the aqueous environment. Residues such 
as Tyr are generally located in the water-membrane interface. The interaction with the 
membrane leads to conformational changes and reduced entropic loss upon receptor 
binding and activation (exemplified by PYY1-36; Figure 2.2).105,106 
 
Figure 2.2. Schematic presentation of the membrane compartment model. Membrane 
association (Ia) followed by lateral diffusion to the receptor (Ib).2 
Zerbe and co-workers recently predicted by NMR that the PP-fold peptides recognize the 
receptor via the membrane compartment model.1,3,4 Besides, the high sequence homology 
of NPY and PYY1-36, the affinities towards the Y receptors are also very similar - in 
contrast, the solution structures are markedly different (Figure 2.3).2 The solution structure 
of the PP-fold peptides shows that PP and PYY1-36 are back-folded, and NPY is not.2 
Nevertheless, NPY and PYY1-36 bound to dodecylphosphocholine (DPC) micelles show 
high structural similarities (Figure 2.3). PP, on the other hand, has a different structure in 
the micelle bound state (Figure 2.3) and also a very different receptor-binding profile 
compared to PYY1-36 and NPY (Table 1.1).1,2,4 Moreover, high sequence identity and 
stability of the C-terminal pentapeptide of NPY and PYY1-36, and similar membrane 
anchoring residues of the amphipathic α-helix has been identified.2 Finally, the membrane-
bound state of PP differs significantly from NPY and PYY - especially in the C-terminal 
receptor recognizing pentapeptide and in N-terminus.2 The almost identical binding 
profiles between PYY1-36 and NPY and the very similar secondary structures as revealed 
by NMR studies conducted in the presence of micelles, indeed suggest that these peptides 
interact with their specific receptors from their membrane-bound state. 
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Figure 2.3 PYY (left), NPY (middle), and PP (right) structures. Top: Solution 
structures (single conformer). Bottom: Micelle-bound structure (superposition of NMR 
ensemble).4  
To summarize; the PP-fold family of peptides are hypothesized to bind to the Y receptors 
via a multistage scenario. First, electrostatic interactions attract the peptide towards the 
membrane. Secondly, the peptide changes conformation such that the hydrophobic 
side-chains of the amphipathic α-helix penetrates into the hydrophobic interior of the 
phospholipids of the membrane, and subsequently diffuses laterally along the membrane 
until receptor binding.2 As Kaiser and Kezdy originally proposed,103,104 it is generally 
believed that the membrane-bound state of the peptide is close to the state from which the 
peptide is recognized by the receptor. The rigid scaffolds of the GPCRs do not allow large 
rearrangements of the extracellular loops. It is not likely that the initial preorganized state 
undergoes further conformational changes by an induced-fit mechanism. 
2.3 Ligand-receptor interactions 
Ala-mutagenesis and structure affinity/activity relationship studies can be used to indentify 
the important interactions between ligand and receptor. As a gold standard to evaluate 
residues within the ligand that are involved in ligand-receptor interactions, Ala-scan 
studies can be conducted. In an Ala-scan all amino acids are substituted with the smallest 
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chiral amino acid, Alanine (Ala). Moreover, to evaluate the importance of the N- or 
C-terminal amino acids the native ligands can be truncated in the N- or C-terminus. Ala-
scan of an entire GPCR is however not feasible thus; single amino acid replacement by Ala 
or other amino acids within the extracellular loops are the method of choice. Additionally, 
to identify the direct interaction partners between the ligand and the receptor 
complementary mutagenesis could be applied. 
2.3.1 Ligand side 
Ala-scans has been conducted both on NPY107 and PYY3-36108 and showed residues 25, 
27, and 32 to 36 to be the most critical residues in the recognition of NPY and PYY3-36 by 
the Y receptors. The importance of Arg-25 is most profound in the interaction with the Y2 
and Y5 receptor subtypes, in contrast to Arg-33 that is most critical for the Y1 and Y4 
receptor subtypes.108 The PYY3-36 C-terminal Arg-35 is a highly important residue for all 
Y receptor subtypes.108 Moreover, the Tyr residues of the PYY3-36 C-terminal is highly 
critical for receptor binding, except Tyr-27 towards the Y2 receptor subtype.108 The 
N-terminal segment of NPY and PYY is essential for Y1 receptor activation, in contrast to 
the Y2 receptor and to some extent also the Y4 and Y5 receptors.80,109-115 The α-helix is 
however essential for activation of all the Y receptor subtype,80 which is in alignment with 
the membrane compartment model. Analogs of NPY containing the conformational 
restricted Pro residue at position 34 has resulted in selective Y1/Y5 agonism.116,117    
2.3.2 Receptor side  
Selected residues of the Y receptors have been point mutated.91,118-120 Walker et al. have 
showed that several aspartic acid residues of the Y1 receptor are highly important for NPY 
binding,119 which were partly confirmed by Beck-Sickinger and co-workers:118 Asp-2.68 
and Asp-6.59 are essential and Asp-5.27 is moderately important for Y1/Y4 receptor 
activation. Additionally, Asp-6.59 is important for Y2/Y5 receptor activation and in 
contrast to the Y1/Y4 receptor residue Glu-5.24 is also a critical residue in ligand binding 
towards the Y2/Y5 receptor.118 Several groups have additionally reported Tyr-2.64, 
Phe-6.58 and His-7.31 of the Y1 receptor to be important for ligand binding.121-124 Even 
though a rhodopsin-derived Y1 receptor structure showed these residues to be to far 
apart,125 the initial hypothesis that the residues form a hydrophobic pocket that directly 
interacts with the C-terminal amide and Tyr-36 of the ligand is still feasible.123  
2.3.3 Complementary mutagenesis 
Asp-6.59 of the Y2/Y5 receptors has been shown to interact with Arg-33 of NPY and 
Asp-6.59 of the Y1/Y4 receptors interact with Arg-35 of NPY or PP trough ionic 
interactions.118 No contact point has been established between ligand and Glu/Asp-5.27, 
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however it has been speculated that Glu-5.27 is partially blocking the active site of the 
Y2/Y5 receptors such that Arg-35 of the ligand can not interact with Asp-6.59.118      
 
 
Figure 2.4. NPY and PP interactions sites between the Y1, Y2, Y4 and Y5 receptor 
subtypes. Two conserved Arg residues, Arg-33 and Arg-35, at the C-terminal of the 
NPY and PP participate in the formation of high affinity interactions to Y receptors.118   
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Part II                                    
‘Methods’ 
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Chapter 3. Methods 
Proteins almost exclusively carry out the control of biological processes in living cells and 
posses an enormous potential for diversity, which makes them well suited for such 
complicated task. Moreover, numerous peptide hormones act as messengers between cells 
by high affinity and selectivity engagement to specific receptors. Several of the advantages 
of utilizing peptides and proteins as therapeutic molecules, compared to small molecules 
include; high activity and specificity, unique three-dimensional characteristics, low toxicity 
and relatively low immunogenicity.126 Peptides have potential as unique therapeutic 
molecules because they can be designed to engage onto a larger portion of the target 
protein surface, compared to small molecules, thus providing greater specificity. The 
protein-protein and protein-peptide interactions surfaces are often relative flat 
consequently, the likeliness of small molecules to engage into a high-affinity and specific 
binding is often limited.127 Moreover, for many protein-protein and protein-peptide 
interactions the apparent complementarities between the two surfaces involves a significant 
degree of protein flexibility and adaptivity.128 The hot-spots of a protein interface may be 
far apart and are therefore particular adept at binding to proteins and peptides.127 Another 
challenge with discovering drug-like small molecules to protein-protein targets is that 
small molecule ligands may act promiscuously by forming large aggregates, micelles or 
liposomes consequently leading to an unspecific binding.129-131 Additionally, some 
compounds act as protein denaturants or covalent inhibitors consequently inhibiting the 
function of a number of proteins without binding to a discrete site.132-134 There is, however, 
also challenges involved in using peptides as therapeutics, which include; low metabolic 
stability in bodily fluids, bioavailability, and often higher manufacturing costs.126  
Insulin was the first protein to be isolated and administrated therapeutically,135 and is still 
the most commonly prescribed biopharmaceutical. Approximately 65 peptides has since 
been approved as pharmaceuticals,136 and roughly 500 peptides are currently being 
developed for therapeutic applications in a variety of diseases and infections e.g. cancer, 
diabetes, cardiovascular diseases, inflammation, CNS diseases and obesity.126,136  
Peptides can be made synthetically, by recombinant methods, or by chemical modification 
of an isolated natural product. The last 20-30 years of development within the field of 
synthetic peptide synthesis has increased the possibilities of making successful 
peptide-based drug discovery programs, even when pursuing long peptide ligands (> 40 
residues). Peptide structure evaluation may provide significant information revealing 
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important characteristics of the secondary structure of the compound of interest. A fast and 
reliable method for evaluating secondary structures of long peptides and proteins is circular 
dichroism (CD). In the field of obesity pharmaceuticals different types of assays and 
animal models has emerged, where the innovative animal model of obesity, especially the 
dietary induce obesity (DIO) models, has led to a detailed, although not complete, 
understanding of the regulation of food intake and energy homeostasis. 
3.1 Peptide synthesis 
The present chapter gives a brief introduction to solid-phase peptide synthesis (SPPS). 
Since the introduction of chemical synthesis of peptides by Emil Fischer in the beginning 
of the 20th century,137 the evolution in the development, analysis, and recently the use of 
synthetic peptides as therapeutics has been dramatic. Fischer was limited to simple 
unprotected amino acids and had trouble with the solubility of longer polypeptides. The 
discovery of the easily removable protecting group, the benzyloxycarbonyl group (Cbz),138 
resulted in the synthesis of a number of native peptides in solution.139-144 The development 
of solid-phase peptide synthesis (SPPS) by Bruce Merrifield in 1963 was a quantum leap in 
peptide science.145 Consequently, SPPS has led to a widespread use of synthetic peptides in 
chemical and biomedical investigations. The basis of SPPS, the functionalized solid 
support that allows for anchoring of an amino acid, revolutionized the field of peptide 
science and the SPPS methodology has become the method of choice for peptide synthesis.  
The strategy of SPPS is to sequentially couple suitably Nα- and side chain-protected amino 
acids to a growing peptide on an insoluble support (resin) in the C→N direction. The SPPS 
reactions are driven to completion by the use of soluble reagents in excess, which can be 
removed by filtration and washing. Subsequent to anchoring the amino acid at the carboxy 
terminus to the solid support via a cleavable handle, the Nα-protecting group can be 
removed without affecting the side chain-protecting groups, thus the polypeptide chain is 
prepared for the next coupling cycle. Following the completion of the desired sequence of 
amino acids, the peptide is released from the solid support, and simultaneously the 
permanent side chain-protecting groups are removed. The principle is illustrated in scheme 
3.1. 
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Scheme 3.1. Overview of the sequential coupling of amino acids used in solid-phase 
peptide synthesis. X is a nucleophilic functionality of the linker. Y represents the 
C-terminal functionality of the peptide that varies with the handle of choice.  
3.1.1 Protecting group strategy 
The two general protecting group strategies for SPPS are the fluoren-9-
ylmethyloxycarbonyl (Fmoc)146-148 and the tert-butoxycarbonyl (Boc)145,149 named for their 
application as the Nα-protecting group. The Boc strategy, initially introduced by Merrifield, 
exploits the differences in acid lability of the Nα- and side chain-protecting groups, that are 
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removed by trifluoroacetic acid (TFA) and hydrofluoric acid (HF), respectively.145,149 Due 
to the use of the corrosive and toxic nature of HF and the necessity of a HF apparatus, the 
Fmoc strategy is superior to the Boc strategy for routine synthesis. The Fmoc group can be 
removed under very mild alkaline conditions, typically 1:4 piperidine-DMF (Scheme 
3.2).150,151 The piperidine induces a β-elimination, resulting in the release of the 
unprotected Nα-amino acid, carbon dioxide and dibenzofulvene. An excess of base will 
subsequently scavenge the latter (Scheme 3.2).   
 
Scheme 3.2. Nα-deprotecting by piperidine as base and scavenger. 
Semi-permanent protecting groups (side chain-protecting groups) for the Fmoc strategy 
have been developed extensively during the past decades. For certain amino acid residues, 
e.g. Cys (cysteine), Asp (aspartic acid), Glu (glutamic acid), Lys (lysine), side chain-
protecting is essential for successful peptide synthesis, however, generally all tri-functional 
amino acids are semi-permanently side chain-protected. The generally used protecting 
groups are: tert-butyl for Glu, Asp, Ser (serine), Thr (threonine), and Tyr (tyrosine); 
2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) for Arg (arginine); and Trt 
(trityl) for Cys, Asn (asparagine), Gln, and His (histidine). 
3.1.2 Coupling conditions  
Activation of the carboxylic acid moiety of the amino acid is required to be able to react 
with the Nα-amino group of the growing peptide chain. Initially, carbodiimide-based 
coupling reagents, such as DCC (N,N’-dicyclohexylcarbodiimide)152-154 or DIC 
(N,N’-diisopropylcarbodiimide)155, were used. The carbodiimide-based reagents were 
adapted from solution-phase chemistry, but has the disadvantage that the O-acylisourea 
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intermediate tends to provoke side-reactions and epimerization, if additives are not 
added.156  
 
Figure 3.1. Commonly used coupling reagents. 
Additives, such as HOBt (1-hydroxybenzotriazole),154,157 ensure that the optical integrity of 
the stereogenic center at the C-terminal of the activated amino acid residue is maintained 
throughout the coupling step.154 An array of different coupling reagents has been 
developed to reduce coupling time and minimize epimerization, since the carbodiimide-
based coupling reagents were introduced - the most important are HBTU (N-[(1H-
benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexa-
fluorophosphate N-oxide), HATU (N-[(dimethylamino)-1H-1,2,3-triazole[4,5-b]pyridine-
1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide), PyBOP 
(1-benzotriazolyloxy-tris-pyrrolidinophosphonium hexafluorophosphate) and the novel 
COMU (1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholino-
methylene)] methanaminium hexafluorophosphate)158 reagents (Figure 3.1).  
Probably the most used coupling reagents, due to a combination of price and performance, 
is HBTU.159 The coupling with HBTU initiates by deprotonation of the Nα-protected amino 
acid by a non-nucleophilic base, such as N,N-diisopropylethylamine (DIPEA). The 
deprotonated amino acid reacts with the coupling reagent by a nucleophilic attack at the 
carboxylate of the positively charged aminium carbon. Consequently, HOBt is displaced 
from the highly reactive O-acylisourea cation and subsequently HOBt attacks the carboxyl 
carbon of the amino acid to form the activated ester (Scheme 3.3). 
The peptides investigated in the present Ph.D. thesis were generally synthesized using 
either (i) HBTU as coupling reagent, HOBt-HOAt (9:1) as additive and DIPEA as base, or 
(ii) DIC and HOBt as coupling reagent and additive.   
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Scheme 3.3. Coupling mechanism for HBTU and HOBt.  
3.1.3 Handles 
Generally the first amino acid of the growing peptide chain is attached at the C-terminus to 
the linker. The linkers are bifunctional handles that at one end can be permanently attached 
to the solid support and at the other end work as the C-terminal protecting group. The 
handles for Fmoc-based SPPS are designed to be easily cleavable by strong acid, such as 
TFA. The handle also determines the final C-terminal functionality of the peptide. The 
peptides investigated in this Ph.D. rapport were made using the Rink amide linker160 
(Figure 3.2) to obtain C-terminal amides.  
 
Figure 3.2. Commonly used linkers in SPPS. 
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Other common handles are the HMPA (4-hydroxymethyl-phenoxyacetic acid) linker161 and 
the 2-chlorotrityl linker162 to obtain C-terminal acids, and the BAL (backbone amide 
linker)163,164 to obtained e.g. C-terminal aldehydes and thioesters (Figure 3.2). 
3.2 CD spectroscopy  
Circular dichroism (CD) spectroscopy plays an important role in the characterization of the 
novel PYY3-36 analogs described in this thesis. The present chapter gives a brief 
introduction to CD spectroscopy and its application to the study secondary structures of 
peptides and proteins.  
3.2.1 Theory 
CD spectroscopy is an excellent and fast technique to evaluate secondary structures and 
folding properties of peptides and proteins. CD spectroscopy is defined as the unequal 
absorption of left- and right-turned circularly polarized light. Electromagnetic radiation is 
associated with time-dependent electric (E) and magnetic (M) fields. The light source in 
CD spectroscopy is plane polarized light. Unpolarized light contains oscillations in all 
directions perpendicular to the direction of propagation, whereas plane polarized light only 
has oscillations in one plane. The plane polarized light is formed as the sum of two beams 
of left and right circularly polarized light (Figure 3.3.A).  
E
EL ER
E
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ER
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Figure 3.3. Plane polarized light can be resolved into two circularly components (A). 
When the light interacts with a chiral compound the two components will absorb 
differently – thus the resultant vector follows an elliptical path (B). Definition of optical 
rotation, α, and ellipticity, θ (C).   
The two polarized beams form a clockwise and a counterclockwise screw in the direction 
of propagation. Hence, at a given time, t, two vectors can be formed from the two circular 
polarized waves, ER and EL, which are opposite in phase (Figure 3.3.A).  
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When applying the circular polarized light on a chromophore that is either chiral or is 
situated in a chrial environment the two vectors ER and EL interact differently. The 
properties of the resulting wave depend on the intensities and difference in phase of the 
components waves (circular birefringence). Chiral molecules absorb right- and left-turned 
circularly polarized light to different extents and degrees of refraction. The result of 
difference in absorbance is that the ER + EL vectors results in a vector that traces out an 
ellipse (Figure 3.3.B). Difference in refraction index, a slow-down of the waves to 
different extents, causes a rotation of the axes by the angle α (Figure 3.3.C).  
CD spectroscopic data are reported either in units of ∆E, the difference in absorbance of ER 
and EL by an asymmetric molecule, or in degrees of ellipticity, which is defined as the 
angle whose tangent is the ratio of the minor to the major axis of the ellipse (Figure 3.3.C), 
or when describing peptides and proteins, mean residue ellipticities (MRE):  
[ ]
ncl ⋅⋅⋅
=
10
θθ  
Where θ [mdeg] is measured ellipticity, l [cm] is the path length, c [mol/L] is the 
concentration of the sample and n is the number of residues.  
3.2.2 CD of peptides and proteins 
The α-helix, β-sheet, and random coil type of protein secondary structure each have a 
characteristic CD-spectrum (Figure 3.4). α-helical peptides and proteins have negative 
bands at 222 nm and 208 nm and a positive band at 193 nm.165 Peptides and proteins 
forming anti-parallel β-sheets have negative bands at 218 nm and positive bands at 195 
nm,166 whereas random coiled peptides and proteins have very low ellipticity above 210 
nm and negative bands near 195 nm.167  
The limitations of far-UV CD spectroscopic data are that sheets tend to be much less 
accurate than those of helices.168 Moreover, secondary structure content can not be 
calculated accurately from circular dichroism (CD) spectra for proteins with mixed α-helix 
and β-sheet elements in their structure.168  
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Figure 3.4. Circular dichroism (CD) spectra of α-helix (H), β-sheet (β) and unordered 
(R) form computed from the CD of five proteins (myoglobin, lysozyme, lactate 
dehydrogenase, papain and ribonuclease).169 
3.2.3 Analysis of α-helices 
The bands from β-sheets and random coil contribute very little to the CD signal at 222 nm 
(Figure 3.4). Thus, the fraction of α-helical structure, fH, in a peptide or protein can be 
estimated: 
[ ]
[ ] 222,
222
H
Hf θ
θ
=
 
However, the reference value [θ]H,222 is dependent on the number of residues, n: 
[ ] 





−=
∞
n
kf HnH 1θ  
Yang and co-workers obtained CD data from proteins with known structures and found 
[ ]∞ 222,Hθ  = -39,500 deg cm2 dmol-1 and k = 2.57.169  
3.3 Assays 
Radioligand binding studies and signal transduction assays are two important techniques 
used to evaluate novel peptide ligands towards membrane bound receptors such as GPCRs. 
Radioligand binding has been used to provide detailed information about receptor-ligand 
interactions on membrane preparations, whole cells, tissue slices, and even whole animals. 
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The most frequently used type is the radioligand competition binding assay in which one 
concentration of peptide radioligand and various concentrations of unlabeled peptide 
ligand compete for binding to their receptor.  
3.3.1 Radioligand competition binding assay 
The radioligand competition binding assay has been used to study the affinity of ligands of 
GPCRs over several years and has gained detailed information of the affinity of the PP-
fold peptides towards the Y receptors.107,117 In general, the radioligand competition binding 
assay is conducted on membrane preparations of Y receptor transfected human cell 
lines.170 The actual binding assay can be performed in a buffered solution containing the 
radioligand (125I labeled agonist), displacer (novel ligand) and membrane preparations. 
Subsequent to incubation the bound ligand is separated from unbound by filtration or 
centrifugation, and the radioactivity is determined using a γ-counter. The concentration of 
unlabeled drug that blocks half the radioligand binding is defined as the IC50 (inhibitory 
concentration 50%). The value of the IC50 is determined by three factors: (i) The Kd of the 
receptor for the competing ligand - the equilibrium dissociation constant for binding of the 
unlabeled ligand, (ii) the concentration of the radioligand, and (iii) the affinity of the 
radioligand for the receptor (Km) - high affinity radioligand low Km. The Kd can be 
calculated from the IC50 according to Cheng and Prusoff171: 
[ ] ( ) 1
50
.1 −⋅+
=
m
d Kradiol
ICK  
If the concentration of radioligand is much smaller than the Km the Kd will approximately 
equal the IC50 value.172  
The radioligand displacement assay used in to characterize the novel PYY3-36 analogs 
presented in this thesis was based on membranes from SK-N-MC and HEK293 Flp-In T-
Rex cell lines expressing the human Y1, Y2 and Y4 receptor subtypes, respectively. The 
used radioligands were 125I-[31Leu,34Pro]-pNPY for Y1 receptor, 125I-hPYY3-36 for Y2 
receptor and 125I-hPP for Y4 receptor. 
3.3.2 Signal transduction assay 
The radioligand competition binding assay is a very strong tool to evaluate novel GPCR 
agonists, however, it reveals only the binding power of a ligands and not the ligands ability 
to activate the receptor. G-protein coupled receptors (GPCR) are activated by an 
extracellular signal that creates a conformational change in the receptor. Depending on the 
receptor subtype, activation is either linked to the cAMP or phosphatidylinositol signaling 
pathways (Figure 3.5). Two main types of cAMP signal transduction pathways exists; the 
stimulatory and inhibitory that leads either to stimuli or to inhibition of adenylyl cyclase 
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through the heterotrimeric G-proteins. Down stream effects of adenylyl cyclase is 
activation or deactivation of transcription factors. In the phosphatidylinositol signally 
parthway phospholipase Cβ (PLC-β) is activated after stimuli from a heterotrimeric 
G-protein. The lipase hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Figure 3.5 and 3.6). IP3 activates 
Ca2+-channels located in the membrane of the smooth endoplasmic reticulum as well as the 
mitochondria, and DAG will activate protein kinase C (PKC), which together will cause 
biological effects. The heterotrimeric G-proteins consist of the Gα and the tightly 
associated Gβγ subunits. The family of the Gα subunit is divided into four main groups 
based on their sequence homology: Gαs (stimulate adenylyl cyclases), Gαi/o (inhibit 
adenylyl cyclases), Gαq/11 (stimulate PLC-β), and Gα12/13 (associated with the regulation of 
a sodium proton exchange protein).173 More than 70 combinations of G-protein subunits is 
possible,174 which regulate more than 865 different GPCRs.175     
 
Figure 3.5. The different GPCR signaling pathways. a) After GPCR activation the 
heterotrimeric G-proteins interact and facilitates its activation via exchange of GDP for 
GTP at the α-subunit. b) Hydrolysis of PIP2 to IP3 and DAG. c) IP3 leads to increased 
Ca2+ levels. d) Adenylyl cyclase leads to changes in cAMP levels. e and f) 
Transcription factors is activated or deactivated.176 
Because GPCRs, via different G-proteins, regulate a variety of second messengers, it is not 
surprising that a range of assays are available to detect GPCR-dependent G-protein 
activation. Aiming at developing a ‘universal’ screening system in which any receptor can 
be assayed with a common assay endpoint, chimeric G-proteins has been intensively 
investigated.174,177 Additionally, Gαi/o coupled GPCRs, such as the Y receptors, has limited 
downstream detection possibilities. However, stimulation of PLC or cAMP offers a series 
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of assay options that are widely applied in ligand screening and drug discovery (Figure 
3.5).176,178-180 Natural promiscuous G-proteins (G-proteins that can activate a wide range of 
GPCRs) exist, but the broadness of their applicability is still limited. Most natural 
promiscuous G-proteins, such as Gα16 (Gαq subtype), fail to activate Gαi/o-selective 
GPCRs.181-183 Replacing C-terminal amino acids of Gαq with the corresponding Gαi residues 
in addition to truncation of the N-terminus enabled interaction between Gi- and Gs-linked 
receptors with PLC-β and IP3 release.184-186 The G-protein mutant (Gα∆6qi4myr) provides a 
very robust signal response for selected Gαi-coupled receptors, such as the Y 
receptors.118,187 Co-transfecting a Y receptor subtype together with the chimeric 
Gα∆6qi4myr-protein into stable cell lines allows for measuring the activity of novel ligands 
towards the Y receptors via the PLC-β/IP3 pathway. The lifetime of IP3 is short thus the 
GPCR activation is monitored by the IP3 degradation product, inositol monophosphate 
(IP1), which accumulates in the cell in the presence of lithium chloride (Figure 3.6). 
Alternatively, a Ca2+ efflux from the endoplasmatic reticulum (ER) can be measured by 
fluorescence sensing (Figure 3.6). 
 
Figure 3.6. Possible measuring techniques when the Gαi coupled receptor is activated 
though chimeric G proteins.188  
Major differences between affinities observed in competition binding studies and potencies 
observed from signal transductions studies may be obtained, which could be related to the 
fact that in heterologous competition binding studies, such as the competition binding 
studies used to characterized novel PYY3-36 analogs in this thesis, the radioligand differ 
chemically from the investigated ligand, which may allow the radioligand to trap the 
receptor in one conformation such that high concentration of the ligand is required to 
induce the conformational changes before binding.189 Another possible explanation for a 
discrepancy between affinity and potency could be that the signal transduction assay 
allows for intracellular amplification of the response, which may increase the potency. 
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3.3.3 Animal model of obesity 
The understanding of the regulation of food intake partly originates from animal studies, 
especially in rodents. Moreover, animal models have provided valuable knowledge of 
environmental effects, such as responses to high-energy diets, and in the development of 
peptide drug candidates for the treatment of obesity.  
The initial animal models of obesity originate from spontaneous single-gene loss-of-
function mutations, which are discovered by noticing an abnormal obese phenotype, 
followed by selective breeding to expose the responsible gene in homozygotes (having two 
copies of the gene). The ob/ob mouse model of obesity is a classic example of spontaneous 
single-gene loss-of-function mutations (loss of the leptin gene).190 Despite the landmark 
discovery of the ob/ob mouse and the leptin gene, genetic screens of the human population 
have revealed small numbers of obese individuals that have loss-of-function mutations in 
this particular gene.191  
It is generally accepted that human obesity is caused by both genetic as well as 
environmental factors, and that the genetic basis is poly- rather than monogenic. Hence, to 
study anti-obesity drugs animal models with a polygenic background disposed to an 
obesogenic environment are the animal models of choice. For example, chronic exposure 
of rodents such as C57BL/6J mice, NMRI mice, and Sprague-Dawley rats to high-fat diets 
results in increasing body-weight and an obese phenotype (Figure 3.7).192-198 
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Figure 3.7. C57BL/6J mice responses to different compositions of diet for 4 months. 
HH; high-fat, high-sucrose diet. HL; high-fat, low-sucrose diet. LH; low-fat, 
high-sucrose diet. LL; low-fat, low-sucrose diet.192 
Diet-induced obesity (DIO) has a late onset in mice, which is similar to common human 
obesity resulting from over-consumption of food and an inactive life-style. Depending on 
the animal strain, the gender, as well as the composition of the diet, and the duration of 
being exposed to a high-fat diet, DIO mice developed increased adiposity that results in 
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hyperleptinemia, peripheral leptin insensitivity and insulin resistance already after 8 weeks 
on high-fat diet.197,198 Thus, the DIO mouse model is an excellent model of obesity. 
Moreover, outbreeding of Sprague-Dawley focusing on low and high weight gainers has 
enabled the development of a diet-induced rat model of human obesity and human leanness 
(obesity resistance).196,199 The diet-induced obese (DIO) rats are prone to become obese 
when offered a diet with an energy content from fat that is very similar to human 
obesogenic environment (31% energy from fat). 
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 Part III                                            
‘Results and discussion’   
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Chapter 4. PYY3-36 project 
The work presented in this thesis is divided into four projects (Figure 4.1) aiming at 
improving the Y receptor selectivity (Y2 over Y1), the Y2 receptor affinity and potency, 
or/and the metabolic stability. The basis of the designs has consistently been that the novel 
ligands should associate with the membrane prior to Y receptor activation - as 
hypothesized for the PP-fold peptides.1-4 Recognizing that the α-helical segment is thought 
to control the secondary conformation of the receptor-recognizing C-terminal pentapeptide 
the native α-helix was generally not modified. PYY3-36 was primarily modified in the 
N-terminus by considerable modifications that could potentially lead to radical alteration in 
the secondary structure of PYY3-36.  
The novel PYY3-36 analogs were mainly developed based on rational designs, except the 
C-terminal Tyr-36 modifications (project 1, Figure 4.1, chapter 4.1) that are based on a 
small combinatorial library of non-proteinogenic Phe analogs. A combinatorial design 
strategy was not the method of choice for the development of the majority of the novel Y2 
receptor ligands because during PYY3-36 synthesis multiple byproducts emerge and as a 
result HPLC purification is required. Moreover, it was believed that the probability of 
discovering new high-affinity Y2 receptor ligands from a combinatorial perspective would 
be low due to a high number of futile compounds. Thus, it was projected that the 
time-benefit of combinatorial design would be unprofitable. With a rational design 
approach it was believed that the development of high-affinity compounds towards the Y2 
receptor was more straightforward – higher probability of finding a hit. Furthermore, the 
rational design approach would provide compounds which were highly original.   
The strategy was to develop novel ligands showing an enhanced pharmacologically profile 
compared to PYY3-36 before formulating it to be a longer-acting analog. Thus, after 
identification of a hit compound (i.e. in this context a novel high-affinity PYY3-36 analog 
with enhanced selectivity and in vivo efficacy), it was to be chemically modified by 
PEGylation or lipidation, which consequently should increase its metabolic stability. Only 
a few hits presented in this thesis were taken into this step of drug development. 
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Figure 4.1. Project overview.  
All novel ligands were made using SPPS, purified by RP-HPLC, characterized as well as 
quantified by LC-MS and the secondary structures were determined by CD spectroscopy. 
Moreover, the novel ligands were assayed by radioligand competition binding assays 
towards the Y1, Y2 and Y4 receptor subtypes. Assays for binding towards the Y5 receptor 
were not performed because it is primarily found in the CNS, and it was anticipated that 
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the novel ligands presented in this thesis do not cross the blood brain barrier and engage 
the Y5 receptor. Moreover, Y5 receptor antagonism does not induce weight-loss in 
overweight and obese adults suggesting the Y5 receptor to be less important in the control 
of energy homeostasis.200 Hits were assayed either by signal transduction assay and/or by 
in vivo efficacy analysis in mouse models of obesity. Finally, several PYY3-36 analogs 
were analyzed for stability against peptidases in buffered solution and/or in mouse serum 
and the half-lives determined by RP-HPLC. 
In the following chapter the main results of each project are given - the papers and 
manuscripts in the appendix section presents a thorough description of the design and the 
results of each project. Moreover, the experimental setup for each project is presented in 
the papers and manuscripts given in the appendix section. 
4.1 Project 1: C-terminal Tyr-36 modifications 
Tyr-36 of PYY3-36 has generally been assumed to be highly important for Y receptor 
activity due to the high conservativeness throughout species.36,91 Tyr-36 is part of the 
C-terminal pentapeptide that is crucial for receptor recognition. The significance of Tyr-36 
in Y2 receptor binding has been demonstrated in both NPY107 and PYY3-36108 Ala-scans 
that show an almost complete elimination of Y2 receptor affinity (>1000 fold decrease). 
However, a few of NPY analogs modified at residue 36 with different aromatic analogs 
showed altered Y receptor selectivity (Scheme 4.1).80  
 
Scheme 4.1. The effect of single amino acid replacement of the C-terminal Tyr-36 on 
binding affinity of NPY to the Y1 and Y2 receptors.80 
The Ala-scans as well as the [36Phe]-NPY and [36Bpa]-NPY analogs indicates that an 
aromatic group may by required for Y2 receptor affinity, however, not for Y1 receptor 
affinity. Moreover, the results of the [36Bpa]-NPY analog indicates that there could be a 
unique pocket in binding site of the Y2 receptor which could be exploited to enhance the Y 
receptor selectivity. This led to the development of nine novel [36X]-PYY3-36 analogs (a 
selection is shown in Table 4.1).   
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Table 4.1. Radioligand competition binding assay and signal transduction assay of PYY3-36 and 
[36X]-PYY3-36 towards the Y receptor subtypes Y1, Y2, and Y4.   
Binding assay, IC50 [nM] Functional assay, EC50 [nM] 
36X 
Y1Ra Y2Rb Y4Rb Y1Rc Y2Rc 
PYY3-36 7.8 ± 1.1 0.50 ± 0.09 255 ± 29 135 ± 32 7.6 ± 1.6 
p-fluoro-Phe > 1000 0.76 ± 0.02 >1000 737 ± 30 12 ± 1.0 
p-chloro-Phe 198 ± 14 1.79 ± 0.22 >1000 >1000 5.2 ± 1.6 
p-bromo-Phe 350 ± 101 1.67 ± 0.06 >1000 >1000 5.4 ± 2.1 
p-iodo-Phe >1000 1.65 ± 0.51 >1000 >1000 11 ± 4.0 
p-amino-Phe 388 ± 175 0.96 ± 0.32 >1000 367 ± 98 11 ± 2.0 
a
 SK-N-MC cells expressing the Y1R. b Y2R or Y4R transfected HEK293 Flp-In T-Rex cells. c Y1R 
or Y2R and Gα∆6qi4myr transfected COS-7 cells. 
 
The novel Y2 receptor ligands showed increased Y receptor selectivity and especially 
analogs having a halogen or amino group in the para position of Phe-36 of PYY3-36 
showed promising results due to the high Y2 receptor binding affinity and potency in 
addition to an almost complete abolishment of Y1 receptor affinity and potency (Table 
4.1). Modifications of residue 36 of PYY3-36 have shown that conservative modifications 
in the C-terminal pentapeptide can lead to a huge increase of Y receptor selectivity. The 
results obtained in this study may be incorporated into metabolically stable PYY3-36 
analogs to increase their Y receptor selectivity. This work was published in Journal of 
Peptide Science (Paper 1).201 
4.2 Project 2: Glyco-scan of PYY3-36 
The Ala-scan is a Gold standard to study the effect of point mutations in a peptide 
sequence. In an Ala-scan all amino acids are substituted with the smallest chiral amino 
acid, Ala. Here the glyco-scan concept has been formulated and introduced. The glyco-
scan will allow the study of effects on one or more of the following properties (i) 
improvement in solubility, (ii) protecting against proteolytic cleavage (which consequently 
increases the half-life of the peptide and enhances the concentration at the pharmacological 
targets), (iii) modification of the clearance, (iv) alteration of the function (e.g. GPCR 
binding), and many more. Peptides has been previously been glycosylated to extent their 
half-lives and to improve solubility, to add specific recognition, etc.202,203 A glyco-scan 
posses the opportunity for a broad degree of variation and diversity, which includes (i) 
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introduction of different carbohydrates (glycans), (ii) glycosylation of side-chains as O-, 
N-, and C-glycosides, and (iii) glycosylation of either a native or a non-proteinogenic 
amino acid.  
In this particular glyco-scan of PYY3-36, hydroxyl side-chain functionalities of Ser and 
Tyr were glycosylated. The glyco-amino acids were synthesized according to procedures 
reported in literature204-206 and incorporated into the PYY3-36 sequence using standard 
Fmoc SPPS. Novel PYY3-36 analogs having a glycan positioned in the water-membrane 
interface (according to the membrane compartment model of the PP-fold peptides) or in 
the N-terminus were assayed for Y receptor affinity and selectivity. Interestingly, the Y2 
receptor could accommodate glycosylations very well in contrast to the Y1 and Y4 
receptors. Especially, glycosylation of the α-helical region showed both increased Y 
receptor selectivity. The glycosylation of Tyr-21, located in the amphipathic α-helix of 
PYY3-36, leads to enhanced selectivity, originating from a reduced affinity towards the Y1 
receptor (Table 4.2).  
Table 4.2. The binding affinity towards the Y receptors as well as the degree of α-helicity in 
solution of PYY3-36 and the novel PYY3-36 analogs glycosylated at Tyr-21 is given. Native 
PYY3-36 sequence: H-IKPEAPGEDASPEELNRY21YASLRHYLNLVTRQRY-NH2 
 Binding affinity, IC50 [nM]a α-helicityb 
Peptide Y1R Y2R Y4R [%] 
PYY3-36 7.8 ± 1.1 0.50 ± 0.09 255 ± 29 26 
[21Y(β-D-Glc)]-PYY3-36 150 ± 44 0.84 ± 0.12 687 ± 104 47 
[21Y(β-D-Gal)]-PYY3-36 70 ± 17 0.51 ± 0.01 714 ± 222 34 
a
 SK-N-MC cells expressing the Y1 receptor or HEK293 Flp-In T-Rex cells expressing the Y2 or 
Y4 receptors. b 10 mM phosphate buffer 
 
Interestingly, CD spectroscopy of the glycosylated PYY3-36 analogs in solution showed 
no disturbance of the inherent PYY3-36 α-helix for the majority of the glyco-PYY3-36 
analogs. The analogs glycosylated on a Tyr residue (position 20, 21, 27) even 
demonstrated a significant increase in stability of α-helix (Table 4.2 and Figure 4.2).  
 37 
20
-10
0
10
190 210 230 250 270
CD
[m
de
g]
Wavelength [nm]
PYY3-36
[21Y(β-D-Glc)]-PYY3-36 
[21Y(β-D-Gal)]-PYY3-36
CD
[m
de
g]
    
Figure 4.2. UV CD spectra of PYY3-36, [21Y(β-D-Glc)]-PYY3-36 and [21Y(β-D-Gal)]-
PYY3-36 in aqueous buffered solution (20 µM peptide in 10 mM phosphate buffer). 
Moreover, a similar metabolic digestion patterns for both PYY3-36 and glycosylated 
analogs were shown by LC-MS - serum carboxy-peptidases cleaves at the amino side of 
Arg-33 and Arg-35 terminating the physiological effects of native PYY3-36 as well as the 
glycosylated PYY3-36 analogs. This work has been accepted for publication in 
ChemBioChem (Paper 2). 
4.3 Project 3: N-terminal isoforms of PYY3-36 
Contrary to NPY, PP and PYY1-36 are backfolded in solution:1-5 The Pro residues of the 
N-terminus of PYY and the Tyr side-chains of the α-helix intercalates in a zipper-type 
fashion.207 Additionally, residues 10-14 of PYY1-36 plays a pivotal role in the formation 
of the backfolding, which has been demonstrated by the complete abolishment of 
backfolding of PYY1-36 when moving the Pro-14 to position 13.207 Given the latter and 
that the N-terminus has been demonstrated to be extremely important for Y1 receptor 
affinity,80,109,112-115 a number of isoformic branched PYY analogs were designed. The aim 
was to alter the native turn motif of PYY such that the Y receptor selectivity was 
increased. The N-terminus of NPY has previously been modified, by replacing the residues 
5-24 with 6-aminohexanoic acid (Ahx), [Ahx5-24]-NPY, which consequently led to an 
abolishment of Y1 receptor affinity.80  
Several different N-terminal PYY segments were introduced to the side-chain of an 
additional Lys-12 of [11Ile,12Lys]-PYY11-36 (Table 4.3). Even though peptides 1 
(PYY1-36 isoform), 2 (PYY2-36 isoform), and 3 (PYY3-36 isoform) were branched 
isoforms of PYY they resulted in Y1 and Y2 receptor potencies equivalent to those for 
PYY3-36. Peptide 3 gave a slight, but insignificant, decrease in Y1 receptor potency 
compared to PYY3-36. Exchanging the GEDA turn with the less flexible GPRRP turn 
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motif (peptides 4 and 5) resulted in five- to sevenfold increase in Y2 receptor potencies 
compared to PYY3-36. The Y1 receptor potencies of peptide 4 and 5 only dropped 2.5-fold 
compared to peptides 1 and 3, respectively, and the Y1 receptor potency of peptide 5 
(PYY3-36 isoform) was only reduced twofold compared to PYY3-36. Thus, the 
introduction of the GPRRP turn motif resulting in major increases in Y2/Y1 receptor 
selectivity.  
Table 4.3. Potencies of PYY3-36, and the Lys-12 branched [11Ile,12Lys]-PYY11-36 
analogs towards the Y1 and Y2 receptors. 
  Y1Ra Y2Ra 
Peptide Lys-12 branch EC50 [nM] EC50 [nM] 
PYY3-36  90 ± 11 5.6 ± 2.1 
1 H-YPIKPEAPGEDA- 12 ± 7 5.6 ± 3.2 
2 H-PIKPEAPGEDA- 80 ± 22 4.3 ± 2.9 
3 H-IKPEAPGEDA- 118 ± 19 4.6 ± 2.4 
4 H-YPIKPEAPGPRRP- 4.5 ± 3.3 1.1 ± 0.3 
5 H-IKPEAPGPRRP- 46 ± 23 0.7 ± 0.3 
a
 Transfected Y1 or Y2 receptors as well as Gα∆6qi4myr in COS-7 cells. 
 
The stability of PYY3-36 and peptides 1-5 were investigated in mouse serum which 
showed the primary sites for cleavage were in the C-terminus between residue Thr-32 and 
Arg-33 as well as between Gln-34 and Arg-35. PYY3-36 and peptides 1-3 resulted in equal 
half-lives in contrast to peptide 4 and 5 which were digested > 10 times faster. The reason 
for the increased digestion is still inconclusive. Due to the latter peptides 4 and 5 were not 
investigated in vivo.     
Peptides 2 and 3 were tested for efficacy in an acute mouse model obesity (NMRI mice) 
showing at least to be as good as PYY3-36 in the ability to reduce body-weight (Figure 
4.3).  
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Figure 4.3. Acute minipump experiment in lean male NMRI mice (3 days). Vehicle 
(▼), 0.25 µmol/kg/day PYY3-36 (□), 0.25 µmol/kg/day peptide 2 (■) and 0.25 
µmol/kg/day peptide 3 (○). Values are means ± SEM (n = 7). One way ANOVA 
followed by a “Dunnett’s multiple comparison test”: (*) P < 0.05 compared to vehicle. 
One analog, peptide 3, an isoform of PYY3-36, was further tested chronically in DIO mice 
(Figure 4.4), resulting in a reduction in body-weight similarly to PYY3-36. Interestingly, 
the isoformic branched PYY3-36 analog resulted in beneficial effects on the fat-cell 
metabolism shown by its ability to increase adiponectin levels significantly compared to 
PYY3-36 (Figure 4.5). 
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Figure 4.4. Chronic minipump experiment in male DIO C57BL/6J mice (2-wk). Vehicle 
(▼), 0.25 µmol/kg/day PYY3-36 (□), 1.0 µmol/kg/day PYY3-36 (■), 0.25 µmol/kg/day 
peptide 3 (○), 1.0 µmol/kg/day peptide 3 (●). Values are means ± SEM (n = 9). One 
way ANOVA with “Dunnett's Multiple Comparison Test“: (*) P < 0.05 compared to 
vehicle. 
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Figure 4.5. Leptin levels on day 14 (A) and adiponectin levels on day 14 (B) of PYY3-
36 and peptide 3. Values are means ± SEM (n = 9). One way ANOVA with “Dunnett's 
Multiple Comparison Test“: (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 compared to 
vehicle. 
Increased adiponectin levels can indicate a positive remodeling of the adipose tissue, 
however, the effect is somewhat surprising because peptide 3 showed equal affinity, 
potency, and selectivity towards the Y receptors compared to PYY3-36. Moreover, the 
stability and pharmacokinetics are also similar between the two ligands. It could be 
speculated whether the beneficial effect could originate from an activation of an orphan 
receptors, such as GPR83 (GIR).208 
Project 3 has resulted in a patent application (WO2009/080608) and one manuscript aimed 
for publication in Organic and Biomolecular Chemistry (Paper 3). 
4.4 Project 4: Additional amphipathic α-helix 
Given that the PP-fold family of peptides interact with the membrane prior to receptor 
interaction1-5 and that truncating the N-terminus of PYY and NPY has proven important for 
Y receptor selectivity,80,109,112-115 an array of novel PYY3-36 analogs modified in the 
N-terminus by introducing an amphipathic α-helix has been designed. The amphipathic 
nature of the additional α-helix, and thereby a possible increase in affinity towards the cell 
membrane, should lead to an accumulation of peptide near the Y receptors. In other words, 
bringing the peptide from the three-dimensional space of solution on to the 
two-dimensional plane of the cell membrane should increase the probability of the peptide 
finding the receptor.  
The project is divided into two series based on their difference in architecture (Figure 4.6). 
Series A, an α-helix was introduced as a branch at Lys-4 of native PYY3-36. Two different 
amphipathic sequences were investigated, (i) PYY17-31, the native α-helix of PYY, and 
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(ii) its retro counterpart, PYY31-17, which is also predicted to form an α-helix. Moreover, 
different turn motifs between the branch point and new helix have been investigated.  
 
Figure 4.6. Overview of project 4.  
Series B, here an amphipathic α-helix was introduced in the N-terminus of PYY13-36. 
Several different amphipathic heptad repeat α-helices were investigated. The novel analogs 
were designed to form helix-loop-helix type of structures in solution - the hydrophobic 
sides of the two α-helices may assemble. Furthermore, the novel analogs may 
self-associate into di- or tetramers in solution.  
4.4.1 Series A 
Several of the novel Y2 receptor ligands showed improved Y receptor selectivity (Y2 over 
Y1) in the radioligand competition binding assay (Table 4.4) and furthermore, two analogs 
showed to be superior to PYY3-36 in their ability to reduce body-weight in acute mice 
studies (Figure 4.7). 
Adding an amphipathic α-helix to the side-chain of Lys-4 of PYY3-36 has only moderate 
impact on binding affinity towards the Y2 and Y4 receptors. The binding data showed a 
slight tendency that the peptides containing the retro sequence were better accepted by the 
Y2 receptor than the natural sequence, however, the nature of the turn region led to more 
significant differences in binding affinities towards the Y2 receptor (Table 4.4). The 
GPRRP turn motif (peptides 8 and 9), adapted from Hill and Degrado,209 were the best 
accepted sequence and gave equivalent to enhanced Y2 receptor binding affinities. The 
GPRRP turn motif limits the flexibility of the additional α-helix more than the other turn 
motifs, which may guide the C-terminal in an optimal conformation for Y2 receptor 
binding and/or prevents Y1 receptor binding. Interestingly, the analogs with a GPRRP turn 
motif (peptides 8 and 9) were also well tolerated towards the Y4 receptor and led to almost 
a threefold increase in binding affinity (Table 4.4). The binding affinities towards the Y1 
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receptor were to a great extent affected by the addition of an additional amphipathic 
α-helix. However, no turn (peptides 6 and 7) and the PE turn motif (peptide 11) showed to 
have little effect on the binding affinity towards the Y1 receptor. Peptides 8-10 and 12-13 
showed a very low Y1 receptor affinity, which consequently leads to improved Y2/Y1 and 
Y4/Y1 receptor selectivity’s compared to PYY3-36 (Table 4.4). 
Table 4.4. PYY1-36, PYY3-36 and H-I4KPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
analogs binding affinity towards the Y receptor subtypes Y1, Y2, and Y4, respectively. 
 Lys-4 branched sequences Y1Ra Y2Rb Y4Rb 
Peptide α-helix Turns 
Nature of 
α-helix IC50 [nM] IC50 [nM] IC50 [nM] 
PYY1-36    4.0±1.7 3.8±1.6 141±79 
PYY3-36    7.8±1.1 2.1±0.2 255±29 
6 H-LNRYYASLRHYLNLV - PYY17-31 11.7±3.7 6.2±1.1 395±121 
7 H-VLNLYHRLSAYYRNL - PYY31-17 7.9±0.5 5.4±0.3 496±91 
8 H-LNRYYASLRHYLNLV GPRRP- PYY17-31 >1000 2.1±0.2 173±60 
9 H-VLNLYHRLSAYYRNL GPRRP- PYY31-17 >1000 0.4±0.1 101±16 
10 H-LNRYYASLRHYLNLV GG- PYY17-31 >1000 14.1±4.5 567±40 
11 H-VLNLYHRLSAYYRNL PE- PYY31-17 17.2±1.8 7.8±2.2 276±5 
12 H-LNRYYASLRHYLNLV SP- PYY17-31 >1000 7.6±0.4 298±15 
13 H-VLNLYHRLSAYYRNL SP- PYY31-17 >1000 5.6±1.8 362±127 
a
 SK-N-MC cells expressing the Y1 receptor. b Transfected Y2 or Y4 receptors in HEK293 Flp-In 
T-Rex cells. 
 
Only peptides 8 and 12 showed significant body-weight lowering effects in acute in vivo 
studies (Figure 4.7). In contrast to the results obtained by the binding experiments, the 
orientation of the additional amphipathic α-helix, i.e. forward vs. retro sequence, was 
important for in vivo efficacy - only forward sequences showed efficacy. Finally, the in 
vivo experiments generally confirmed the results from the affinity studies, i.e. the turn 
motif was of central importance. 
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Figure 4.7. Acute effect of peptides 8 and 12 in lean male NMRI mice. The mice were 
given either 0.9% saline as vehicle (□), 1.0 µmol/kg/day PYY3-36 (▲) or 1.0 
µmol/kg/day branched peptide (■) two times a day for two days, shown by and arrow, 
with a total of five injections. The body-weight were calculated every morning for four 
days and given as mean body-weight (percent of day zero). There was seven mice in 
each group (n=7). 
4.4.2 Series B  
It is anticipated that the novel analogs of series B in association with a membrane are 
unfold in a position where the two amphipathic helices are located on the surface of the 
lipid bilayer analogous to the PP-fold peptides (Figure 4.8). Because the peptides of series 
B are designed to have increased affinity to the membrane, an increased potency towards 
the Y receptor could follow. Moreover, the additional α-helix may contribute to guide the 
C-terminal α-helix into a conformation favorable for Y2 receptor affinity and activity.  
Unfolding and
sebsequent
membrane
association
 
Figure 4.8. Schematic representation of the hypothesized membrane association of 
the PYY analogs with an additional N-terminal α-helix. The inherent PYY13-36 
segment is shown in red and the novel heptad repeat α-helical sequence is shown in 
blue.   
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More than 20 PYY analogs of series B have been designed, synthesized, characterized, and 
assayed. Several showed increased Y receptor selectivity (Y2 over Y1) and a few even 
showed increased Y2 receptor affinity and potency. A selection of the most selective 
compounds is given in Table 4.5. Especially peptides 15-18 showed to be very potent Y2 
receptor agonists with a two- to fivefold increase in potency compared to PYY3-36. The 
increase in Y2/Y1 receptor selectivity mainly originates from an increase in Y2 receptor 
potency, thus somewhat unexpected the addition of an α-helix instead of the N-terminus of 
PYY did not disturb the activation of the Y1 receptor. Peptide 17 is currently being 
investigated in a fluorescence-based single liposome assay. Here, the binding affinity 
towards the membrane and compound density vs. vesicle size can be established.210 The 
aim with this study is to establish a correlation between increased membrane binding 
affinity and receptor activation. Moreover, the fluorescence-based single liposome assay 
can further support a membrane compartment model for PYY3-36.1-5 Finally, the 
secondary structure of peptide 17 is being studied by CD in the presents of liposomes to 
establish the degree of α-helicity when associated to a membrane. 
Table 4.5. PYY3-36 and R1-NRYYASLRHYLNLVTRQRY-NH2 (R1-PYY18-36) binding to Y receptor 
subtypes Y1, Y2, and Y4, in addition to functional Y1 and Y2 receptor evaluation of the most potent 
Y2R agonists.   
Binding affinity                                     
assay, IC50 [nM] 
Signal transduction    
assay, EC50 [nM] 
Peptide N-terminal, R1 Y1Ra Y2Rb Y4Rb Y1Rc Y2Rc 
PYY3-36 H-IKPEAPGEDASPEEL- 7.8 ± 1.1 0.50 ± 0.09 255 ± 29 90 ± 12 5.6 ± 1.1 
14 H-AEELLKKLEELLKKASPEEL- 424 ± 2 6.1 ± 1.8 >1000 141 ± 11 32 ± 13 
15 H-YESLLKKLSELLKKASPEEL- 239 ± 124 4.9 ± 2.7 >1000 94 ± 33 3.9 ± 2.8 
16 H-YLERKLKELERKLKELSPEEL- 11 ± 1.4 0.9 ± 0.4 >1000 113 ± 21 2.3 ± 1.2 
17 H-YLERELKKLERELKKLSPEEL- >1000 3.2 ± 2.6 >1000 97 ± 31 3.1 ± 1.8 
18 H-YLKALKEALKALKEALKSPEEL- >1000 4.3 ± 0.5 664 ± 276 63 ± 27 1.1 ± 1.0 
19 H-NLEELKKKLEELKGSPEEL- 27 ± 0.4 2.1 ± 0.5 532 ± 354 - - 
a
 SK-N-MC cells expressing the Y1R. b Y2R or Y4R transfected HEK293 Flp-In T-Rex cells. c Y1R or 
Y2R and Gα∆6qi4myr transfected COS-7 cells. 
 
The work of project 4 has resulted in two manuscripts - one for each series. Series A: 
Manuscript submitted for publication in ChemMedChem (Paper 4). Series B: Manuscript 
under preparation (Paper 5). 
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Chapter 5. Concluding remarks and perspective 
The increasing research in gut-brain interactions are resulting in an increasing 
understanding of the control and regulation of food intake and energy homeostasis. New 
targets and ligands are still appearing, however, GLP-1 and PYY3-36 are still among the 
most interesting biopharmaceuticals as anti-obesity therapeutics. Thus, the thesis aim of 
developing PYY3-36 analogs, which are more selective, highly potent, and metabolically 
stable, is still highly relevant. In the present thesis, numerous novel Y2 receptor ligands 
with increased affinity and potency as well as enhanced Y receptor selectivity were 
designed, synthesized, characterized and assayed. The peptides were synthesized using 
standard Fmoc SPPS at room temperature. Especially the de-novo designed PYY analogs 
of project 4, series B (linear two helix), showed to be complicated to synthesize and purify 
– typically long coupling times (2 × 2.5 hours) as well as multiple purifications by 
RP-HPLC were required. The glyco-peptides were also somewhat difficult to synthesize. 
The resultant yields of the glyco-peptides were generally low, possibly because of high 
steric hindrance in the coupling steps of the glyco-amino acids. 
As part of the Ph.D.-project and in close cooperation with Rheoscience scientists and 
technicians, the radioligand competition binding assay was set up and further improved to 
enhance the performance of the assay. The radioligand competition binding assay was used 
as first line of evaluation in the pursuit of potent and selective Y2 receptor agonists.  
Four successful novel peptide designs of PYY3-36 have been explored: i) Modifying the 
conserved C-terminal Tyr-36 by non-proteinogenic phenylalanine analogs has led to 
several highly potent and selective Y2 receptor of which especially the halogenated 
analogs showed to be prosperous. Phe-36 analogs have the potential to improve the Y 
receptor selectivity in other PYY3-36 agonists, where the C-terminus is intact. ii) Using 
PYY3-36 as a model peptide, the glyco-scan concept has been formulated and introduced. 
The glyco-scan concept has the potential for a broad applicability in drug discovery 
alongside the Ala-scan. A glyco-scan can, as shown by PYY3-36, provide novel 
compounds with unique physical properties that can led to altered affinities towards a 
given target. iii) Alteration of the turn motif of PYY has resulted in analogs giving sub-
nanomolar affinity towards the Y2 receptor as well as animal experiments showing a 
significant reduction in body-weight and food intake. One analog showed beneficial effects 
on the fat-cell metabolism. The reason for these unexpected results is speculative, but 
activation of orphan receptors in the adipose tissue or in the hypothalamus could be an 
explanation. iv) An additional amphipathic α-helix was introduced either at, or instead of, 
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the N-terminus of PYY3-36 to increase the affinity towards the membrane prior to receptor 
recognition. Both series showed interesting results, i.e. increased affinity, potency and 
selectivity towards the Y receptors. Moreover, two analogs of series A reduced body-
weight in acute mouse studies. The novel analogs of series B resulted in highly potent and 
selective analogs, which via their design partly confirm the membrane compartment model 
for the PP-fold peptides. The introduction of an additional α-helix also led to an improved 
Y2/Y1 receptor selectivity, mainly as result of the increase in Y2 receptor potency. 
Generally, the affinity towards the Y1 receptor was unaffected which was somewhat 
unexpected because the N-terminus of PYY previously has been shown to be of great 
importance for Y1 receptor activity. Further studies are currently been performed to 
establish the binding affinity of peptide 17 to the membrane and to determine its secondary 
structure in the presents of liposomes. These studies will hopefully support and confirm the 
underlying principle of the design of the analogs of series B.      
The rational design has resulted in several highly potent and selective Y2 receptor agonists 
from a fairly small set of novel analogs. The hit rate has been reasonably high, which 
support the basis for doing rational designs on medium sized peptide hormones such as 
PYY3-36. Besides providing several highly potent and selective compounds the rational 
designs has lead to valuable knowledge about ligand-receptor and ligand-membrane 
interactions, which can be used in the design of new Y2 receptor agonists.      
Second-generation PYY analogs could involve introducing de novo heptad repeat 
sequences as the branch at Lys-4 of PYY3-36. Selected de novo heptad repeat sequences 
showed very attractive results in the series B of project 4, and could lead to enhanced 
pharmacological effects of the branched analogs (series A). Moreover, altering the linear 
two helix analogs (series B) in the hinge (turn) region, for example by the GPRRP turn or 
as a branch at an additional Lys, could lead to increased selectivity. Moreover, p-bromo-
Phe could be introduced instead of the C-terminal Tyr of analogs of projects 2, 3, and 4 to 
further increase Y receptor selectivity. Finally, the highly potent linear two helix (series B) 
analogs should be either lipidated or PEGylated to increase their half-lives. 
From a physiological perspective, the energy balance is regulated by numerous hormones 
that act in concert. In response to a reduction in food intake and adiposity the body mounts 
a counter-regulatory response to stop further weight-loss which might limit the 
effectiveness of single-agent weight-loss therapies. Consequently, the effects of combining 
two or more anorectic agents that act on different receptor systems have been reported to 
give additive effects (e.g. combined administration of native GLP-1 and PYY3-36).44 
Novel long-acting, highly potent and selective analogs of PYY3-36 should further improve 
the effect of dual therapeutics. Recently, a new series of novel peptides with agonism at 
both the glucagon and GLP-1 receptors has been published.211  
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The results gained in this thesis provide a greater understanding of the pharmacology of 
PYY3-36 and the pharmacology of the Y receptors, which hopefully can lead to new and 
more efficacious therapeutics against obesity.  
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Modifying the conserved C-terminal tyrosine
of the peptide hormone PYY3-36 to improve Y2
receptor selectivity
Søren L. Pedersen,a,b Birgitte Holst,c Niels Vrangb,d∗ and Knud J. Jensena∗
The Y2 selective PYY derived peptide PYY3-36 was recently shown to play a role in appetite regulation. Novel PYY3-36 analogs
with high selectivity for the Y2 receptor could be potential drug candidates for the treatment of obesity. The C-terminal
pentapeptide segment of PYY3-36 is believed to bind to the Y receptors. Tyr-36 is highly conserved across species and only few
successful modifications of Tyr-36 have been documented. PYY3-36 analogs were prepared using solid-phase peptide chemistry
and tested for binding to the Y1, Y2 and Y4 receptor subtypes by radioligand displacement assay. The Y2 receptor agonists with
the best affinity and selectivity were further investigated for activity towards the Y1 and Y2 receptor subtypes. Unexpectedly,
modifications of Tyr-36 were well-tolerated, and the analogs of PYY3-36 in which the Tyr-36 hydroxyl group was substituted
with a halogen or an amino group were particularly well tolerated and yielded an improved selectivity and approximately
equipotent affinity to the Y2 receptor. These modifications could be used to design new potential drug candidates for the
treatment of obesity. Copyright c© 2009 European Peptide Society and John Wiley & Sons, Ltd.
Keywords: PYY; PYY3-36; Y2 receptor agonist; gut hormone; tyrosine analogs; obesity
Introduction
More than 35 peptides with either stimulatory or inhibitory effects
on appetite have been identified to date. [1] A number of these
peptides are produced by endocrine cells lining the gut and are
released during ingestion and digestion of a meal. One well-
known gut hormone recently implicated in appetite regulation
is the 36 amino acid linear ‘peptide tyrosine tyrosine’ (PYY) first
isolated from porcine intestine. [2] PYY is secreted by intestinal
L-cells following ingestion of a meal. [3] After secretion, PYY
is N-terminally truncated by dipeptidyl peptidase IV (DPP-IV) to
produce PYY3-36. PYY and PYY3-36 exert a number of actions
on gastrointestinal functions including inhibition of pancreatic
exocrine secretion, [4–7] inhibition of gastrointestinal motility,
[8–11] inhibition of gastric acid secretion [12,13] and stimulation
of gallbladder contraction [14]. Recently, PYY3-36 was shown to
inhibit food intake in rats and humans. [15,16] Subsequently,
several studies in rats and mice using intraperitoneal [17–19] or
intravenous [20,21] administration of PYY3-36 have shown acute
reductions of food intake. Chronic administration of PYY3-36, in
different animal models, has been shown to reduce body weight,
[19,22] further supporting a role of PYY3-36 in appetite and weight
control.
PYY belongs to the PP-fold family of peptides together with
NPY and pancreatic polypeptide (PP). PP is a circulating peptide
hormone produced and released from the endocrine pancreas
in response to ingestion of food. [23] The peptide hormone
alters biliary function and inhibits pancreatic secretion, as well as
gastric and intestinal motility [24–26] and was recently shown to
inhibit food intake in humans. [15,16] The second family member,
NPY, acts as a neurotransmitter and is abundant in the central and
peripheral nervous system. [27] The physiological functions of NPY
are numerous, e.g. related to feeding, memory, blood pressure,
cardiac contractility and intestinal secretion. [28] All three peptides
bind to the family of Y receptors; the Y1, Y2, Y4 and Y5 subtypes.
While PP is a potent Y4 receptor agonist, it displays very low affinity
to the Y1, Y2 and Y5 receptors. NPY and PYY1-36 have very similar
binding profiles, and their orexigenic effects are believed to be
predominantly mediated via a nanomolar affinity to hypothalamic
Y1 receptor. PYY3-36 is believed to be the endogenous ligand
for the Y2 receptor to which it binds with sub-nanomolar affinity,
however, it also binds with sub-micromolar affinity to both Y1 and
Y4 receptors. [29] The appetite suppressing properties of PYY3-36 is
believed to be mediated by central Y2 receptors. [16] Interestingly,
recent data from rodents and humans suggests that PYY3-36
administration could interact with Y1 and/or Y5 receptors, and
thereby counteract the anorectic effects of Y2 stimulation. [30,31]
If this is indeed the case, novel highly Y2 selective compounds
should show more anorectic and body-weight lowering potential.
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Table 1. Sequences of human NPY, human PP, human PYY1-36 and
[36X]-PYY3-36
Peptide Sequence C-terminala
PP H-APLEPVYPGDNATPEQMAQYAADLRRYINML TRPRY-NH2
NPY H-YPSKPDNPGEDAPAEDMARYYSALRHYINLI TRQRY-NH2
PYY1-36 H-YPIKPEAPGEDASPEELNRYYASLRHYLNLV TRQRY-NH2
[36X]-PYY3-36b H-IKPEAPGEDASPEELNRYYASLRHYLNLV TRQRX-NH2
a Conserved pentapeptide.
b Human PYY3-36: X = Y.
Peptide Design
Since the discovery of the PP-fold peptides, a vast num-
ber of studies have investigated the PP-fold peptide structure
and their Y receptor affinities. The C-terminal pentapeptide
sequences of native NPY, PYY1-36 and PP are highly conserved
and play a pivotal role for the affinity to the binding pocket of the
Y receptors (Table 1). [32,33] Diverse interaction between acidic Y
receptor residues and the C-terminal arginines at position 33 and
35 of the PP-fold of peptides are most likely leading to differences
in the docking mode of the ligands to the Y receptors, which could
be one reason for the affinity differences. [34] An exception to the
conserved C-terminal is Pro-34 of PP, which could partly explain its
differentiated Y receptor selectivity. The C-terminal Tyr is assumed
to be essential for NPY binding and changes will lead to dramatic
reduction in affinity to both the Y1 and Y2 receptor subtypes. [33]
Ala scans of NPY [35] and PYY3-36 [36] both report complete loss of
affinity to the Y1 and Y2 receptors when replacing Tyr-36 with Ala.
These results strongly indicate that the effect from the aromatic
side-chain of Tyr-36 is extremely important for the binding to
the Y receptor subtypes. [35,36] NPY has additionally been point-
substituted at position 36 by replacing Tyr with Phe, which lowered
the affinity (13-fold for Y1R and 11-fold for Y2R) but had no impact
on selectivity. [35] However, incorporation of the large, hydropho-
bic residue 4-benzoyl-phenylalanine, [36Bpa]-NPY, gave a 590-fold
decrease in affinity to the Y1 receptor and a moderate eightfold-
drop in binding to the Y2 receptor. [37] The steric prerequisite for
receptor binding was further explored by introducing a D–Tyr at
position 36 of NPY, which resulted in a highly reduced affinity to
the Y1 receptor (100-fold), compared to modest 10-fold drop to the
Y2 receptor. [38] These results indicate that the Y receptors favour
an aromatic side-chain at residue 36, and the size could lead to Y2
receptor selectivity due to steric limitations of the Y1 receptor.
Here we describe a number of [36X]-PYY3-36 analogs; we aimed
at increasing Y2 receptor selectivity while maintaining its potency.
This series included peptides of unnatural Phe or Tyr analogs,
which could aid in understanding the structural requirements in
the receptor binding pocket.
Materials and Methods
Materials
The organic solvents and reagents for peptide synthesis were all
of analytical reagent grade and were obtained from Iris Biotech
GmbH (Germany), except for DMF which was obtained from Sigma-
Aldrich (Denmark). TentaGel S Rink Amide resin was obtained from
Novabiochem. Milli–Q (Millipore) water was used for RP–HPLC
analyses and purifications. Human Embryonic Kidney (HEK) 293
cells (HEK293 Flp-In T-Rex) and pcDNA3.1 vector were purchased
from Invitrogen. Dulbecco’s Modified Eagle’s Medium (D-MEM),
FCS, penicillin–streptomycin solution, phosphate buffered saline
(PBS), sucrose and 99% glycerol were obtained from Sigma-Aldrich.
FuGENE 6 transfection reagent, complete protease inhibitor
cocktail tablets and BSA were purchased from Roche. 2-Amino-
2-hydroxymethyl-propane-1,3-diol (TRIS), MgCl2 · 6H2O, CaCl2
and NaCl were obtained from AppliChem GmbH. (2S,3S)-1,4-bis-
sulfanylbutane-2,3-diol (DTT) was obtained from GE Healthcare,
and radioactive labeled agonists were purchased from Phoenix
pharmaceuticals. 96-Well filtration multiscreen HTS, DV plates
were obtained from Millipore. [3H]-myo-inositol (PT6-271) was
purchased from Amersham.
Peptide Synthesis
The peptides were prepared by automated peptide synthesis
on a Syro II peptide synthesiser (MultiSynTech) by standard
SPPS on TentaGel S Rink Amide resin with Fmoc for protection
of Nα-amino groups. Side-chain protecting groups were tert-
butyl (Ser, Thr, Tyr), 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-
sulfonyl (Pbf, for Arg), and trityl (Trt, for Asn, Gln, His). Nα-Fmoc
amino acids (4.0 equiv) were coupled using N-[(1H-benzotriazol-
1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexa-
fluorophosphate N-oxide HBTU (3.8 equiv), 1-HOBt (4.0 equiv)
and N,N-DIEA (8.0 equiv) as coupling agents in DMF for
45 min, except unnatural amino acids which reacted for 120 min.
Nα -Fmoc deprotection was performed using piperidine-DMF (2 : 3)
for 3 min, followed by piperidine-DMF (1 : 4) for 12 min. The peptide
amides were released from the solid support by treatment with
TFA-triethylsilane (TES)-H2O (95 : 2 : 3) for 2 h. The TFA solutions
were concentrated by nitrogen flow and the compounds were
precipitated with diethylether to yield the crude materials as
white powders. Purification was accomplished by preparative RP-
HPLC (Dionex Ultimate 3000 system) on a preparative column
(FeF Chemicals, 300 Å 5 µm C4 particles, 2.1 × 200 mm) using the
following solvent system: solvent A, water containing 0.1% TFA;
solvent B, acetonitrile containing 0.1% TFA. B gradient elution
(0–50 min: 10–60%) was applied at a flow rate of 10 ml min−1
and column effluent was monitored by UV absorbance at 215 and
254 nm simultaneously. Identification was carried out by ESI-MS
(MSQ Plus Mass Spectrometer, Thermo). The peptides were ana-
lysed by analytical HPLC (Dionex Ultimate 3000 system equipped
with a PDA UV detector or Dionex P580 pump equipped
with Waters 996 PDA and Waters 717plus autosampler) using
‘orthogonal’ eluent systems, first A–B (solvent A, water containing
0.1% TFA; solvent B, acetonitrile containing 0.1% TFA, as above),
then eluent system C–D (solvent C, 10 mM NH4OAc; solvent D,
10% 100 mM NH4OAc in AcN). First analysis; eluent system A–B
was applied on a C4 analytical column (Phenomenex, Jupiter,
300 Å 5 µm C4 particles, 3.9 × 150 mm) where a B gradient elution
(0–14 min: 5–100%) was applied at a flow rate of 1.0 ml min−1.
Second analysis; eluent system C–D was applied on a C18 analytical
column (Phenomenex, Gemini, 110 Å 3 µm C18 particles, 4.60×50
mm) where a C gradient elution (0–14 min: 5–100%) was applied
at a flow rate of 1.0 ml min−1. Quantification and characterisation
data are given in Table 2.
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Table 2. Quantification and characterisation data of PYY3-36 and H-IKPEAPGEDASPEELNRYYASLRHYLNLVTRQR36X-NH2 analogs
ESI-MS (m/z)a Purity (%)
No 36X Calculated MS Found Assigned
Eluent
system A-Bb
Eluent
system C-Dc
PYY3-36 Tyr 4049.46 1012.76 [M + 4H]4+ 98 99
810.21 [M + 5H]5+
1 homo-Tyr 4063.49 1016.87 [M + 4H]4+ 99 99
813.36 [M + 5H]5+
2 D-Tyr 4049.46 1013.03 [M + 4H]4+ 97 97
810.40 [M + 5H]5+
3 p-fluoro-Phe 4052.44 1013.51 [M + 4H]4+ 99 99
810.83 [M + 5H]5+
4 p-chloro-Phe 4061.91 1017.19 [M + 4H]4+ 99 99
814.17 [M + 5H]5+
5 p-bromo-Phe 4112.36 1028.66 [M + 4H]4+ 99 100
823.19 [M + 5H]5+
6 p-iodo-Phe 4160.35 1040.09 [M + 4H]4+ 95 95
832.35 [M + 5H]5+
7 p-nitro-Phe 4078.46 1019.81 [M + 4H]4+ 96 95
816.18 [M + 5H]5+
8 p-amino-Phe 4048.48 1013.12 [M + 4H]4+ 99 96
810.16 [M + 5H]5+
9 m-nitro-Tyr 4094.16 1024.15 [M + 4H]4+ 98 98
819.20 [M + 5H]5+
a Identified by ESI-MS on an MSQ Plus Mass Spectrometer (Dionex).
b Quantified by RP-HPLC at 215 nm. Eluent A: 0.1% TFA in H2O. Eluent B: 0.1% TFA in AcN.
c Quantified by RP-HPLC at 215 nm. Eluent C: 10 mM NH4OAc. Eluent D: 10% 100mM NH4OAc in AcN.
Radioligand Displacement Assay
Cell culture and receptor expression: The SK-N-MC cells were
cultured in a 1 : 1 mix of HAM F12 and D-MEM 1885, containing
15% (v/v) FCS, 1% non-essential amino acids and 1% (v/v)
penicillin–streptomycin in humidified atmosphere of 5% carbon
dioxide and 95% air, at 37 ◦C. The HEK-derived (293 Flp-In T-Rex)
cell line was cultured in D-MEM, containing 10% (v/v) FCS and 1%
(v/v) penicillin–streptomycin. Cells were grown as monolayers in
humidified atmosphere of 5% carbon dioxide and 95% air, for 48 h
at 37 ◦C. Using serum-free D-MEM and FuGENE, six transfection
reagent HEK293 Flp-In T-Rex cells were transiently transfected
by pcDNA3.1 vectors which encode either the human Y2 or Y4
receptor (FuGENE 6/pcDNA3.1, 3 : 1). The transfected HEK293 Flp-
In T-Rex cells were set to express the receptors in humidified
atmosphere of 5% carbon dioxide and 95% air, for another 48 h at
37 ◦C.
Preparation of membrane fractions
The SK-N-MC and the transiently transfected HEK293 Flp-In
T-Rex cells were washed with PBS and homogenized in cold
homogenisation buffer (50 mM Tris (pH 7.5), 2.5 mM MgCl2, 1.0 mM
CaCl2, 1.0 mM DTT, complete protease inhibitor cocktail (one tablet
per 50 ml buffer)). An equal amount of 0.6 M sucrose was added
to the cell-mixture. The homogenate was centrifuged (10,000 g,
10 min at 4 ◦C). Cell pellets were washed in washing buffer (50 mM
TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, complete protease
inhibitor cocktail (one tablet per 50 ml buffer), 1.0% (w/w) BSA
fraction V), and subsequently the suspensions were centrifuged
(10,000 g, 10 min at 4 ◦C). The pellets were re-suspended in glycerol
containing binding buffer [50 mM TRIS (pH 7.5), 2.5 mM MgCl2,
1.0 mM CaCl2, complete protease inhibitor cocktail (one tablet per
50 ml buffer), 1.0% (w/w) BSA fraction V, 20% (v/v) glycerol] and
concentration was adjusted to an OD600 of 1.6.
Binding affinity
All binding experiments were performed in 96-well filtration
MultiScreen HTS, DV plates and every concentration point
was performed as triplicates. The unlabeled peptide (25 µl)
at concentrations between 10 pM and 10 µM, cell membrane
suspension (3.5 µl), binding buffer (61.5 µl, 50 mM TRIS, pH
7.5, 2.5 mM MgCl2, 1.0 mM CaCl2, complete protease inhibitor
cocktail [one tablet per 50 ml buffer), 1.0% (w/w) BSA fraction V)],
radioligand solution (10 µl; Y1R: 125I-[31Leu,34Pro]-pNPY; Y2R: 125I-
PYY3-36; and Y4R: 125I-PP; specific activity of 800–1000 Ci/mol).
After 1–2 h of incubation, the assay was terminated by filtration.
Finally, the membrane-receptor ligand complexes were washed
twice in cold TRIS buffer (50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM
CaCl2) containing 5.0 % (w/w) BSA fraction V. Bound radioactivity
was determined as counts per minute (Wallac 1470 Wizard
Automated Gamma Counter). Binding data were analysed with
GraphPad Prism 5.0 (GraphPad Software, Inc. San Diego, CA, USA).
The displacement experiments were replicated until the standard
error of mean (S.E.M.) of − log IC50 was below 0.1 (n = 2–5).
Functional Assay
Transfections and tissue culture: COS-7 cells were grown in D-
MEM 1885 supplemented with 10% FCS, 2 mM glutamine and
0.01 mg/ml gentamicin. Cells were transfected with 10 µg cDNA
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of wild type Y1 or Y2 receptors and 10 µg cDNA of a Gα6qi4myr
[39], using the calcium phosphate precipitation method with
chloroquine addition. The chimeric G-protein allow the Gαi
coupled receptors to signal through the signal transduction
pathways known for the Gαq coupled receptors. Receptors from
the PP-fold family of peptides – the Y1 and Y2 receptors – were
cloned from a human cDNA library and expressed in a pcDNA3.1
vector.
Phosphatidylinositol turnover
One day after transfection, COS-7 cells were incubated for 24 h
with 5 µCi of [3H]-myo-inositol in 1 ml medium, washed twice in
buffer, 20 mM HEPES, pH 7.4, and were subsequently incubated in
0.5 ml buffer supplemented with 10 mM LiCl at 37 ◦C for 30 min.
After stimulation with various concentrations of PYY3-36 or the
synthetic analogs for 45 min at 37 ◦C, cells were extracted with 10%
ice-cold formic acid followed by incubation on ice for 30 min. The
generated [3H]-inositol phosphate was purified on Bio-Rad AG 1-X8
anion-exchange resins. Determinations of each measuring point
were made in duplicates. The functional assays were replicated
three times (except PYY3-36 which was replicated four times).
Results and Discussion
Peptide Synthesis
All peptides were assembled using the Fmoc/t-Bu strategy by
automated SPPS on Rink Amide TentaGel resin. The Nα-Fmoc-
protected amino acids were coupled using HBTU as coupling
reagent, DIEA as base and HOBt as additive, in DMF. Coupling
times were generally 45 min, except for the unnatural amino
acid derivatives which were coupled for 2 h. The peptides were
side-chain deprotected and simultaneously cleaved from the solid
support by a TFA cocktail containing TES and water as scavengers.
Finally, the peptides were purified by RP-HPLC and characterized
orthogonally by analytical HPLC and mass spectrometry. The final
products were obtained with >95% purity (Table 2).
Affinity and Activity Evaluation
To characterize the influence of substituting Tyr-36 with unnatural
amino acid analogs, the binding affinity of the novel PYY3-36
analogs were tested using a radioligand displacement assay
(competition binding assay) based on membranes from SK-N-
MC and HEK293 Flp-In T-Rex cell lines expressing the human
Y1, Y2 and Y4 receptor subtypes, respectively. 125I-[31Leu,34Pro]-
pNPY for Y1R, 125I-hPYY3-36 for Y2R and 125I-hPP for Y4R were
used as radioligands. The analogs with the highest affinity and
potency for the Y2 receptor were additionally tested for their
ability to activate the Y1 and Y2 receptors. Binding affinities (IC50
values) and activation potencies (EC50 values) for the [36X]-PYY3-36
analogs as well as native PYY3-36 are summarized in Table 3.
Structure–Affinity Relationship
PYY3-36 is highly potent but only moderately selective, whereas
all the novel peptides in this series had an increased Y receptor
selectivity. First, extending the length of the Tyr-36 side-chain
by an extra methylene moiety moves the phenol group further
away from the peptide backbone, which potentially influences the
aromatic π –π interaction and the hydroxyl hydrogen bonding
interactions between the receptor and the ligand in a positive
manner. [36homoTyr]-PYY3-36 (Table 3, peptide 1) lowered the
affinity more than 100-fold for the Y1 receptor, whereas only a
modest threefold drop in affinity to the Y2 receptor was observed.
These results could indicate steric restrictions in the Tyr-36 binding
pocket of the Y1 receptor, compared to the Y2 receptor. Other
explanations for the decreased Y1 receptor affinity could be due
to the side-chain of homo-Tyr having one more rotatable bond,
compared to Tyr, and hence the possibility that it binds to another
region of the Y1 receptor binding pocket.
The binding affinities of the Y-receptors were poorer when
the orientation of the side-chain of Tyr-36 was converted to the
corresponding D-analog. The binding affinity of [36D-Tyr]-PYY3-
36 (Table 3, peptide 2) to the Y2 receptor decreased sevenfold
and basically had no affinity to the Y1 receptor (>100-fold drop).
The relative Y2 receptor affinity corresponds to that of [36D-Tyr]-
NPY, [38] but [36D-Tyr]-PYY3-36 (Table 3, peptide 2) was far more
Table 3. PYY3-36a and [36X]-PYY3-36 binding to Y receptor subtypes Y1, Y2, and Y4, in addition to functional Y1 and Y2 receptor evaluation of the
most potent Y2R agonists
Binding assay Functional assay
Peptide 36X
Y1Rb
IC50 [nM]
Y2Rc
IC50 [nM]
Y4Rc
IC50 [nM]
Y1Rd
EC50 [nM]
Y2Rd
EC50 [nM]
PYY3-36 7.8 ± 1.1 0.50 ± 0.09 255 ± 29 135 ± 32 7.6 ± 1.6
1 homo-Tyr >1000 1.63 ± 0.44 >1000 >1000 51 ± 6.0
2 D-Tyr >1000 3.50 ± 0.15 >1000 n.d. 36 ± 13
3 p-fluoro-Phe >1000 0.76 ± 0.02 >1000 737 ± 30 12 ± 1.0
4 p-chloro-Phe 198 ± 14 1.79 ± 0.22 >1000 >1000 5.2 ± 1.6
5 p-bromo-Phe 350 ± 101 1.67 ± 0.06 >1000 >1000 5.4 ± 2.1
6 p-iodo-Phe >1000 1.65 ± 0.51 >1000 >1000 11 ± 4.0
7 p-nitro-Phe >1000 8.27 ± 2.85 >1000 n.d. 55 ± 4.0
8 p-amino-Phe 388 ± 175 0.96 ± 0.32 >1000 367 ± 98 11 ± 2.0
9 m-nitro-Tyr 246 ± 87 12.0 ± 5.9 >1000 n.d. 50 ± 11
a Native peptide.
b SK-N-MC cells expressing the Y1R.
c Y2R or Y4R transfected HEK293 Flp-In T-Rex cells.
d Y1R or Y2R and Gα6qi4myr transfected COS-7 cells.
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selective. The results above show that the position and orientation
of the aromatic side-chain relative to the peptide backbone is
very important for binding to the Y1 and Y4 receptors, but the Y2
receptor seems more tolerant of the conformational changes.
Replacing the hydroxyl group with electron-withdrawing
substituents at the para position of residue Phe-36 (Table 3,
peptides 3–7) resulted in a moderate to significant decrease
in the affinity to the Y1 receptor, in the affinity order Cl ≈ Br >
F ≈ I ≈ NO2, but only moderate decreases in the affinity to the
Y2 receptor, in the affinity order F ≈ Cl ≈ Br ≈ I  NO2. The
fact that the introduction of electron-withdrawing substituents in
the para position of Phe-36 negatively affects Y1 receptor binding
could be due to steric interactions in the active site as binding
affinity decreased with size of the substituents. As [36Phe(p-Cl)]-
PYY3-36 (Table 3, peptide 4), [36Phe(p-Br)]-PYY3-36 (Figure 1 and
Table 3, peptide 5) and [36Phe(p-I)]-PYY3-36 (Table 3, peptide 6)
all bound with nanomolar affinity to the Y2 receptor, and neither
chlorine, bromine nor iodine participates in hydrogen bonding,
shows that the interaction between residue 36 of PYY3-36 and the
Y2 receptor could be influenced by van der Waals forces and π –π
bonding. Interestingly, the fluorinated compound, [36Phe(p-F)]-
PYY3-36, both increased Y1/Y2 receptor selectivity and maintained
a high affinity to the Y2 receptor (Figure 1 and Table 3, peptide
3). Hydroxyl and fluorine share several properties, in particular
polarity. [40,41] Fluorine is not a sterically demanding substituent,
given its small van der Waals radius (1.35 Å) which resembles the
one of hydrogen (1.20 Å). [42] Fluorine cannot donate a hydrogen
bond but may rather, due to its electronegative properties,
accept them. [41] Finally, fluorine-containing compounds cause
the substituent to be more resistant to metabolic degradation,
because of the high carbon-fluorine bond energy. [42] The fact
that [36Phe(p-F)]-PYY3-36 (Figure 1 and Table 3, peptide 3) is a
good agonist for the Y2 receptor indicates that interactions with
the active site resembles that of PYY3-36.
Exchanging the hydroxyl group of Tyr-36 with an amine, such
as that found in [36Phe(p-NH2)]-PYY3-36 (Table 3, peptide 8),
resulted in sub-nanomolar affinity to the Y2 receptor. This amino
group is a hydroxyl isostere because the anilino amino group of
phenylalanine is not protonated at physiological pH. [36Phe(p-
NH2)]-PYY3-36 may introduce a minor steric disturbance, as the
amino group is slightly larger than the hydroxyl group and a
reduced affinity to the Y1 and Y4 receptor subtypes was observed
(Table 3, peptide 8).
None of the peptides in this series showed improved Y4 binding
or even an affinity comparable with that of the native PYY3-36. All
[36X]-PYY3-36 analogs resulted in poor Y4 affinities above 1000 nM.
The receptor sequence homology between the Y1 and Y4 receptor
is high (42%) but comparatively it is low between the Y1 and Y2
receptor (31%). [43] Thus, a loss in Y1 receptor affinity is also likely
to lead to a decrease in Y4 receptor affinity, which is indeed what
is observed (Table 3).
Structure–Activity Relationship
All the PYY3-36 analogs were investigated for Y2 receptor activity
and the most potent analogs were additionally tested for Y1
receptor activity (Figure 2 and Table 3). The decreases in affinity
observed in competition binding studies for the PYY3-36 analogs,
compared to the native PYY3-36, were also mirrored in the
functional assay for the Y2 receptor. Only [36homoTyr]-PYY3-
36 (Table 3, peptide 1) was slightly more affected in potency
compared to binding, as a sevenfold reduction in Y2 receptor
potency was observed compared to a threefold decrease in affinity.
This difference could be explained by a steric interference of homo-
Tyr with the conformational changes to the active state of the
receptor independent of the high affinity. [36homoTyr]-PYY3-36
shows a small drop in Y2 receptor activity, however, it also results
in a considerable reduction in Y1 receptor activity (Table 3, peptide
1), which confirms that the introduction of one more rotatable
bond increases the Y1/Y2 receptor selectivity considerably.
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Figure 1. Radioligand binding curves. The binding of PYY3-36, [36Phe(p-F)]-PYY3-36 (3) and [36Phe(p-Br)]-PYY3-36 (5) towards the Y1 () and Y2
() receptors.
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Figure 2. Functional assay. The activity of PYY3-36, [36Phe(p-F)]-PYY3-36 (3) and [36Phe(p-Br)]-PYY3-36 (5) towards the Y1 () and Y2 () receptors.
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[36D-Tyr]-PYY3-36 (Table 3, peptide 2), [36Phe(p-NO2)]-PYY3-36
(Table 3, peptide 7) and [36Tyr(m-NO2)]-PYY3-36 (Table 3, peptide
9) resulted in four- to sevenfold reduction in Y2 receptor activity,
as a result these analogs were not investigated for Y1 receptor
activity.
Functional data demonstrate that [36Phe(p-NH2)]-PYY3-36 was
slightly better accepted by the Y1 receptor than initially shown
by the binding assay. The potency of the anilino analog was
only modestly decreased for the Y1 receptor leading to a
small increase in Y1/Y2 receptor selectivity. The halogenated
compounds (Figure 2 and Table 3, peptide 3–6) as well as the
anilino analog (peptide 8, Table 3) gave Y2 receptor activities
equivalent to PYY3-36, which shows that the Y2 receptor was
fairly flexible towards substition in the para position of Phe-
36. The activity of the Y1 receptor appears to be intolerant to
even small changes in the para position of Phe-36, as shown by
the large drop in affinity for [36Phe(p-F)]-PYY3-36 with the small
4-fluoro substituent (Table 3, peptide 3). The functional activity
studies of the chlorine, bromine and iodine analogs (Figure 2,
Table 3, peptide 4–6) confirmed that hydrogen bonding was very
important in the ability to activate the Y1 receptor. All halogenated
PYY3-36 analogs were poor Y1 receptor activators and resulted in
major increases in Y1/Y2 receptor selectivity.
Conclusion
Previously, a significant number of PYY and NPY analogs have
been synthesized and analysed, however, the present results
show that novel compounds with Y receptor selectivity can be
developed by careful modifications of Tyr-36 in the pentapeptide
part of PYY3-36, which binds to the receptors. Selectivity was
improved using unnatural amino acid derivatives such as para
substituented phenylalanines. Analogs which were halogenated
as well as aminated in the para position of Phe-36 of PYY3-36
(3–6 and 8) maintained the high Y2 receptor potency shown by
native PYY3-36 and all the novel PYY3-36 compounds gave rise
to an increased Y1/Y2-receptor selectivity. Most profound were
the analogs where the Tyr-36 hydroxyl group was substituted
with a halogen (3–6), because of their major decreases in Y1
receptor potency, while maintaining an excellent Y2-receptor
affinity and activity. C-terminal Tyr modified PYY3-36 analogs with
sub-nanomolar affinity to the Y2 receptor and simultaneously
high Y1/Y2 receptor selectivity have not, to our knowledge, been
reported in literature. We believe the insights gained in this study
will be useful for the development of potential drug candidates
derived from PYY3-36 for the treatment of obesity.
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Glyco-scan: Varying glycosylation in the 
sequence of the peptide hormone PYY3-36 and 
its effect on receptor selectivity 
Søren L. Pedersen,[a,b] Catharina Steentoft,[a] Niels Vrang*[c] and Knud J. 
Jensen*[a] 
The increasing prevalence of obesity worldwide calls for safe and 
highly efficacious satiety drugs. PYY3-36 has been implicated in food 
intake regulation and novel peptide analogs with high Y2 receptor 
subtype selectivity and potency, have potential as drugs for the 
treatment of obesity. It has been hypothesized that PYY3-36 
associates with the plasma membrane prior to receptor activation 
such that the amphipathic α-helix of PYY3-36 possibly guides the 
C-terminal pentapeptide into the correct conformation for receptor 
activation. Ala-scans are used routinely to study the effect of 
individual amino acids in a given peptide sequence. Here we report 
the glyco-scan of the peptide hormone PYY3-36 in which hydroxyl 
side-chain functionalities were glycosylated; in addition new 
glycosylation sites were introduced. An array of novel PYY3-36 
analogs having a glycan positioned in the water-membrane interface 
or in the N-terminal were screened for Y receptor affinity and 
selectivity as well as metabolic stability. Interestingly, the Y2 receptor 
readily accommodated glycosylations in contrast to the Y1 and Y4 
receptors. Especially glycosylations in the α-helical region of PYY3-36 
were favorable both in terms of Y receptor selectivity and in terms of 
endopeptidase resistance. We thus report several PYY3-36 analogs 
with enhanced Y receptor selectivity. Our results can be used in the 
design of novel PYY analogs for the treatment of obesity. The glyco-
scan concept, as systematically demonstrated here, has the potential 
for a wider applicability. 
 
Introduction 
Peptide tyrosine tyrosine (PYY) is a member of the PP-fold family 
of peptides that also consists of pancreatic polypeptide (PP) and 
neuropeptide Y (NPY).1 The physiological actions of the PP-fold 
family of peptides occur through their activation on a group of 
G-protein coupled receptors (GPCR), the so-called Y receptors 
(Y1, Y2, Y4 and Y5), which belong to the rhodopsin-like 
superfamily (class A) of receptors.2 
PYY (PYY1-36) is secreted from the endocrine L-cell 
following the ingestion of a meal.3 Following secretion PYY1-36 is 
N-terminally cleaved by dipeptidyl peptidase IV (DPP-IV) to yield 
PYY3-36.4 The major blood-circulating form of PYY, PYY3-36, 
has a high affinity towards the Y2 receptor, and to a lesser extent 
the Y1 receptor.5 PYY1-36 and PYY3-36 exert several actions on 
gastrointestinal functions including inhibition of pancreatic 
exocrine secretion,6 inhibition of gastrointestinal motility,7 
inhibition of gastric acid secretion8 and stimulation of gallbladder 
contraction.9 Moreover, PYY3-36 reduces food intake.10-15 The 
anorectic properties of PYY3-36 has been proposed to be 
mediated by centrally located presynaptic Y2 receptors located in 
the hypothalamic arcuate nucleus.15 Activation of these Y2 
receptors would inhibit NPY release leading to a diminished 
feeding.15,16 It should be noted, however, that Y2 receptors are 
also expressed in several other brain areas including the caudal 
brainstem, areas that could play a role in PYY3-36 mediated 
appetite suppression.17 Several studies in both rats and mice 
using intraperitoneal11,12,18 or intravenous13,14 administration of 
PYY3-36 have shown acute reductions of food intake. Even 
though Tschop et al. questioned the initial findings,19 chronic 
administration of PYY3-36, in different animal models, has shown 
reductions in body-weight,12,13 supporting the initial findings by 
Batterham et al.15 that PYY3-36 is involved in appetite and weight 
control. A role of PYY3-36 in human appetite regulation is further  
supported by findings that 90 minutes infusion of PYY3-36 to lean 
or obese humans leads to significant 24-hour reductions in buffet 
intake.15,20 
Native PYY3-36 as a pharmaceutical drug candidate suffers 
from low selectivity and metabolic stability. The half-life of 
intravenous administrated PYY3-36 has been reported to be 13 
minutes in mouse21 and 19 minutes in rabbit,22 making 
metabolically stable and longer-acting analogs of PYY3-36 highly 
desirable. Several PEGylated versions of full-length and 
truncated PYY3-36 have shown half-lives that are enhanced up to 
24 hours. However, the increased metabolic stability of 
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PEGylation leads to significant decreases in receptor potency for 
all Y receptor subtypes and show only minor in vivo efficacy 
superiorities over PYY3-36.23 Longer-acting PYY3-36 analogs 
showing better Y2 receptor affinity and selectivity are therefore in 
demand.  
Peptides have previously been glycosylated to extend their 
half-lives, to improve solubility, to add specific recognition, etc.24 
Also, numerous peptides have been synthesized for studies on 
recognition, e.g. of mucin glycopeptides.25 Whereas Ala-scans 
are generally regarded as the gold standard to study the effect of 
individual amino acids in a peptide sequence only one very recent 
study26 used systematic variation of glycosylation in a peptide 
sequence for structure function studies. Here we introduce the 
concept of glyco-scan of a peptide. While in an Ala-scan all amino 
acids are substituted with the smallest chiral amino acid, Ala, a 
glyco-scan has wider potentials, including (i) introduction of 
different carbohydrates (glycans), (ii) glycosylation of side-chains 
as O-, N-, and C-glycosides, and (iii) glycosylation of either a 
native or a mutated amino acid. A peptide glyco-scan will allow 
the study of the effect of one or more of the following properties 
(i) improvement in solubility, (ii) protection against proteolytic 
cleavage (which can increase the half-life of the peptide and 
enhances the concentration at the pharmacological targets), (iii) 
modification of the clearance, (iv) binding to carbohydrate specific 
receptors, (v) alteration of the function (e.g. GPCR binding), and 
many more. A limitation in the application of the glyco-scan 
concept is that glycopeptides most often are only accessible by 
chemical synthesis, as current molecular biology allows only 
some control of N-glycosylation but not full control of location of 
O-glycosylation in a sequence. However, reliable protocols for the 
solid-phase synthesis of glycopeptides have been developed and 
a range of glycosylated amino acids are commercially available. 
Hence, a glyco-scan not only offers great possibilities for variation, 
but can also potentially address more parameters than an Ala-
scan. Given the large numbers of possibilities for glycosylation, 
we anticipate that a subset of structural possibilities will most 
often be addressed in the glyco-scan of a peptide.  
Here we report the application of the glyco-scan concept for 
the study of the peptide hormone PYY3-36 by the introduction of 
O-glycosides (Figure 1).  
Results and Discussion 
Starting from the hypothesis by Zerbe and co-workers27,28 that 
PYY3-36 binds to the membrane prior to receptor binding, we did 
not include side-chains from the hydrophobic face but chose 
amino acids from the hydrophilic side of the helix as well as from 
the N-terminal end. We included residues, such as Tyr, which 
could be located at the membrane-water interface and where the 
hydrophobic side of a monosaccharide could potentially interact 
with the membrane. Glycopeptides are believed to be able to 
enter the CNS by the glucose transporter (GLUT-1).29 C-linked, 
N-linked and α-O-linked sugar conjugates are not expected to 
promote transport since the glucose transporter is specific for β-
O-linked glucosides.29,30 Therefore β-O-linked glycosylated PYY3-
36 analogs have the potential of enhancing the CNS permeability 
and thereby increasing the agonist concentration at the 
hypothalamic Y2 receptors. As the C-terminal pentapeptide of 
PYY3-36 is highly important for Y receptor potency, no 
carbohydrates were incorporated into this section of the peptide 
hormone. Additionally, it has been shown that the α-helix of 
PYY3-36 is vital for Y receptor activation. It has been 
hypothesized that the α-helix is guiding the C-terminus into the 
correct conformation for receptor activation31 and that the 
amphipathic nature of the PP-fold peptides are leading to an 
association with the membrane prior to receptor activation.27,32 
The Tyr residues of the α-helix are likely to be located in the 
water-membrane interface and glycosylation of these residues 
could potentially stabilize the amphipathic α-helix of PYY3-36. 
Galactose itself can participate in van der Waals interactions and 
stacking with aromatic moieties, due to the orientation of 
hydroxyls in or above the pyranosyl 4C1 plane (Figure 1).33 Hence, 
galacto-PYY3-36 could lead to an enhanced amphipathic nature 
of PYY3-36. It has previously been hypothesized that the Y 
receptor selectivity could originate from at least two different 
lateral positions of the α-helix tube, when being docked into the 
active site of the Y receptor.34 Hence, pre-organizing the α-helix 
and the C-terminal pentapeptide, both when bound to the lipid 
bilayer and in the receptor, could disfavour one of the 
conformations and thereby increase Y receptor selectivity. Thus, 
the carbohydrate residues will function as a lateral support of the 
α-helix tube - like an outrigger canoe - preventing it from turning 
into the unfavoured conformation. Mutations of Tyr-20 and Tyr-27 
have been reported to destabilize back-folding in solution more 
than mutations at Tyr-21. The side-chains of Tyr-20 and Tyr-27 
are part of the hydrophobic core in the backfolded structure in the 
absence of membranes, however Tyr-21 also shows a major 
impact on backfolding.35 Thus, O-glycosylation of these Tyr side-
chains are likely to selectively destabilize the back-folded 
conformers in solution due to steric repulsion. This may also 
make these particular PYY3-36 glycoforms more susceptible to 
proteolytic degradation. 
Thus, PYY3-36 was glycosylated at the following Ser and Tyr 
side-chain hydroxyls: (i) The native Ser and Tyr in human PYY3-
36, (ii) position 18 that is Ser in porcine PYY3-36, (iii) residue 3 
(Ser) and 22 (Tyr) which were adapted from the NPY sequence, 
(iv) Gly-9 was mutated to Ser(β-D-Gal) (the only uncharged polar 
residue in the N-terminal of PYY3-36). This particular glyco-scan 
Figure 1. Illustration of the PYY3-36 glycosylation sites. Either β-D-Glc or β-D-Gal are O-linked to Ser (red) or Tyr (blue) residues positioned in the flexible N-
terminal or in the amphipathic α-helix.  
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of PYY3-36 thus called for the synthesis of 15 novel glycoforms of 
the peptide hormone. Given the possibility that PYY3-36 in 
pharmacological doses affecting appetite and food intake, also 
engage central orexigenic Y1 receptors and the poor metabolic 
stability of native PYY3-36, we aimed at developing more 
selective (Y2 over Y1) PYY3-36 analogs with the possible 
additive effect of enhanced metabolic stability. 
Peptide synthesis 
All peptides were prepared using the Fmoc/t-Bu strategy by 
automated solid-phase peptide synthesis on Rink Amide 
TentaGel resin (0.1 mmol scale). The Nα-Fmoc-protected amino 
acids were coupled using HBTU, HOBt and DIPEA as coupling 
reagents, in DMF, with coupling times of 45 minutes, except for 
the glycosylated Nα-Fmoc-protected Ser and Tyr 
pentafluorophenyl esters which were coupled using HOBt as 
auxilliary nucleophile in DMF for 2 hours. The glycosylated 
amino-acid derivatives; Nα-Fmoc-Ser(Bz4-β-D-Glc)-OPfp, Nα-
Fmoc-Ser(Ac4-β-D-Gal)-OPfp, Nα-Fmoc-Tyr(Bz4-β-D-Glc)-OPfp 
and Nα-Fmoc-Tyr(Ac4-β-D-Gal)-OPfp were synthesized according 
to the literature.36-38 The Fmoc group was removed using 
piperidine-DMF (1:4) for 3 + 12 minutes. After completion, the 
carbohydrates were deprotected on-resin using 1.0% NaOCH3 in 
MeOH (apparent pH 9.5) for 1 hour. Subsequently, the peptides 
were side-chain deprotected and simultaneously cleaved from the 
solid support using TFA-TES-H2O (95:2:3). Finally, the peptides 
were purified by preparative RP-HPLC, quantified by analytical 
RP-HPLC and characterized by mass spectrometry. The final 
products were obtained with >95% purity (Table 3). 
Circular dichroism.  
UV CD of PYY3-36 and peptide 1-15 (20 μM) in 10 mM 
phosphate buffer (pH 7.4) were obtained using a JASCO J-810 
circular dichroism spectrometer. The spectra acquired were 
typical for the α-helical structure, showing characteristic minima at 
208 nm and 222 nm (Figure 2). The results of PYY3-36 are in 
agreement with the literature.39 The degree of α-helicity of the 
glyco-peptides were between 23 and 41% (Table 1), except 
peptides 7 (Figure 2) and 12 which gave 47 and 15%, 
respectively (Table 1). Unexpectedly, the [Tyr(β-D-Glc)]-PYY3-36 
analogs (peptide 6 and 7) and to a lesser extent [Tyr(β-D-Gal)]-
PYY3-36 analogs (peptide 13-15) exhibited a higher degree of α-
helicity, indicating a stabilization of the α-helix (Table 1 and 
Figure 2). The introduced carbohydrates were well tolerated and 
did not, besides peptide 12, result in disruption of the secondary 
structure. Given that peptide 4 (28%) and 12 (15%) have 
significant differences in their degree of α-helicity, and that neither 
the gluco- nor galacto-PYY3-36 analogs lead to significant 
differences in Y receptor affinity, we conclude that in this 
particular case there is no correlation between the degree of α-
helicity and Y receptor affinity or selectivity (Table 1).  
Structure affinity relationship.  
The consequence of glycosylation of PYY3-36 for receptor 
binding was evaluated using a radioligand displacement assay 
(competition binding assay) based on membranes from SK-N-MC 
and HEK293 Flp-In T-Rex cell lines expressing the human Y1, Y2 
and Y4 receptor subtypes, respectively. 125I-[31Leu,34Pro]-pNPY 
for Y1 receptor, 125I-hPYY3-36 for Y2 receptor and 125I-hPP for Y4 
receptor were used as radioligands. Binding affinities (IC50 
values) for PYY3-36 and glycosylated PYY3-36 analogs (peptide 
1-15) are summarized in Table 1 and binding curves of PYY3-36 
and peptide 7 are given in Figure 3. 
In general, all the glycosylated PYY3-36 analogs only showed 
a slight (2-3 fold) decrease in Y2 receptor binding affinity. At 
position 3 an Ile was substituted with a glycosylated Ser (peptide 
1 and 8) leading to an increase in polarity of the PYY3-36 
N-terminal segment, however, the potency was only slightly 
affected and equivalent to the Ala-substitution.40 The N-terminally 
modified analogs (peptide 1, 2 and 8-10) generally showed 10-
fold decreases in Y1 receptor affinity, except [13S(β-D-Gal)]-PYY3-
36 which demonstrated a 20-fold drop in potency towards the Y1 
receptor. However, due to the concurrent loss of Y2 binding the 
Y2/Y1 receptor selectivity remained almost unchanged for these 
compounds. Interestingly, mutation of Gly-9 to Ser(β-D-Gal) gave 
only a small reduction in Y2 receptor affinity (Table 1, peptide 9) 
even though Gly in that position may be critical for forming the 
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PP-fold structure.35 The flexible Gly-9 residue has the ability to 
adopt certain backbone angles which is not possibly for other 
amino acids.  
All our analogs showed at least a twofold drop in binding 
affinity towards the Y4 receptor. Glycosylation of the N-terminus 
caused the most profound changes in Y4 receptor affinity and it 
can be hypothesized that this is due to a disturbance of a low 
affinity binding between the agonist and the N-terminal domain of 
the receptor prior to activation, 
similar to the interaction between 
PP and the N-terminal domain of 
the Y4 receptor.41 Changing the 
carbohydrate in a specific position 
only gave small variations in Y2 
receptor binding affinity, however, 
two analogs showed major 
changes towards the Y1 receptor: 
Peptide 5, [23S(β-D-Glc)]-PYY3-36, 
dropped almost 10-fold in affinity 
towards the Y1 receptor compared 
to peptide 12, [23S(β-D-Gal)]-
PYY3-36. No obvious pattern 
appears and the affinity variations 
are sequence and position specific. 
In other positions the Y1 receptor 
binding affinity demonstrates a 
decrease of the galactose (peptide 
11) over the glucose (peptide 4) 
substituents (4-fold).  
Glycosylation of the amphipathic α-helix of PYY3-36 gave the 
most interesting changes in affinity (Table 1 and Figure 3 and 4). 
The binding affinities towards the Y2 receptor were preserved, 
however, major changes in Y1 and Y4 receptor binding affinity 
was shown. As mentioned, all analogs with glycosylation in the 
helix were designed to place the glycan in the membrane-water 
interface or on the hydrophilic side (Figure 4). The observed 
Table 1. The binding affinity of PYY3-36 and the novel glyco-PYY3-36 analogs towards the Y receptor subtypes Y1, Y2, and Y4, respectively.  Moreover, the 
degree of α-helicity in solution is given in percent. Sequence of native PYY3-36: H-3IKPEAP9GEDA13SPEEL18NR20Y21Y22A23SLRH27YLNLVTRQRY-NH2. 
  Y1R[a] Y2R[b] Y4R[b] Selectivity α-helicity[d] 
Peptide  IC50 [nM] IC50 [nM] IC50 [nM] Y2/Y1 Rel. Y2/Y4 Rel. [%] 
PYY3-36  7.8 ± 1.1 0.50 ± 0.09 255 ± 29 0.064 1.0 0.0020 1.0 26 
1 [3S(β-D-Glc)]-PYY3-36 57 ± 18 1.53 ± 0.00 >1000 0.027 2.4 < 0.0015 > 1.3 39 
2 [13S(β-D-Glc)]-PYY3-36 44 ± 11 1.96 ± 0.37 >1000 0.045 1.4 < 0.0020 > 1.0 28 
3 [18S(β-D-Glc)]-PYY3-36 29 ± 10 0.83 ± 0.01 639 ± 89 0.029 2.2 0.0013 1.5 37 
4 [22S(β-D-Glc)]-PYY3-36 63 ± 18 1.03 ± 0.01 >1000 0.016 4.0 < 0.0010 > 2.0 28 
5 [23S(β-D-Glc)]-PYY3-36 76 ± 20 0.58 ± 0.14 456 ± 123 0.008 8.0 0.0013 1.5 28 
6 [20Y(β-D-Glc)]-PYY3-36 20 ± 4 0.83 ± 0.21 >1000 0.042 1.5 < 0.0008 > 2.5 41 
7 [21Y(β-D-Glc)]-PYY3-36 150 ± 44 0.84 ± 0.12 687 ± 104 0.006 10.7 0.0012 1.7 47 
8 [3S(β-D-Gal)]-PYY3-36 - 1.20 ± 0.01 >1000 - - < 0.0012 > 1.7 - 
9 [9S(β-D-Gal)]-PYY3-36 92 ± 15 1.03 ± 0.25 >1000 0.011 5.8 < 0.0010 > 2.0 25 
10 [13S(β-D-Gal)]-PYY3-36 168 ± 84[c] 1.44 ± 0.35 >1000 0.009 7.1 < 0.0014 > 1.4 31 
11 [22S(β-D-Gal)]-PYY3-36 238 ± 124[c] 0.91 ± 0.27 519 ± 80 0.004 16 0.0018 1.1 23 
12 [23S(β-D-Gal)]-PYY3-36 8.1 ± 0.5 1.14 ± 0.35 >1000 0.141 0.5 < 0.0011 > 1.8 15 
13 [20Y(β-D-Gal)]-PYY3-36 40 ± 23[c] 0.99 ± 0.19 >1000 0.024 2.7 < 0.0010 > 2.0 26 
14 [21Y(β-D-Gal)]-PYY3-36 70 ± 17 0.51 ± 0.01 714 ± 222 0.007 9.1 0.0007 2.8 34 
15 [27Y(β-D-Gal)]-PYY3-36 10 ± 2 0.72 ± 0.07 >1000 0.072 0.9 < 0.0007 > 2.8 31 
[a] SK-N-MC cells expressing the Y1 receptor. [b] Transfected Y2 or Y4 receptors in HEK293 Flp-In T-Rex cells. [c] S.E.M of –log IC50 was only below 0.2.   
[d] 10 mM NaH2PO4. 
Figure 4. Glycosylation of the α-helix tube of PYY3-36 and the relative Y2:Y1 receptor ratio. The highest selectivity 
originates from glycosylation of the Tyr-21 and Ser-22 on the same side of the amphipathic α-helix.
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increase in relative Y2/Y1 receptor selectivity ratio for novel 
analogs having a glycan in the α-helix of PYY3-36 originates from 
a decrease in Y1 receptor potency. One exception was [23S(β-D-
Gal)]-PYY3-36 (peptide 12) which was equipotent towards the Y1 
receptor compared to PYY3-36. None, or minor decreases in Y1 
receptor affinity was observed for peptide 6, 12 and 15, however, 
significant drops in Y1 receptor affinity was observed for peptide 
4, 7, 11 and 14 (Table 1 and Figure 3). 
The latter were all positioned at the same side of the α-helix 
(Figure 4), thus we speculate that the glycan may guide a 
movement of the α-helical tube leading to a more or less 
favourable conformation for Y1 receptor binding. Menten et al. 
have previously hypothesized two different orientations of the 
α-helix in the Y2/Y5 and Y1/Y4 receptor subtypes for NPY and 
PP.34 Beck-Sickinger et al. reported that residue Asp6.59 of the Y2 
receptor primarily interacts with Arg-33 of NPY and Asp6.59 of the 
Y1 and Y4 receptors interacts with Arg-35 of NPY.34 Addition of a 
glycan may more or less prevent the α-helix tube to be turned into 
a conformation where Arg-35 of PYY3-36 and Asp6.59 of Y1 
receptor can interact. Another possibility is steric interaction 
between the carbohydrate and the Y1 and Y4 receptors, in 
contrast to the Y2 receptor which may be more receptive to bulky 
substituents in that region.  Peptide 7, [21Y(β-D-Glc)]-PYY3-36, 
and peptide 11, [22S(β-D-Gal)]-PYY3-36, were the glyco-PYY3-36 
analogs giving the highest Y2 receptor selectivity (19 and 38 fold 
increase) and potency (below a twofold decrease) (Table 1, 
Figure 3 and 4).  
Stability studies. 
Several studies have shown that glycosylation could reduce the 
susceptibility of a peptide to proteolytic digestion and result in 
extended peptide activity.26,29,42 The metabolic stability of native 
PYY3-36 and glycosylated analogs were evaluated by testing 
their resistance against trypsin and proteinase K catalyzed 
digestion. Monitoring by RP-HPLC analysis during the incubation 
time showed that in the presence of trypsin or proteinase K, 
PYY3-36 was gradually digested and the half-life of PYY3-36, 
was 233 and 196 minutes, respectively (Table 3). Degradation 
curves were performed to all the glycosylated PYY3-36 analogs, 
except peptide 6, 8, 11 and 15.  
Trypsin catalyzed cleavage of glycosylated PYY3-36 analogs 
generally demonstrated equivalent or reduced degradation half-
lives compared to PYY3-36. However, peptide 7, [21Y(β-D-Glc)]-
PYY3-36, demonstrated an increase in stability towards trypsin 
(Table 2). Trypsin is a serine protease and predominantly 
cleaves at the carboxyl side of Lys and Arg, except when either 
is followed by proline. Residue Tyr-21 is positioned at the 
carboxyl side of Arg-20 and glycosylation of Tyr-21 could 
therefore prevent trypsin from cleaving at this position leading to 
the observed changes in half-life.  
Proteinase K (endopeptidase K) is a promiscuous serine 
proteinase predominantly cleaving at the carboxyl side of 
aliphatic and aromatic amino acids with blocked α-amino groups. 
Peptide 5 and 7 showed increases in stability towards proteinase 
K (Table 2), which further confirms that glycosylation of Tyr-21 
can prohibit certain types of endopeptidases from cleaving, 
hence increasing the half-life of the glycopeptide. 
Mouse serum degradation of the glyco-peptides and native 
PYY3-36 showed no significant differences during incubation 
Table 2. Trypsin and proteinase K catalyzed cleavage studies, as well as 
metabolic digestion in mouse serum of native and glycosylated PYY3-36. 
 Trypsin[a] Proteinase K[b] Mouse serum[c] 
Peptide Half life  
[min] 
Half life  
[min] 
Undigested peptide  
after 300 min [%] 
PYY3-36 233 196 69 
1 176 168 73 
2 153 214 69 
3 188 206 69 
4 168 151 73 
5 176 271 63 
7 269 231 66 
9 217 171 54 
10 154 200 64 
12 - 150 - 
13 197 188 - 
14 225 210 - 
[a] 12.5 M peptide and 625 ng mL-1 trypsin in 0.1 M NH4HCO3 at RT. [b] 12.5 M 
peptide and 313 ng mL-1 proteinase K in 3.0 mM CaCl2 at RT. [c] Water-mouse 
serum (40:1) at 37°C. 
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Figure 5. Peptide metabolism in diluted mouse serum. LC-MS analysis of the 
initial crude mixture of PYY3-36 (A) and after 300 min incubation (B), as well as 
glyco-peptide 7 after 0 min (C) and 300 min (D) incubation. Serum to peptide 
(107 μM) ratio 1:40. After 300 min incubation both PYY3-36 and peptide 7 were 
metabolized to Des Arg35-Tyr36 (peptide 16 and 18) and Des Arg33-Gln-Arg-
Tyr36 (peptide 17 and 19).   
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after 30, 60, 180 (not shown), and 300 min (Table 2) at 37°C. 
Native PYY3-36 was primarily digested by carboxy-peptidases 
cleaving at the amino side of Arg-33, to give peptide 16, and Arg-
35, to give peptide 17 (Figure 5). Glycosylation of Tyr-21 did not 
increase the half-life of peptide 7 in mouse serum and gave the 
same degradation pattern as for PYY3-36 (Figure 5). Identical 
half-lives were observed for all the novel glyco-PYY3-36 analogs 
(Table 2). Even though the glyco-scan did not provide a PYY3-36 
analog with a significantly longer half-life in serum the results 
from trypsin and proteinase K digestion studies show that 
glycosylation may prevent endopeptidases, located in different 
tissues, from digesting glyco-PYY3-36 analogs in vivo. Medeiros 
and Turner have reported that PYY is indeed metabolized by 
endopeptidases in human kidney and jejunum.43  
Conclusion 
In conclusion, we have introduced the concept of a glyco-scan of 
a peptide. Using glycosylation of human PYY3-36 at selective 
positions peptide sequence, which have different roles in peptide-
receptor interaction we show that (i) glycosylation in most 
positions is relatively well tolerated with regard to Y2 receptor 
binding, (ii) the glyco-scan provided novel PYY3-36 analogs with 
improved Y2/Y1 selectivity, and (iii) the introduction of 
monosaccharides in this system did not increase metabolic 
stability. We report that especially glycosylation of Tyr-21, located 
in the amphipathic α-helix of PYY3-36, leads to enhanced Y2 
receptor selectivity originating from a reduced affinity towards the 
Y1 receptor. We have recently reported C-terminal modified 
PYY3-36 analogs with sub-nanomolar affinity to the Y2 receptor 
and simultaneously high relative Y2/Y1 receptor ratio.44 We 
believe that insights gained in this study will be useful for the 
development of potential drug candidates derived from PYY3-36. 
The glyco-scan concept, as systematically demonstrated here, 
has the potential for wider applicability in peptide biochemistry 
and in peptide drug design.  
Experimental Section 
Materials. The organic solvents and reagents for peptide synthesis 
were all of analytical reagent grade and were obtained from Iris 
Biotech GmbH (Germany), except for DMF which was obtained from 
Sigma Aldrich (Denmark). TentaGel S Rink Amide resin was obtained 
from Novabiochem or Rapp Polymere GmbH. Milli-Q (Millipore) water 
was used for RP-HPLC analyses and purifications. Human Embryonic 
Kidney 293 cells (HEK293 Flp-In T-Rex), and pcDNA3.1 vector were 
purchased from Invitrogen. Dulbecco’s Modified Eagle’s Medium (D-
MEM), fetal calf serum, penicillin-streptomycin solution, phosphate 
buffered saline (PBS), sucrose, and 99% glycerol were all obtained 
from Sigma-Aldrich. FuGENE6 transfection reagent, complete 
protease inhibitor cocktail tablets and bovine serum albumin (BSA) 
were purchased from Roche. 2-Amino-2-hydroxymethyl-propane-1,3-
diol (TRIS), MgCl2·6H2O, CaCl2, and NaCl were obtained from 
AppliChem GmbH. (2S,3S)-1,4-bis-sulfanylbutane-2,3-diol (DTT) was 
obtained from GE Healthcare and radioactive labeled agonists were 
purchased from Phoenix pharmaceuticals. 96-Well filtration 
MultiScreen HTS, DV plates were obtained from Millipore.  
Circular dichroism. UV CD spectra were recorded on a JASCO J-
810 circular dichroism spectrometer using rectangular Hellma quartz 
cells with a light path of 1 mm. The peptide solutions were 
approximately 20 μM in 10 mM NaH2PO4, pH 7.4. The absolute 
concentration was determined spectroscopically (tyrosine absorption 
at 274 nm, using ε = 1420 cm−1M−1). The mean residue ellipticity 
(MRE) was calculated according to Yang and co-workers.45 The 
number n refers to the number of residues. The helicity was 
calculated according to a formula by Yang and co-workers.45  
Peptide synthesis. The peptides were prepared by automated 
peptide synthesis on a Syro II peptide synthesizer (MultiSynTech) by 
standard solid-phase peptide synthesis (SPPS) on TentaGel S Rink 
Amide resin (0.24 mmol/g) with 9-fluorenylmethyloxycarbonyl (Fmoc) 
for protection of Nα-amino groups. Side-chain protecting groups were 
tert-butyl (Glu, Asp, Ser, Thr, Tyr), 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), and trityl (Trt, for Asn, Gln, 
His). Nα-Fmoc-Ser(Bz4-β-D-Glc)-OPfp, Nα-Fmoc-Ser(Ac4-β-D-Gal)-
OPfp were synthesized according to procedures reported by Meldal 
and Jensen,37 as well as Sjölin and Kihlberg,38 moreover Nα-Fmoc-
Tyr(Bz4-β-D-Glc)-OPfp, Nα-Fmoc-Tyr(Ac4-β-D-Gal)-OPfp were 
synthesized according to procedures reported by Jensen et al.36 The 
peptides syntheses were conducted in 0.1 mmol scale. Nα-Fmoc 
amino acids (4.0 equiv) were coupled using N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide HBTU (3.8 equiv), 1-
hydroxybenzotriazole (HOBt) (3.6 equiv), 1-hydroxy-7-
azabenzotriazole (HOAt) (0.4 equiv) and N,N-diisopropylethylamine 
(DIEA) (7.8 equiv) as coupling reagents in DMF for 45 min. However, 
the glycosylated amino acid derivatives (2.0 equiv) were coupled 
using HOAt (2.0 equiv) as coupling reagent in DMF for 120 min. D-
glucose was either β-O-glycosidically linked to Ser (residue 3, 13, 18, 
22 or 23) or Tyr (residue 20 or 21), furthermore D-galactose was 
either β-O-glycosidically linked to Ser (residue 3, 9, 13, 22 or 23) or 
Tyr (20, 21 or 27). Nα-Fmoc deprotection was performed using 
piperidine-DMF (2:3) for 3 min, followed by piperidine-DMF (1:4) for 
12 min. The carbohydrates were deprotected on-resin using 1.0% 
NaOCH3 in anhydrous methanol (pH 9.5) for 1 hour. The glyco-
peptide were released from the solid support by treatment of 
Table 3. LC-MS data of PYY3-36 and peptide 1-15. 
 ESI-MS (m/z)[a] Purity[b] 
Peptide Calcd. MS Found, [M+4H]4+ [%] 
PYY3-36 4049.5 1012.8 98 
1 4185.5 1046.6 100 
2 4211.6 1053.7 95 
3 4184.6 1047.0 100 
4 4227.6 1057.3 100 
5 4211.6 1053.5 99 
6 4211.6 1053.3 99 
7 4211.6 1053.3 96 
8 4185.5 1046.9 100 
9 4241.6 1061.1 100 
10 4211.6 1053.3 98 
11 4227.6 1057.1 100 
12 4211.6 1053.4 96 
13 4211.6 1053.3 95 
14 4211.6 1053.3 100 
15 4211.6 1053.8 100 
[a] Identified by ESI-MS on a MSQ Plus Mass Spectrometer, Thermo.  
[b] Quantified by RP-HPLC at 215 nm. Eluent A: 0.1% TFA in H2O. Eluent 
B: 0.1% TFA in AcN. 
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trifluoroacetic acid (TFA)-triethylsilane (TES)-H2O (95:2:3) for 2 hours. 
The TFA solutions were concentrated by nitrogen flow and the 
compounds were precipitated with diethylether to yield the crude 
materials as white powders. Purification was accomplished by 
preparative RP-HPLC (Dionex Ultimate 3000 system) on a 
preparative column (FeF Chemicals, 300 Å 5 μm C4 particles, 
2.1×200 mm) followed by a second purification on a preparative C18 
column (FeF Chemicals, 200 Å 10 μm C18 particles, 2.1×200 mm) 
using the following solvent system: solvent A, water containing 0.1%  
TFA; solvent B, acetonitrile containing 0.1% TFA. B gradient elution 
(0-50 min: 10% to 60%) was applied at a flow rate of 10 mL min-1 and 
column effluent was monitored by UV absorbance at 215 and 254 nm 
simultaneously. Identification was carried out by ESI-MS (MSQ Plus 
Mass Spectrometer, Thermo). The peptides were quantified by 
analytical HPLC (Dionex Ultimate 3000 system equipped with a PDA 
UV detector) using the eluent system A-B (solvent A, water containing 
0.1% TFA; solvent B, acetonitrile containing 0.1% TFA). Eluent 
system A-B was applied on a C4 analytical column (phenomenex, 
Jupiter, 300 Å 5 μm C4 particles, 3.9×150 mm) where a B gradient 
elution (0-14 min: 5% to 100%) was applied at a flow rate of 1.0 mL 
min-1. Quantification and characterization data are given in Table 3.   
Radioligand displacement assay. Cell culture and receptor 
expression: The SK-N-MC cells were cultured in a 1:1 mix of HAM 
F12 and Dulbecco’s Modified Eagle’s Medium (D-MEM 1885), 
containing 15% (v/v) fetal calf serum (FCS), 1% non essential amino 
acids and 1% (v/v) penicillin-streptomycin in humidified atmosphere of 
5% carbon dioxide and 95% air, at 37°C. The human embryonic 
kidney (HEK293 Flp-In T-Rex) derived cell line was cultured in 
Dulbecco’s Modified Eagle’s Medium (D-MEM), containing 10% (v/v) 
fetal calf serum (FCS) and 1% (v/v) penicillin-streptomycin. Cells were 
grown as monolayers in humidified atmosphere of 5% carbon dioxide 
and 95% air, for 48 hours at 37°C. Using serum-free D-MEM and 
FuGENE6 transfection reagent HEK293 Flp-In T-Rex cells were 
transiently transfected by pcDNA3.1 vectors which encode either the 
human Y2 or Y4 receptor (FuGENE6-pcDNA3.1, 3:1). The 
transfected HEK293 Flp-In T-Rex cells were set to express the 
receptors in humidified atmosphere of 5% carbon dioxide and 95% air, 
for another 48 hours at 37°C.  
Preparation of membrane fractions: The SK-N-MC and the transiently 
transfected HEK293 Flp-In T-Rex cells were washed with phosphate 
buffered saline (PBS) and homogenized in cold homogenization 
buffer (50 mM Tris (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, 1.0 mM 
DTT, complete protease inhibitor cocktail (one tablet per 50 mL 
buffer)). An equal amount of 0.6 M sucrose was added to the cell 
mixture. The homogenate was centrifuged (10,000 g, 10 min at 4°C). 
Cell pellets were washed in washing buffer (50 mM TRIS (pH 7.5), 2.5 
mM MgCl2, 1.0 mM CaCl2, complete protease inhibitor cocktail (one 
tablet per 50 mL buffer), 1.0% (w/w) BSA fraction V), and 
subsequently the suspensions were centrifuged (10,000 g, 10 min at 
4°C). The pellets were re-suspended in glycerol containing binding 
buffer (50 mM TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, complete 
protease inhibitor cocktail (one tablet per 50 mL buffer), 1.0% (w/w) 
BSA fraction V, 20% (v/v) glycerol) and concentration was adjusted to 
an OD600 of 1.6.   
Binding affinity: All binding experiments were performed in 96-well 
filtration MultiScreen HTS, DV plates at room temperature and every 
concentration point was performed as triplicates. The unlabeled 
peptide (25 μL) at concentrations between 10 pM and 10 μM, cell 
membrane suspension (3.5 µL), binding buffer (61.5 µL, 50 mM TRIS, 
pH 7.5, 2.5 mM MgCl2, 1.0 mM CaCl2, complete protease inhibitor 
cocktail (one tablet per 50 mL buffer), 1.0% (w/w) BSA fraction V)), 
radioligand solution (10 µL; Y1R: 125I-[31Leu,34Pro]-pNPY; Y2R: 125I-
PYY3-36; and Y4R: 125I-PP; specific activity of 800-1000 Ci/mmole). 
After 1-2 hours of incubation the assay was terminated by filtration. 
Finally, the membrane-receptor-ligand complexes were washed twice 
in cold TRIS buffer (50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM 
CaCl2). Bound radioactivity was determined as counts per minute 
(Wallac 1470 WizardTM Automated Gamma Counter). Binding data 
were analyzed with GraphPad Prism 5.0 (GraphPad Software, Inc. 
San Diego, CA, USA). The displacement experiments were replicated 
until the standard error of mean (S.E.M.) of –log IC50 was below 0.1 (n 
= 2-5), except when otherwise stated. 
Trypsin and protease K catalyzed cleavage. PYY3-36 and the 
glycosylated analogs were dissolved in 175 μL protease free water to 
a final peptide concentration of 50 μM. Trypsin; to the peptide solution 
20 μL of 1.0 M NH4HCO3 and 5 μL of 25 μg mL-1 trypsin (Sigma 
Aldrich) was added. Protease K; to the peptide solution 20 μL of 30 
mM CaCl2 and 5 μL of 12.5 μg mL-1 protease K (Sigma Aldrich) was 
added. Samples (25 μL) were directly injected into the HPLC for every 
75 min over a period of 6 hours. The half-life was established based 
on the assumption of first order catalysis. The percentage of digested 
peptide was monitored by RP-HPLC (Dionex Ultimate P580 pump 
equipped with a Waters 996 PDA UV detector and 717 autosampler) 
using eluent system C-D (solvent C, water containing 0.1% TFA; 
solvent D, MeOH containing 0.1% TFA) applied on a C18 analytical 
column (phenomenex, Gemini, 110 Å 3 μm C18 particles, 4.60×50 
mm) where a C gradient elution (0-14 min: 5-100%) was applied at a 
flow rate of 1.0 mL min-1. 
In vitro metabolism of PYY3-36 and the glycosylated analogs in 
mouse serum. PYY3-36 and the glycosylated analogs were 
dissolved in 195 μL protease free water to a final peptide 
concentration of 107 μM. To the peptide solution 5 μL of freshly 
prepared mouse serum (male NMRI mice) was added. After 
incubation at 37°C for 0, 30, 60, 180, and 300 min 20 μL of diluted 
serum deproteinated with 60 μL of ethanol. After centrifugation 
(14,000 rpm, 4°C, 15 min) the supernatant was analyzed by LC-MS 
(Dionex Ultimate 3000 system equipped with a PDA UV detector, 
MSQ Plus Mass Spectrometer, Thermo) using eluent system A-B 
(solvent A, water containing 0.1% TFA; solvent B, acetonitrile 
containing 0.1% TFA) applied on a C18 analytical column 
(phenomenex, Gemini, 110 Å 3 μm C18 particles, 4.60×50 mm) 
where an A gradient elution (0-12 min: 5-100%) was applied at a flow 
rate of 1.0 mL min-1.  
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The prevalence of obesity is increasing with an alarming rate worldwide and there is a need for 
efficacious satiety drugs. PYY3-36 has been shown to play a role in hypothalamic appetite 10 
regulation and novel analogs targeting the Y2 receptor have potential as drugs for the treatment of 
obesity. We have designed a new series of PYY3-36 analogs, by introducing different N-terminal 
segments of PYY as a branch at position 12 of the native sequence. We hypothesized that such 
modifications would alter the back-folding of PYY, due to changes in the turn motif, which could 
change the binding mode to the Y receptor subtypes and possibly also alter metabolic stability. In 15 
structure-affinity/activity relationship experiments one series of PYY isoforms displayed 
equipotency towards the Y receptors. However, an increased Y2 receptor potency for the second 
series of PYY isoforms resulted in enhanced Y receptor selectivity compared to PYY3-36. 
Additionally, acute as well as chronic mice studies showed body-weight lowering effects for one of 
the PYY isoforms, which was also reflected in a reduction of circulating leptin levels. 20 
Interestingly, while the stability and pharmacokinetic profile of PYY3-36 and the N-terminally 
modified PYY3-36 analog were identical, only mice treated with the branched analog showed 
marked increases in adiponectin levels as well as reductions in non-esterified free fatty acids and 
triglycerides. 
Introduction 25 
The native Y2 receptor agonist PYY3-36 plays a role in 
appetite regulation and Y2 receptor agonists are potentially a 
novel class of compounds for the treatment of obesity.1 Indeed 
a number of studies in rodents have shown that chronic Y2 
agonism lowers body-weight.2-4 30 
 PYY is a member of the PP-fold family of peptides that 
also consist of pancreatic polypeptide (PP) and neuropeptide 
Y (NPY).5 The PP-fold peptides bind and activate a family of 
G-protein coupled receptors, the so-called Y receptors (Y1, 
Y2, Y4 and Y5).6 Full length PYY is released postprandially 35 
from endocrine L-cells lining the gut7 and subsequent to 
secretion PYY1-36 is N-terminally truncated by dipeptidyl 
peptidase IV (DPP-IV) to produce PYY3-36.8,9 PYY1-36 is a 
powerful but nonselective agonist stimulating both the 
Y1 and Y2  receptors,6,10 leading to numerous actions 40 
especially on the gastrointestinal function.11 The 
N-terminally truncated form of PYY1-36 - PYY3-36 -  
has a high affinity towards the Y2 receptor, and to a 
lesser extent the Y1 receptor.10 Moreover, the anorectic 
and body-weight lowering effects of peripherally 45 
administered PYY3-36 is believed to be mediated by 
central Y2 receptors, possibly located in the 
hypothalamic arcuate nucleus.1  
 Herein, we present data from a novel class of PYY 
isoforms, which displays changes in the selectivity 50 
towards the Y receptors, body-weight lowering effects in 
different mice models, and finally additional beneficial effects 
on circulating lipids as well as on fat-cell metabolism. While 
the body-weight lowering effects of PYY3-36 and a PYY3-36 
isoform (peptide 4) was similar, unexpectedly, 14-days 55 
infusion of peptide 4 to DIO-mice lead to significantly higher 
adiponectin levels compared to PYY3-36, which is an 
additional beneficial effects on fat cell metabolism. 
 
Peptide design.  60 
The sequences of the PP-fold peptides consist of a C-terminal 
receptor-recognizing segment, an amphipathic α-helix and a 
more flexible N-terminus. It has been hypothesized that all 
members of the PP-fold family of peptides bind to the 
membrane prior to interaction with the receptors.12 The 65 
Table 1. Sequences of human NPY, PP, PYY1-36, PYY3-36, as well as main 
chain of the PYY isoforms. 
Peptide Sequence 
PP H-APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
NPY H-YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
PYY1-36 H-YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
PYY3-36 H-IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
Isoformsa     H-IKSPEELNRYYASLRHYLNLVTRQRY-NH2 
a Novel analogs: N-terminal sequences branches from the ε-amine of an 
additional Lys (bold) positioned at the amino end of PYY13-36. 
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N-terminal segments (residue 1-12) have proven very 
important for the Y receptor selectivity and essential for Y1 
receptor activity, which has been shown by N-terminally 
truncating both PYY1-36 and NPY.13,14 Pro-14 of the turn 
motif of PYY1-36 is highly important for controlling back-5 
folding in solution; moving Pro-14 to position 13, as seen in 
the NPY sequence, abolishes all hairpin structure.15 
Consequently, the [13Pro,14Ala]-PYY1-36 mutant shows a 
destabilized C-terminal α-helix.15 Moreover, Ser-14 has also 
been shown to be important for PYY1-36 back-folding in 10 
solution.15 Given the importance of the turn motif of PYY for 
back-folding and α-helix stability, we designed two series of 
branched PYY analogs: Series 1 were branched at an ε amine 
of an additional Lys positioned before Ser-13 of the native 
sequence. This additional N-terminal amine (Ile N) near the 15 
native PYY α-helix provides an additional positive charge. In 
series 2 - which were branched similarly to series 1 - we 
replaced the inherent turn motif of PYY with a GPRRP turn to 
guide the branch into a favorable Y2 receptor binding 
conformation via a tighter back-folding, consequently altering 20 
the binding mode towards the Y receptors or increasing the 
affinity towards the membrane, which possibly leads to an 
enhanced concentration of ligand in the vicinity of the Y 
receptors. 
Results and discussion. 25 
Peptide synthesis.  
Human PYY1-36, PYY3-36 and the PYY isoforms were 
assembled using the Fmoc/t-Bu strategy by automated solid-
phase peptide synthesis on Rink Amide TentaGel resin. The 
Nα-Fmoc-protected amino acids were coupled using DIC and 30 
HOBt as coupling reagent and additive, in DMF, with 
coupling times of 2 hours. The Fmoc group was removed 
using 1:4 piperidine-DMF, for 3 + 17 min. The sequences of 
PYY1-36, PYY3-36 and PYY13-36 were assembled using 
standard Fmoc/t-Bu chemistry as described above. The 35 
sequence of the resin-bound PYY13-36 was additionally 
modified by coupling of the Dde (1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethyl) side-chain protected Lys 
followed by Fmoc removal and coupling of a Nα-Boc-
protected Ile (Scheme 1). The Dde group was removed by 2.5 40 
% (v/v) hydrazine hydrate in DMF making the ε-amino group 
available for elongation of the peptide branch (Scheme 1, a-
d), which additionally was performed by standard Fmoc/t-Bu 
chemistry. 
 Series 1 maintained the turn motif from native PYY 45 
(PYY9-12, GEDA), however series 2 the turn motif (Xa-Xb, 
Scheme 1) was exchanged with the less flexible GPRRP turn 
(adapted from helix-loop-helix structures originally designed 
by Degrado et al.).16 The branched N-terminal segments 
(Xc-Xd, Scheme 1), either originated from PYY1-8, PYY2-8, 50 
or PYY3-8 and the branched N-terminus was either free amine 
or lipidated (R1, Scheme 1). After completion, the peptides 
were side-chain deprotected and simultaneously cleaved from 
the solid support using reagent K. Finally, the peptides were 
purified by preparative RP-HPLC, quantified by analytical 55 
RP-HPLC and characterized by mass spectrometry. The final 
products were obtained with > 95 % purity (Table 5).  
 
Circular dichroism. 
The secondary structures of PYY1-36, PYY3-36, and peptides 60 
1-7 in solution were assessed by circular dichroism (CD) in 10 
mM phosphate buffer. The spectra obtained were typical for 
the α-helical structure, showing characteristic minima at 208 
nm and 220 nm (Figure 1). The degree of α-helicity of the 
analyzed PYY analogs were between 22 and 29%, furthermore 65 
PYY1-36 and PYY3-36 had an α-helicity of 27 and 26%, 
respectively, which shows that the branch was well tolerated 
and did not disturb the overall secondary structure of the 
inherent α-helix. 
In vitro pharmacology. 70 
To characterize the influence of the alteration of secondary 
structure of the PYY isoforms, both the novel and inherent 
ligands were assayed by radioligand displacement binding 
assay (competition assay) based on membranes from SK-N-
MC and HEK293 Flp-In T-Rex cell lines expressing the 75 
human Y1, Y2 and Y4 receptor subtypes, respectively. 
125I-[31Leu,34Pro]-pNPY for Y1R, 125I-hPYY3-36 for Y2R and 
125I-hPP for Y4R were used as radioligands. The non-lipidated 
analogs were additionally evaluated for activity in a signal 
transduction assay (functional assay). Peptide 1, branched 80 
version of PYY1-36, showed higher Y2 receptor affinity and 
 HNFmoc
Automated SPPS
NH
O
1) Piperidine-DMF (1:4)
2) Fmoc-Lys(Dde)-OH, DIC, HOBt
3) Piperidine-DMF (1:4)
4) Boc-Ile-OH, DIC, HOBt
Fmoc-S13PEELNRYYASLRHYLNLV31TRQRY36
NH
O
Boc-IKS13PEELNRYYASLRHYLNLV31TRQRY36
Dde
1) 2.5% hydrazin hydrate-DMF
2) Fmoc-Aaa-OH, DIC, HOBt
Automated SPPS
NH
O
Boc-IKS13PEELNRYYASLRHYLNLV31TRQRY36
Reagent K
R1-Xd--------------XcXb---Xa
NH2H-IKS13PEELNRYYASLRHYLNLV31TRQRY36
R1-Xd--------------XcXb---Xa
Scheme 1. Reaction scheme describing the solid-phase synthesis of the 
PYY isoforms. Underlined sequences represent the inherent α-helical 
segment. Residues Xa-Xb shows the position of the turn motifs and 
residues Xc-Xd illustrates the position of the branched N-terminal 
segments derived from the native PYY sequence. R1 represents 
modifications to the branched Nα-amino group of the PYY isoforms. 
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better selectivity compared to PYY1-36 - a fourfold increase 
in Y2 receptor affinity and an almost threefold drop in Y1 
receptor affinity compared to PYY1-36 and equal affinity 
compared to PYY3-36 – however, the signal transduction 
assay only show equipotency towards the Y2 receptor (Table 5 
2, entry 1). Nevertheless, it is very interesting that branching 
of full length PYY1-36 can lead to an analog performing 
approximately as native PYY3-36 towards the Y2 receptor. 
The lipidated analog (peptide 2) resulted in decreased 
(3.5-fold) Y1 receptor affinity compared to PYY3-36 but also 10 
an inauspicious threefold decrease in Y2 receptor affinity. 
However, compared to PYY1-36 peptide 2 showed a 2.5-fold 
improvement in Y2 receptor affinity and a 9-fold decrease in 
affinity towards the Y1 receptor (Table 2, entry 2). Moreover, 
peptide 2 also results in a drop in Y4 receptor affinity. Peptide 15 
3 (the branched version of PYY2-36) had a Y receptor binding 
profile very similar to PYY3-36, as did peptide 4 (branched 
version of PYY3-36). Although binding showed peptide 4 to 
have a higher selectivity (Y2/Y1) than native PYY3-36, the 
functional assay only gave a marginal increase in selectivity 20 
(Table 2, entry 4). The affinities towards the Y4 receptor were 
unaffected for all the novel analogs except peptides 2 and 4, 
which gave a twofold decrease in binding. 
 The second series of PYY analogs (containing the GPRRP 
modified turn motif)  were able to displace the Y2 receptor 25 
selective radioligand 125I-hPYY3-36 with high affinity and 3- 
(peptide 5) and 2.5-fold (peptide 6) improvement in IC50 value 
was observed compared to the native peptide. These affinities 
correspond well with the potencies observed in the functional 
characterization. Surprisingly, these two peptides displaced 30 
the Y1 selective radioligand 125I-[31Leu,34Pro]-pNPY with 
very low apparent affinity – the IC50 was shifted 50- and 
12-fold respectively for peptides 5 and 6, compared to the 
native peptide. However, the potencies obtained from the 
functional study show that these peptides actually activated 35 
the Y2 receptor with a high potency. The peptide 5 displayed 
a 5-fold improved potency compared to the native peptide 
(PYY3-36) and peptide 6 showed 8-fold improved potency 
compared to PYY3-36. The explanation for this discrepancy 
between apparent affinity observed in competition binding 40 
studies and the potency observed in functional 
characterization is most likely related to the fact that a 
heterologous competition binding study has been used. In 
heterologous competition studies the radioligand differ 
chemically from the investigated ligand, which allow the 45 
radioligand to trap the receptor in one conformation and high 
concentration of the ligand is required to induce the 
conformational changes before binding.17 Another possible 
explanation for the discrepancy between affinity and potency, 
is that the functional assay allow for intracellular 50 
amplification of the response, which may increase the 
potency. 
 It is well known that N-terminally truncated versions of 
both NPY, such as NPY3-36 and NPY13-36, and N-terminally 
truncated versions of PYY, such as PYY3-36, PYY13-36, 55 
improves the Y2/Y1 receptor specificity.14 Recently, even 
shorter versions of PYY, the N-terminal PEGylated PYY22-36 
Table 2. Binding affinities of PYY1-36, PYY3-36, and the novel PYY isoforms towards the Y receptors and potencies of PYY3-36 and the non-
lipidated PYY isoforms. The sequence of the isoforms main chain:  H-IKSPEELNRYYASLRHYLNLVTRQRY-NH2                                                         
Peptide Branch sequences Binding affinity,  IC50 [nM] Potency,  EC50 [nM] 
  
Y1Ra Y2Rb Y4Rb Y1Rc Y2Rc 
PYY1-36  4.0 ± 1.7 3.8 ± 1.6 141 ± 79 - - 
PYY3-36  24.6 ± 15 0.50 ± 0.09 255 ± 29 90 ± 11 5.6 ± 2.1 
1 H-YPIKPEAPGEDA- 10 ± 1.5 0.88 ± 0.05 239 ± 15 12 ± 7 5.6 ± 3.2 
2 CH3(CH2)4CO-YPIKPEAPGEDA- 36 ± 7 1.43 ± 0.09 627 ± 204 - - 
3 H-PIKPEAPGEDA- 25 ± 16 0.90 ± 0.01 277 ± 29 80 ± 22 4.3 ± 2.9 
4 H-IKPEAPGEDA- 19 ± 5 0.95 ± 0.07 617 ± 24 118 ± 19 4.6 ± 2.4 
5 H-YPIKPEAPGPRRP- 229 ± 22 0.17 ± 0.02 275 ± 80 4.5 ± 3.3 1.1 ± 0.3 
6 H-IKPEAPGPRRP- 535 ± 182 0.20 ± 0.05 524 ± 155 46 ± 23 0.7 ± 0.3 
7 CH3(CH2)4CO-IKPEAPGPRRP- 174 ± 5 0.15 ± 0.04 571 ± 52 - - 
a SK-N-MC cells expressing the Y1 receptor. b Transfected Y2 or Y4 receptors in HEK293 Flp-In T-Rex cells. c Transfected Y1 or Y2 receptors as well 
as GαΔ6qi4myr in COS-7 cells. 
Figure 1. Circular dichroism (CD) of PYY1-36, PYY3-36, peptides 1-7
in phosphate buffer as well as degree of α-helicity for each compound. 
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analogs, were shown to retain some Y2 activity while greatly 
reducing Y1 activity.18 Interestingly, however, while 
PEGylation and N-terminal truncation also reduces Y2 affinity 
(10-50 fold) our N-terminal branched peptides retain high 
affinity towards the Y2 receptor. 5 
 
Mouse serum stability. 
The serum stability of native PYY3-36 and the PYY isoforms 
was evaluated after 60, 120, and 300 min by analytical 
RP-HPLC. The first series of PYY analogs showed no 10 
significant variation in serum stability compared to PYY3-36 
during a 300 min incubation period at 37°C (Table 3, entry 
1-4). PYY3-36 and peptides 1-4 were primarily digested by 
carboxy-peptidases cleaving at the amino side of Arg-33 and 
Arg-35 (Figure S1-S8). Likewise, peptides 5-7 were digested 15 
in a similar mode however, unexpectedly rapidly (> 10 times 
as fast). We speculate that the additional Arg residues bind 
with high affinity to an in-active site of the carboxy-peptidase, 
which then may induce the C-terminal of PYY into the active 
site of the peptidase leading to an increased digestion. Due to 20 
the unexpected low half-life in serum peptides 5-7 were not 
further investigated. 
Body-weight lowering effects in acute mouse study. 
The effect of three days of subcutaneous minipump 
administration of PYY3-36, peptides 3 and 4 on body-weight 25 
in male NMRI mice was investigated. The two novel PYY 
analogs were selected for in vivo investigation based on their 
potency and serum stability. Pre-treatment 
analysis showed PYY3-36 and peptide 4 to be 
stable in 0.9% saline over a period of 14 days 30 
(data not shown) similar to what has been 
reported previously for PYY3-36.3 On the first 
day of the study the animals were implanted 
with an Alzet osmotic minipump providing a 
continuous administration of either vehicle 35 
(0.9% saline), PYY3-36, peptide 3, or 4 in 
peptide concentrations of 0.25 μmol/kg/day. A 
reduction in body-weight gain was observed at 
day 3 for animals treated with PYY3-36 (~ 6%), 
peptide 3 (~ 4%) and 4 (~ 7%), as well as at day 40 
6 for peptide 4 (~ 4%) treated animals.  
Pharmacokinetic analysis of PYY3-36 and peptide 4. 
Based on affinity, potency and the acute in vivo data peptide 4 
was further investigated. The pharmacokinetic profile of 
PYY3-36 and peptide 4 were examined following an 45 
intravenous bolus injection. The calculated half-life of both 
compounds was approximately 35 min. 
Chronic body-weight reduction in DIO-mice. 
We next examined the effect of 14 days of administration of 
PYY3-36 and peptide 4 by osmotic minipumps in male diet-50 
induced obese C57BL/6J mice. Mice were randomized 
according to body-weight and implanted subcutaneously in 
the back with an Alzet osmotic minipump delivering either 
vehicle (0.9% saline), PYY3-36 (0.25 or 1.0 μmol/kg/day) or 
peptide 4 (0.25 or 1.0 μmol/kg/day) (Figure 3). Both doses of 55 
PYY3-36 and peptide 4 reduced food intake and body-weight 
dose-dependently. A one-way ANOVA test followed by a 
“Dunnett’s multiple comparison test” at day 7 and 14 showed 
PYY3-36 and peptide 4 reduced body-weight significantly 
compared to vehicle (Figure 3A).  60 
 The reduction in body-weight was correlated to a reduction 
in food intake during the first week of the study (Figure 3B 
and 3C), which was decreased similarly for all for treated 
animal groups compared to vehicle (Figure 3B and 3C). The 
degree of body-weight loss (~ 10%) during the first seven 65 
Table 3. Metabolic digestion in diluted mouse seruma of native PYY3-
36 and peptide 1-7. 
 Undigested peptideb [%] 
Peptide After 60 min  After 120 min After 300 min 
PYY3-36 > 95 93 69 
1 88 89 n.d. 
2 > 95 86 66 
3 > 95 83 53 
4 94 88 69 
5 ~ 50 < 5 < 5 
6 > 95 < 5 < 5 
7 > 95 < 5 < 5 
a Water-mouse serum (40:1) at 37°C. b Analyzed by analytical RP-
HPLC. 
Table 4. Amount of free fatty acids, triglycerides and cholesterol on day 14. Values are 
means ± SEM (n = 9). 
        
Peptide conc. 
[µmol/kg/day] 
Free fatty acids 
[mmol/L] 
Triglycerides 
[mg/dL] 
Total cholesterol 
[mg/dL] 
Vehicle   1.26 ± 0.27 217 ± 21 153 ± 56 
0.25  1.07 ± 0.26  191 ± 37 136 ± 53 PYY3-36 1.0  1.00 ± 0.18 201 ± 27 104 ± 27 
0.25  0.92 ± 0.15 (*) 199 ± 26 111 ± 22 Peptide 4 1.0  0.86 ± 0.22 (**) 187 ± 26 (*) 96 ± 30 
One way ANOVA with “Dunnett's Multiple Comparison Test“: (*) p < 0.05, (**) p < 0.01 
compared to vehicle. 
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Figure 2. Acute minipump experiment in lean male NMRI mice (3 
days). Vehicle (▼), 0.25 μmol/kg/day PYY3-36 (□), 0.25 μmol/kg/day 
peptide 3 (■) and 0.25 μmol/kg/day peptide 4 (○). Values are means ±
SEM (n = 7). One way ANOVA followed by a “Dunnett’s multiple 
comparison test”: (*) P < 0.05 compared to vehicle. 
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days was compatible to previous reports using PYY3-36 
analogs.1-3,9,19 
 After the final dosing at day 14, blood was collected to 
measure leptin, non-esterified free fatty acids, triglycerides, 
cholesterol and adiponectin. In accordance with the body-5 
weight loss both PYY3-36 and peptide 4 treated mice had 
lower levels of circulating leptin at termination (Figure 4A). 
Interestingly, adiponectin levels were increased to a larger 
extent in peptide 4 treated mice when compared to PYY3-36 
(Figure 4B). Also, peptide 4 led to higher reductions in 10 
triglycerides and free fatty acids than PYY3-36, suggesting 
that peptide 4 exert additionally beneficial effects on fat cell 
metabolism. Although it can be speculated that the differential 
effects of peptide 4 on adiponectin levels and plasma lipids 
could be due to an alteration in Y2/Y1 selectivity, the change 15 
in this selectivity ratio is rather modest and therefore other 
factors should be considered. First, the PYY3-36 isoform 
exemplified by peptide 4 may have an altered back-folding; 
the branch and the additional N-terminal amino group could 
lead to a changed secondary structure in the solution and 20 
membrane bound state.  
 It is also possible that peptide 4 activated other receptors 
than the Y receptors. The orphan GPCR, glucocorticoid-
induced receptor (GIR, GPR83), has previously been 
speculated to be a target for PYY3-36. GIR is found in brain 25 
regions such as hypothalamus, however, the pharmaceutical 
action of the receptor is awaiting.20  
 In conclusion, we have characterized a new series of 
branched PYY analogs with remarkable lipid lowering and 
adiponectin stimulating effects in a mouse model of diet 30 
induced obesity. These analogs could be explored further in 
the search for novel drugs for the treatment of the metabolic 
syndrome and obesity. 
Materials and methods.  
Materials.  35 
Human Embryonic Kidney 293 cells (HEK293 Flp-In T-Rex), 
and pcDNA3.1 vector were purchased from Invitrogen. 
Dulbecco’s Modified Eagle’s Medium (D-MEM), fetal calf 
serum, penicillin-streptomycin solution, phosphate buffered 
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Figure 3. Chronic minipump experiment in male DIO C57BL/6J mice (2-
wk). Body weight (A), daily food intake (B) and cumulative feed intake 
(C). Vehicle (▼), 0.25 μmol/kg/day PYY3-36 (□), 1.0 μmol/kg/day 
PYY3-36 (■), 0.25 μmol/kg/day peptide 4 (○), 1.0 μmol/kg/day peptide 4
(●). Values are means ± SEM (n = 9). One way ANOVA with “Dunnett's 
Multiple Comparison Test“: (*) P < 0.05 compared to vehicle. 
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Figure 4. Leptin levels on day 14 (A) and adiponectin levels on day 14 
(B). Values are means ± SEM (n = 9). One way ANOVA with “Dunnett's 
Multiple Comparison Test“: (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 
compared to vehicle. 
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saline (PBS), sucrose, and 99% glycerol were all obtained 
from Sigma-Aldrich. FuGENE 6 transfection reagent, 
complete protease inhibitor cocktail tablets and bovine serum 
albumin (BSA) were purchased from Roche. 2-Amino-2-
hydroxymethyl-propane-1,3-diol (TRIS), MgCl2·6H2O, CaCl2, 5 
and NaCl were obtained from AppliChem GmbH. (2S,3S)-1,4-
bis-sulfanylbutane-2,3-diol (DTT) was obtained from GE 
Healthcare and radioactive labeled agonists were purchased 
from Phoenix pharmaceuticals. 96-Well filtration MultiScreen 
HTS, DV plates were obtained from Millipore. [3H]-myo-10 
inositol (PT6-271) was purchased from Amersham.  
Peptide synthesis.  
The peptides were prepared by automated peptide synthesis on 
a Symphony parallel synthesizer (PTI) by standard solid-
phase peptide synthesis (SPPS) on TentaGel S Rink Amide 15 
resin (0.24 mmol/g loading) with 9-fluorenylmethyl-
oxycarbonyl (Fmoc) for protection of Nα-amino groups except 
for the N-terminal Ile of the main-chain, where Boc (tert-
butoxycarbonyl) was used. Side-chain protecting groups were 
tert-butyl (Ser, Thr, Tyr, Asp, Glu), tert-butoxycarbonyl 20 
(Lys), 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl 
(Dde, for branching at Lys), 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), and trityl (Trt, 
for Asn, Gln, His). Nα-Fmoc amino acids (6.0 equiv) were 
coupled using diisopropylcarbodiimide (DIC) (6.0 equiv) as 25 
coupling agent and 1-hydroxybenzotriazole (HOBt) (6.0 
equiv) as additive in DMF for 120 min. Nα-Fmoc deprotection 
was performed using piperidine-DMF (1:4) for 3 min, 
followed by piperidine-DMF (1:4) for 17 min. The Lys(Dde) 
residue was side-chain deprotected with 2.5% (v/v) hydrazine 30 
hydrate in DMF at room temperature for 15 min. The peptide 
amides were released from the solid support by treatment of 
reagent K (trifluoroacetic acid (TFA)-phenol-thioanisol-1,2-
ethanedithiol (EDT)-H2O (82.5:5:5:2.5)) for 2.5 hours. The 
TFA solutions were concentrated by nitrogen flow and the 35 
compounds were precipitated with diethylether to yield the 
crude materials as white powders.  
 Purification was accomplished by RP-HPLC (Agilent 1200 
series) on a preparative column (Zorbax-Eclipse XDB-C18, 7 
μm particles, 21.2×250 mm) using the following solvent 40 
system: solvent A, water containing 0.1%  TFA; solvent B, 
acetonitrile containing 0.1% TFA. B gradient elution (0-2 min 
5%, 2-5 min 5-25%, 5-50 min 25-60%) was applied at a flow 
rate of 20 mL min-1 and column effluent was monitored by 
UV absorbance at 220 nm.  Identification and quantification 45 
were carried out by LC-MS (Agilent Technologies LC/MSD 
VL) using the eluent system A-B (solvent A, water containing 
0.1% TFA; solvent B, acetonitrile containing 0.1% TFA). The 
eluent system A-B was applied on a C18 analytical column 
(Zorbax Eclipse XDB, 80 Å 5 μm 4.6×150 mm) where the B 50 
gradient elution (0-25 min: 5-50%) was applied at a flow rate 
of 1.0 mL min-1. Quantification and characterization data are 
given in Table 5. 
Circular dichroism.  
UV CD spectra were recorded on a JASCO J-810 circular 55 
dichroism system using rectangular Hellma quartz cells with a 
light path of 1 mm. The peptide solutions were approximately 
20 μM in 10 mM phosphate buffer, pH 7.4. The absolute 
concentration was determined spectroscopically (tyrosine 
absorption at 274 nm, using ε = 1420 cm−1M−1). The mean 60 
residue ellipticity (MRE) was calculated according to Yang et 
al. in which the number n refers to the number of residues.21  
Radioligand displacement assay.  
Cell culture and receptor expression: The SK-N-MC cells 
were cultured in a 1:1 mix of HAM F12 and Dulbecco’s 65 
Modified Eagle’s Medium (D-MEM 1885), containing 15% 
(v/v) fetal calf serum (FCS), 1% non essential amino acids 
and 1% (v/v) penicillin-streptomycin in humidified 
atmosphere of 5% carbon dioxide and 95% air, at 37°C. The 
human embryonic kidney (HEK293 Flp-In T-Rex) derived cell 70 
line was cultured in Dulbecco’s Modified Eagle’s Medium 
(D-MEM), containing 10% (v/v) fetal calf serum (FCS) and 
1% (v/v) penicillin-streptomycin. Cells were grown as 
monolayers in humidified atmosphere of 5% carbon dioxide 
and 95% air, for 48 hours at 37°C. Using serum-free D-MEM 75 
and FuGENE 6 transfection reagent HEK293 Flp-In T-Rex 
cells were transiently transfected by pcDNA3.1 vectors which 
encode either the human Y2 or Y4 receptor (FuGENE 
6/pcDNA3.1, 3:1). The transfected HEK293 Flp-In T-Rex 
cells were set to express the receptors in humidified 80 
atmosphere of 5% carbon dioxide and 95% air, for another 48 
hours at 37°C.  
Preparation of membrane fractions. The SK-N-MC and the 
transiently transfected HEK293 Flp-In T-Rex cells were 
washed with phosphate buffered saline (PBS) and 85 
homogenized in cold homogenization buffer (50 mM Tris (pH 
7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, 1.0 mM DTT, complete 
protease inhibitor cocktail (one tablet per 50 mL buffer)). An 
equal amount of 0.6 M sucrose was added to the cell mixture. 
The homogenate was centrifuged (10,000 g, 10 min at 4°C). 90 
Cell pellets were washed in washing buffer (SK-N-MC cells: 
50 mM TRIS (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 2.5 mM 
CaCl2, 0.2% (w/w) BSA fraction V. HEK293-Flp-In-T-Rex: 
50 mM TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, 
complete protease inhibitor cocktail (one tablet per 50 mL 95 
Table 5. Quantification and characterization data of inherent PYY1-
36, PYY3-36 and peptide isoforms. 
 ESI-MS (m/z)a Purityb 
Peptide Calcd. MS Found, [M+4H]4+ [%] 
PYY1-36 4309.8 1078.1 98 
PYY3-36 4049.5 1012.8 98 
1 4551.2 1138.4 96 
2 4650.3 1162.0 95 
3 4388.0 1097.7 95 
4 4291.0 1073.4 97 
5 4743.5 1186.4 95 
6 4482.2 1121.4 95 
7 4581.2 1145.3 96 
a Identified by ESI-MS on a Agilent Technologies LC/MSD VL. b 
Quantified by RP-HPLC at 215 nm. Eluent A: 0.1% TFA in H2O. 
Eluent B: 0.1% TFA in AcN. 
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buffer), 1.0% (w/w) BSA fraction V), and subsequently the 
suspensions were centrifuged (10,000 g, 10 min at 4°C). The 
pellets were re-suspended in glycerol containing binding 
buffer (50 mM TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, 
complete protease inhibitor cocktail (one tablet per 50 mL 5 
buffer), 1.0% (w/w) BSA fraction V, 20% (v/v) glycerol) and 
concentration was adjusted to an OD600 of 1.6.   
Binding affinity. All binding experiments were performed in 
96-well filtration MultiScreen HTS, DV plates and every 
concentration point was performed as triplicates. The 10 
unlabeled peptide (25 μL) at concentrations between 10 pM 
and 10 μM, cell membrane suspension (3.5 µL), binding 
buffer (61.5 µL, 50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 
mM CaCl2, complete protease inhibitor cocktail (one tablet 
per 50 mL buffer), 1.0% (w/w) BSA fraction V)), radioligand 15 
solution (10 µL; Y1R: 125I-[31Leu,34Pro]-pNPY; Y2R: 125I-
PYY3-36; and Y4R: 125I-PP; specific activity of 800-1000 
Ci/mmole). After 1-2 hours of incubation at room temperature 
the assay was terminated by filtration. Finally, the membrane-
receptor-ligand complexes were washed twice in cold TRIS 20 
buffer (50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM CaCl2) 
containing 5.0% BSA fraction V. Bound radioactivity was 
determined as counts per minute (Wallac 1470 WizardTM 
Automated Gamma Counter). Binding data were analyzed 
with GraphPad Prism 5.0 (GraphPad Software, Inc. San 25 
Diego, CA, USA). The displacement experiments were 
replicated until the standard error of mean (S.E.M.) of -log 
IC50 was below 0.1 (n = 2-5). 
Functional assay.  
Transfections and tissue culture. COS-7 cells were grown in 30 
Dulbecco’s modified Eagle’s medium 1885 supplemented 
with 10 % fetal calf serum, 2 mM glutamine and 0.01 mg/mL 
gentamicin. Cells were transfected with 10 μg cDNA of wild 
type Y1 or Y2 receptors and 10 μg cDNA of a GαΔ6qi4myr22 
using the calcium phosphate precipitation method with 35 
chloroquine addition.  The chimeric G-protein allow the Gi 
coupled receptors to signal through the signal transduction 
pathways known for the Gq coupled receptors. Receptors 
from the PP fold family of peptides - the Y1 and Y2 receptors 
- were cloned from a human cDNA library and expressed in a 40 
pcDNA3.1 vector.  
Phosphatidylinositol turnover. The assay was performed as 
previously described23 and only described in brief in the 
following. One day after transfection, COS-7 cells were 
incubated for 24 hours with 5 μCi of [3H]-myo-inositol in 1 45 
mL medium, washed twice in buffer, 20 mM HEPES, pH 7.4, 
and were subsequently incubated in 0.5 mL buffer 
supplemented with 10 mM LiCl at 37˚C for 30 min. After 
stimulation with various concentrations of PYY3-36 or the 
synthetic analogs for 45 min at 37˚C, cells were extracted 50 
with 10 % ice-cold formic acid followed by incubation on ice 
for 30 min. The generated [3H]-inositol phosphate was 
purified on Bio-Rad AG 1-X8 anion-exchange resins. 
Determinations of each measuring point were made in 
duplicates. The functional assays were replicated 3 times. 55 
In vitro metabolism of PYY3-36 and PYY isoforms.  
Mouse serum stability. PYY3-36 and peptide 1-7 were 
dissolved in 195 μL protease free water to a final peptide 
concentration of 107 μM. To the peptide solution 5 μL of 
freshly prepared mouse serum (male NMRI mice) was added. 60 
After incubation at 37°C for 0, 60, 120, and 300 min 20 μL of 
diluted serum deproteinated with 60 μL of ethanol. 
Subsequent to centrifugation (14,000 rpm, 4°C, 15 min) the 
supernatant was analyzed by LC-MS (Dionex Ultimate 3000 
system equipped with a PDA UV detector, MSQ Plus Mass 65 
Spectrometer, Thermo), using eluent system A-B (solvent A, 
water containing 0.1% TFA; solvent B, acetonitrile containing 
0.1% TFA) applied on a C18 analytical column (phenomenex, 
Gemini, 110 Å 3 μm C18 particles, 4.60×50 mm) where an A 
gradient elution (0-12 min: 5-100%) was applied at a flow rate 70 
of 1.0 mL min-1.  
Saline stability. PYY3-36 and peptide 4 (10 μM) were 
incubated in 0.9% saline at 37°C for 14 days. The samples 
were analyzed by analytical RP-HPLC at day 2, 7, and 14.   
In vivo experiments.  75 
All experiments were conducted in accordance with 
internationally accepted principles for the care and use of 
laboratory animals and the protocols were approved by the 
Danish Committee for Animal Research (intravenous PK 
study and acute mice study) or the Institutional Animals 80 
Ethics Committee of Aurigene Discovery Technologies Ltd, 
Bangalore, India (chronic mice study).  
Intravenous pharmacokinetic study.  
 Animals. Fifty-two male NMRI mice (Charles River), 8-9 
weeks old at the time of arrival at the In Vivo Pharmacology 85 
Department of Rheoscience are used. Upon arrival (day -7), 
the animals were kept on a 12:12-h light-dark cycle (lights on 
at 03:00 AM) in a temperature-controlled environment (22-
24°C). The mice have ad libitum access to standard chow 
(Altromin 1324, Brogaarden ApS, Denmark).  90 
 General procedure. At day -5 the mice are weighted and 
randomized according to body weight and divided into dosage 
groups (n = 3) which were terminated at t = 0, 2, 5, 15, 30, 60, 
120, and 240 min. PYY3-36 and peptide 4 were investigated. 
The compounds (or vehicle) are administered by intravenous 95 
route (i.v.) at t = 0 min. Dosage for both peptides were 0.25 
μmol/kg (2 mL/kg). Exact concentration of the peptide 
solutions are determined spectroscopically (tyrosine 
absorption at 274 nm, using ε = 1420 cm−1M−1). At time of 
termination, eye-blood was collected in cold EDTA tubes 100 
(containing 0.6 TIU (trypsin inhibitor unit) of aprotinin pr. 
mL of blood) and the mice are immediately euthanized by 
decapitation. Immediately after collection, the blood in the 
EDTA tubes were gently mixed several times to inhibit the 
activity of proteases. 105 
 Bioanalysis. The blood samples were centrifuged at 1600 X 
g for 15 min at 40°C, plasma was collected and stored at -
70°C until analysis. Plasma concentrations of PYY3-36 and 
peptide 4 were determined by PYY ELISA kit (for human 
PYY, Phoenix Pharmaceuticals, lot # 600448; LLoQ 10 110 
pg/mL). The interference from endogenous PYY was 
corrected by, subtracting the mean binding values of PYY in 
the control group from the mean binding values of PYY3-36 
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and peptide 4 at the different time points in the in vivo study. 
The human PYY ELISA kit (Phoenix Pharmaceuticals) was 
tested using dilutions of PYY3-36 and peptide 4 respectively, 
and showed that PYY ELISA kit was very useful for 
measuring both PYY3-36 as well as peptide 4. The standard 5 
curve showed a linear range between 0.1 to 1 ng/mL for 
PYY3-36 and 0.1 to 3 ng/mL for peptide 4 (not shown).  
Acute mice study.  
 Animals. The studies were carried out in lean male NMRI 
mice (Naval Medical Research Institute, Charles River) 8-9 10 
weeks old. Animals were kept on a 12:12-h light-dark cycle 
(lights on at 03:00 AM) in a temperature-controlled 
environment (22-24°C). Food for the entire experiment: 
Standard chow (Altromin standard chow 1324; C. Petersen, 
Ringsted, Denmark). 15 
 Sample preparation. Vehicle for all experiments was 0.9% 
saline. Compounds were administered via Alzet osmotic 
minipumps (model 1003; 100µl; 1.0 µl/h, 3 days of delivery). 
The animals were given either vehicle (0.9% saline), PYY3-
36, peptide 3 or 4 in concentrations of 0.25 µmole/kg/day. 20 
Pumps were filled in the morning of day 0 and “primed” for 4 
hours (pump filled and kept in 0.9% saline at 37 C until 
operation, approximately 4-6 hours). 
 General procedure. The animals (n = 7) were on the day of 
arrival given water and food for the entire experiment 25 
(standard chow; Altromin standard chow 1324; Petersen, 
Ringsted, Denmark). Upon arrival the animal were transferred 
to single cages in which they were housed until the start of the 
experiment (~ 10 days). Body-weight was recorded on the 
morning of day 0 (7:00-8:00 AM) and the mice were 30 
randomized. On day 0, animals were anaesthetized using gas 
anaesthesia (halothane) and Alzet osmotic pumps (model 
1003) implanted subcutaneously in the lower back and 
surgical between 12:00 and 14:00 PM, wound closed with 
surgical staples. Povidone iodine solution was applied 35 
topically on surgical site. Following the operation, the mice 
were allowed to recover, and subsequently transferred back to 
their cages. Pentazocin (5 mg/kg SQ) was administered once 
as analgesic. Body-weight was recorded in the morning 
between 8:00 and 10:00 AM from day 0 to day 6. 40 
Chronic DIO mice study.  
 Animals. Studies were carried out in male C57BL/6J mice. 
Animals were kept on a 12:12-h light-dark cycle (lights on at 
0700) in a temperature-controlled environment (22-24°C) with 
free access to food and water. 45 
 Sample and pump preparation. Vehicle for all experiments 
was 0.9% saline. Compounds were administered via Alzet 
osmotic minipumps (model 2002; 200µL; 0.5µL/h, 14 days of 
delivery). The animals were given either vehicle, PYY3-36 
(batch no: IN1009-041) or peptide 2 (batch no: IN1094-071) 50 
in concentrations of 0.25 µmole/kg/day or 0.1 µmole/kg/day. 
Pumps were filled the day before experiment start and 
“primed” overnight (pump filled and kept in 0.9% saline at 
37°C). 
 General procedure. The animals (n = 9) were aged 6-8 55 
weeks at the time of arrival to the in vivo facility. Mice were 
housed 5 per cage for 20 weeks before experiment start. 
During this period, mice were given free access to water and a 
high energy diet containing 60% energy from fat (Diet # 
D12492; Research Diets, New Jersey, USA). Two weeks prior 60 
to pump implantation the animals were transferred to 
individual cages. Seven days before the experiment start and 
until end of experiment body-weight (BW) and food intake 
(FI) were recorded daily at 9.00 AM. The animals were 
randomized according to body-weight on the day before 65 
implantation of the Alzet osmotic mini-pumps. On day 0, 
animals were anaesthetized using gas anaesthesia (halothane) 
and Alzet osmotic pumps (model 2002) implanted 
subcutaneously in the lower back and surgical wound closed 
with surgical staples. Povidone iodine solution was applied 70 
topically on surgical site. Following the operation, mice were 
allowed to recover, and then transferred back to their cages. 
Pentazocin (5 mg/kg SQ) was administered once as analgesic. 
On day 14 of the experiment a morning (9:00 AM) blood 
sample from ad lib fed mice was obtained for analysis of 75 
plasma triglyceride, total cholesterol, free fatty acids, leptin 
and adiponectin. 
 Plasma analysis. For measuring plasma triglycerides and 
total cholesterol and non-esterified free fatty acids (NEFA) 
blood was sampled from the retroorbital plexus into pre-80 
cooled EDTA coated tubes (K3-EDTA, 1.6 mg/mL). Samples 
were immediately centrifuged at 4,800 x G for 15 min and 
plasma was stored at -80°C until analysis. NEFA was 
measured in duplicates using a colorimetric enzyme assay kit 
purchased from FA115, Randox Laboratories, Antrim, United 85 
Kingdom). Triglycerides (kit #30364) and total cholesterol 
(kit #30183) were measured using Labkit from Chemelex S.A. 
(Barcelona, Spain). For the analysis of plasma leptin and 
adiponectin blood was sampled into pre-cooled EDTA tubes 
(K3-EDTA, 1.6 mg/mL) and plasma stored at -80°C until 90 
analysis. Leptin and adiponectin levels were measured using 
mouse leptin (EZML-82K) and mouse adiponectin 
(EZMADP-60K) ELISA kit, respectively (Millipore). 
Fluorescence readout was measured using SpectraMax Gemini 
Spectrofluorometer (Molecular Devices Corporation, USA). 95 
Conclusions 
In conclusion, we report the design of PYY analogs with a 
different peptide architecture - mainly isoforms, their 
synthesis, and their pharmacological characterization, which 
led to the identification of a number of selective and potent 100 
Y2 receptor agonists. Particularly, the compounds effectively 
reduce body-weight in both lean and DIO mice. Interestingly, 
despite identical stability and PK-profile between peptide 4 
and native human PYY3-36, peptide 4 has additional effects 
on plasma lipids and presumably fat-cell metabolism reflected 105 
in increased adiponectin levels. The reported isoforms of PYY 
hold interesting and unforeseen pharmacological properties, 
and should be explored further due to their lipid-lowering 
effects. 
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Figure S1. LC-MS. Serum stability of native PYY3-36. 
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Figure S2. LC-MS. Serum stability of Peptide 1. 
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Figure S3. LC-MS. Serum stability of Peptide 2. 
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Figure S4. LC-MS. Serum stability of Peptide 3. 
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Figure S5. LC-MS. Serum stability of Peptide 4. 
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Figure S6. LC-MS. Serum stability of Peptide 5. 
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Figure S7. LC-MS. Serum stability of Peptide 6. 
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Figure S8. LC-MS. Serum stability of Peptide 7. 
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Peptide-architecture: Adding an α-helix to the 
PYY Lys side-chain provides nanomolar binding 
and body-weight lowering effects 
Søren L. Pedersen,[a,b] Pottayil G. Sasikumar,[c] Niels Vrang*[d] and Knud J. 
Jensen*[a] 
The gut hormone PYY3-36 influences food intake and body-weight 
via interaction with hypothalamic pre-synaptic Y2 receptors. Novel Y2 
receptor selective analogs of PYY3-36 are therefore potential drug 
candidates for the treatment of obesity. It has been hypothesized that 
PYY3-36 and possibly also the related PP-fold peptides, NPY and 
PP, bind to the membrane via their amphipathic α-helix prior to 
receptor interaction. In this view the amphipathic α-helix of PYY3-36 
leads to the association of the peptide with the membrane and it is 
essential for Y receptor potency, as it possibly guides the C-terminal 
pentapeptide into the correct conformation for receptor activation. 
Based on this hypothesis, the importance of the amphipathic nature of 
PYY3-36 as well as the ability of amphipathic α-helices to interact in 
solution to form di- and tetramers, we re-designed the peptide 
architecture by addition an amphipathic α-helix via the Lys-4 side-
chain of PYY3-36. Two different amphipathic sequences were 
introduced; first, PYY17-31, the native α-helix of PYY, and secondly, 
its retro counterpart, PYY31-17, which is also predicted to form an 
α-helix. Moreover, several different turn motifs between the branching 
point and the additional α-helix were tested. Several novel peptides 
with nanomolar Y2 receptor binding affinity as well as increased Y 
receptor selectivity were synthesized in high purity. CD experiments 
showed the modifications to be well accepted and an increase in 
mean ellipticity (ME) per molar peptide at 220 nm was observed, 
which signifies an increased degree of α-helix per molar peptide. 
Structure-affinity relationship experiments indicated that the direction 
of the additional α-helix is less important, in contrast to the turn motifs, 
which were of high importance for reducing the Y1 receptor binding. 
The turn motif thus determined the Y1 receptor activity. On the other 
hand, the structure-activity relationship experiments from acute mice 
studies showed that the peptide containing the retro-sequences was 
inactive even though the binding data demonstrated high affinity and 
selectivity. This demonstrates that radical re-design of peptide 
architecture can provide nanomolar binding with improved sub-type 
selectivity and with in vivo efficacy. 
 
Introduction 
The worldwide obesity epidemic and the dramatic increases in 
obesity-associated diseases such as cardiovascular disease and 
type-II diabetes, calls for not only major emphasis on obesity 
prevention but also for novel pharmacological approaches to 
appetite regulation. Over the past 30 years a number of gut 
peptides with anorectic potential have been described.1 One of 
these gut-hormones is PYY3-36 (Table 1), a Y2 receptor agonist, 
which plays a role in appetite regulation.2-4 PYY is a member of 
the PP-fold family of peptides that also consists of pancreatic 
polypeptide (PP) and neuropeptide Y (NPY) (Table 1).5 The 
physiological actions of the PP-fold peptides are expressed 
through their activation of G-protein coupled receptors (GPCR), 
the so-called Y receptors (Y1, Y2, Y4 and Y5), which belong to 
the rhodopsin-like superfamily (class A) of receptors.6 Both 
PYY1-36 and NPY display high Y1 and Y5 affinity, while PP is a 
potent and highly selective Y4 receptor agonist with low affinity to 
the Y1, Y2, and Y5 receptor subtypes. The endogenous ligand for 
the Y2 receptor is believed to be PYY3-36. PYY1-36 is 
co-secreted with GLP-1 postprandially from endocrine L-cells 
lining the gut7 and following secretion, PYY1-36 is N-terminally 
cleaved by dipeptidyl peptidase IV (DPP-IV) to produce 
PYY3-36.8 The major blood-circulating form of PYY, PYY3-36, 
has a high affinity towards the Y2 receptor, and to a lesser extent 
the Y1 receptor.9 The Y2 receptor is expressed primarily on pre-
synaptic terminals in the arcuate nucleus of the hypothalamus, 
and has been hypothesized to be key mediators of the anorectic Table 1. Sequences of human NPY, PP, PYY1-36 and PYY3-36. The extra 
amphipathic α-helix is branching from the side chain amine of Lys-4 in the 
PYY3-36 sequence. 
Peptide Sequence 
PP H-APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
NPY H-YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
PYY1-36 H-YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
PYY3-36[a]     H-I4KPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
[a] Novel analogs: Additional sequence positioned at the ε-amine of Lys-4 of 
PYY3-36.  
[a] S. L. Pedersen, Prof. Dr. K. J. Jensen,                                          
IGM, Faculty of life Sciences, University of Copenhagen, 
Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark,                  
Fax: (+45) 3533 2398,                                                                       
E-mail: kjj@life.ku.dk 
[b] S. L. Pedersen,                                                                    
Rheoscience A/S, Glerupvej 2, 2610 Rødovre, Denmark 
[c] Dr. P. G. Sasikumar,                                                              
Aurigene Discovery Technologies Limited 
39-40, KIADB Industrial Area, Electronic City Phase II,                 
Hosur Road, Bangalore 560 100, India 
[d] Dr. N. Vrang,                                                                                   
Gubra ApS. Ridebanevej 12, 1870 Frederiksberg C, Denmark,        
E-mail: niels@gubra.dk
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effects of peripherally administered PYY3-36.2 Indeed, several 
studies in both rats and mice using intraperitoneal4,10 or 
intravenous11,12 administration of PYY3-36 have shown acute 
reductions of food intake as well as chronic effects of PYY3-36 on 
Body-weight.4,11 However, since PYY3-36 displays a rather short 
plasma half-life and also binds to Y1 receptors – potentially 
counteracting anorectic effects - we aimed to develop more 
selective (Y2 over Y1) PYY3-36 analogs.  
Results and Discussion 
Peptide design.  
The sequences of the PP-fold family of peptides consist of a 
C-terminal receptor recognizing segment, an amphipathic α-helix 
and a more flexible N-terminus. PYY1-36, as well as PP, are 
back-folded in solution unlike NPY which is more unstructured.13 
However, when bound to a membrane all the PP-fold peptides 
show almost identical tertiary structure which led Zerbe and 
co-workers to the hypothesis that the peptides are not 
recognized by their receptors directly from solution, but after an 
association with the membrane, followed by a lateral diffusion 
along the membrane before binding to the receptor.13,14 The 
native amphipathic α-helix of the PP-fold peptides has two 
functions in the membrane-compartment model15: First to direct 
the peptides to the membrane-water interface and secondly, to 
guide the C-terminal receptor binding segment in the right 
conformation for activity. The membrane stabilizes both the 
α-helix and especially the C-terminus, which has been shown to 
be relatively flexible in solution.13,14 The N-terminus (residue 1-
12) has been proven very important for the Y receptor selectivity 
and essential for Y1 and Y4 receptor activity.16 Recently, it has 
been suggested that the N-terminal segments bind with low 
affinity to extracellular Y receptor sections thereby acting as an 
anchor in the transfer from the membrane-bound state into the 
genuine binding pocket of the receptor for the peptide 
hormones.17  
We aimed for a radical re-design of the PYY3-36 architecture 
based on the original hypotheses regarding peptide hormone 
interactions with membranes by Kaiser and Kezdy,18 and 
Schwyzer,15 as well as recent results by Zerbe and co-workers 
regarding PYY3-36.13,14 The overall aim was to (i) improve 
membrane binding, (ii) improve the selectivity for Y2 over Y1, 
and (iii) to test this through binding affinities to Y1, Y2, and Y4 
receptors. Rather than trying to obtain this by single amino acid 
substitutions, we decided for re-designing the overall peptide 
topology. To achieve this we ornamented PYY3-36 by (i) addition 
of one of two α-helices (PYY17-31 and its retro-sequence) to the 
ε-amino group in the native Lys-4 (a ‘helix branch’), and (ii) 
insertion of one of four different turn motifs between the ε-amine 
and the new helix, as well as the control without a turn motif 
(Tables 1 and 2). As previously stated the N-terminus of PYY is 
very important for Y1 receptor affinity16 and branching from Lys-4 
could lead to a decrease in Y1 receptor affinity. We hypothesized 
that the amphipathic nature of the additional α-helix, and its 
potentially increased affinity towards the cell membrane, could 
lead to an accumulation of peptide near the Y receptors. Bringing 
the peptide from the three-dimensional space in solution on to 
the two-dimensional plane of the cell membrane should increase 
the probability of the peptide finding the receptor as well as the 
ability of activating the receptor multiple times. Secondly, the 
additional α-helix could in solution potentially back-fold alongside 
the native α-helix and/or the N-terminal segment. Third, as the 
N-terminal end is important for binding to the Y1 receptor, 
addition of the N-terminal branched helix might suppress binding 
to the Y1 receptor thus providing better Y2 receptor selectivity. 
Finally, the additional α-helix could possibly support a 
conformational stabilization of the C-terminal pentapeptide 
leading to an increase in Y receptor selectivity via a decreased 
Y1 receptor potency. 
These analogs of PYY3-36 with α-helical branches gave 
increased Y receptor selectivity (Y2 over Y1), and body-weight 
lowering effects in lean male NMRI mice over a period of 3 days. 
Circular dichroism (CD) indicates that all the novel analogs 
maintained the native α-helical nature of PYY3-36. Several 
α-helical branched analogs showed an increased Y receptor 
selectivity and two of these compounds showed a promising 
ability to reduce body-weight in a mouse model of obesity. 
Scheme 1. Synthetic scheme for solid-phase synthesis of α-helical branched 
PYY3-36 analogs. The dark grey boxes represent the regions theoretically 
α-helical, light grey boxes corresponds to the unstructured regions, the 
C-terminal binding segment, turns and the N-terminus. Region a-b shows the 
variable turn motif and b-c illustrates the position of the additional 
amphipathic α-helix.
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Peptide synthesis 
All peptides were assembled 
using the Fmoc/t-Bu strategy 
by automated solid-phase 
peptide synthesis on Rink 
Amide TentaGel resin. The 
Nα-Fmoc-protected amino 
acids were coupled using DIC 
and HOBt as coupling reagent 
and additive, in DMF, with 
coupling times of 2 hours. The 
Fmoc group was removed 
using piperidine-DMF (1:4; 3 + 
17 min). The sequences of 
PYY1-36, PYY3-36 and 
resin-bound PYY5-36 were 
assembled using standard 
Fmoc/t-Bu chemistry as 
described above. The 
sequence of resin-bound 
PYY5-36 was additionally 
modified by coupling of the 
Dde (1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene)ethyl) 
side-chain protected Lys at 
position 4. After Fmoc removal Nα-Boc-protected Ile was coupled 
at position 3 (Scheme 1). The Dde group was removed by 2.5 % 
(v/v) hydrazine hydrate in DMF making the side-chain ε-amino 
group available for assembly of the peptide branch (Scheme 1, a-
c), which additionally was performed by standard Fmoc/t-Bu 
chemistry. Except for peptides 1 and 2, a spacer or turn motif 
(Scheme 1, a-b) was incorporated between the branch point and 
the additional α-helix. After completion, the peptides were side-
chain deprotected and simultaneously cleaved from the solid 
support using reagent K. Finally, the peptides were purified by 
preparative RP-HPLC, quantified by analytical RP-HPLC and 
characterized by mass spectrometry. The final products were 
obtained with >95% purity (Table 3). 
Structure affinity relationship.  
To characterize the influence of adding an amphipathic α-helix 
and modifying the turn sequence to the side-chain of Lys-4, the 
binding affinity of the novel PYY3-36 analogs were tested using a 
radioligand displacement assay (competition binding assay) 
based on membranes from SK-N-MC and HEK293 Flp-In T-Rex 
cell lines expressing the human Y1, Y2 and Y4 receptor subtypes, 
respectively. 125I-[31Leu,34Pro]-pNPY for Y1R, 125I-hPYY3-36 for 
Y2R and 125I-hPP for Y4R were used as radioligands. Binding 
affinities (IC50 values) for PYY1-36, PYY3-36 and the novel 
analogs (peptides 1-8) are summarized in Table 2. 
Adding an amphipathic α-helix to the side-chain of Lys-4 of 
PYY3-36 has only moderate impact on binding affinity towards 
the Y2 and Y4 receptors. In general, 1-3 fold decreases in affinity 
towards the Y2 receptor were observed, except for peptide 5, 
which gave a 7-fold reduction in Y2 receptor binding affinity. 
Peptide 4 gave a 5-fold increase in affinity towards the Y2 
receptor. The binding data revealed a slight tendency that the 
peptides containing the retro sequence to be better accepted by 
the Y2 receptor than the natural sequence, however, the nature 
of the turn region led to more significant differences in binding 
affinity towards the Y2 receptor (Table 2 and Figure 1). The GG 
spacer sequence (helix stop motif) caused poor binding towards 
all three Y receptor subtypes. The Y2 receptor affinity of analogs 
without a spacer or turn motif (peptides 1 and 2) were equipotent 
to both the PE (peptide 6) and SP (peptides 7 and 8) turn motifs, 
which are relative restricted turns because of the proline residue. 
The GPRRP turn motif (peptides 3 and 4) were the best accepted 
sequence and gave equivalent to enhanced Y2 receptor binding 
affinities. The GPRRP turn motif was adapted from Hill and 
Table 2. PYY1-36, PYY3-36 and the H-I4KPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 analogs binding to the Y 
receptor subtypes Y1, Y2, and Y4, respectively. 
        Lys-4 branched sequences  Y1R[a] Y2R[b] Y4R[b] 
Peptide               α-helix  Turns Nature of α-helix IC50 [nM] IC50 [nM] IC50 [nM] 
PYY1-36    4.0 ± 1.7 3.8 ± 1.6 141 ± 79 
PYY3-36    7.8 ± 1.1 2.1 ± 0.2 255 ± 29 
1 H-LNRYYASLRHYLNLV - PYY17-31 11.7 ± 3.7 6.2 ± 1.1 395 ± 121 
2 H-VLNLYHRLSAYYRNL - PYY31-17 7.9 ± 0.5 5.4 ± 0.3 496 ± 91 
3 H-LNRYYASLRHYLNLV GPRRP- PYY17-31 >1000 2.1 ± 0.2 173 ± 60 
4 H-VLNLYHRLSAYYRNL GPRRP- PYY31-17 >1000 0.4 ± 0.1 101 ± 16 
5 H-LNRYYASLRHYLNLV GG- PYY17-31 >1000 14.1 ± 4.5 567 ± 40 
6 H-VLNLYHRLSAYYRNL PE- PYY31-17 17.2 ± 1.8 7.8 ± 2.2 276 ± 5 
7 H-LNRYYASLRHYLNLV SP- PYY17-31 >1000 7.6 ± 0.4 298 ± 15 
8 H-VLNLYHRLSAYYRNL SP- PYY31-17 >1000 5.6 ± 1.8 362 ± 127 
[a] SK-N-MC cells expressing the Y1 receptor. [b] Transfected Y2 or Y4 receptors in HEK293 Flp-In T-Rex cells. 
Figure 1. Binding of PYY3-36, peptides 3 and 7 towards the Y1 (■), the Y2 (▲) and Y4 (●) receptors. The curves are given as means of the replicates 
for each peptide.  
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Degrado19 and limited the flexibility of the additional α-helix even 
more than both the SP and PE turn motifs, which in so doing may 
guide the C-terminal in an optimal conformation for Y2 receptor 
binding and/or prevents Y1 receptor binding. In addition, the 
GPRRP motif has a double positive charge. A similar change in 
binding affinity appears for the Y4 receptor, except the type of the 
amphipathic α-helix seems to have no consequence for the 
binding affinity towards the Y4 receptor. Interestingly, the analogs 
with a GPRRP turn motif (peptides 3 and 4) were also well 
tolerated towards the Y4 receptor and led to almost a threefold 
increase in binding affinity (Table 2 and Figure 1). The PE 
(peptide 6) and SP (peptides 7 and 8) turns were again 
equipotent to PYY3-36, however, excluding the turn motif 
(peptides 1 and 2) proved to be slightly unfavorable. The GG turn 
(peptide 5) was equipotent to the analogs without a turn motif and 
demonstrated about half the potency of PYY3-36 towards the Y4 
receptor. The binding affinities towards the Y1 receptor were 
greatly affected by the addition of an additional amphipathic 
α-helix. No turn (peptides 1 and 2) and the PE turn motif (peptide 
6) had little effect on the binding affinity towards the Y1 receptor. 
The latter gave an almost identical Y receptor binding profile as 
PYY3-36, which indicates that the additional α-helix has to be 
positioned in a certain fashion to have influence on the Y receptor 
binding affinity. Peptides 3-5 and 6-8 showed a very low Y1 
receptor affinity, which consequently leads to improved Y2/Y1 
and Y4/Y1 receptor selectivity’s compared to PYY3-36 (Table 2 
and Figure 1). 
Biophysical data 
The secondary structures of peptides 1-8 in solution were 
assessed by circular dichroism (CD) in 10 mM phosphate buffer. 
The spectra obtained are typical for the α-helical structure, 
showing characteristic minima at 208 nm and 222 nm (Figure 2). 
The degree of α-helicity of the analyzed peptides were between 
20 and 31%, while PYY1-36 and PYY3-36 had an α-helicity of 27 
and 26%, respectively. Several branched PYY3-36 analogs 
showed nearly a doubling in mean molar ellipticity (ME) at 220 
nm, i.e. per mol peptide, compared to PYY3-36, originating from 
the increase in the number of α-helical residues (not shown). 
Peptides 2, 5, and 7 show equal ME at 220 nm, compared to 
PYY3-36, thus for these peptides the addition of a potential 
α-helix surprisingly did not give a higher ME in solution. For all the 
novel analogs the introduction of an additional α-helix appears to 
be well tolerated and do not result in disruption of the secondary 
structure. Size exclusion chromatography of 40 μM peptide in 
phosphate buffered saline (PBS) showed the novel analogs to be 
monomers. The amphipathic nature of the α-helix of the PP-fold 
peptides is, as previously explained, important for the binding 
affinity towards the Y receptors.20 Since the branched peptides 
are monomeric and several have higher ellipticity per molar (ME) 
at 220 nm they theoretically have more amphipathic structure 
exposed for either intra-molecular back-folding of the two 
α-helices in solution and/or membrane binding. 
Structure activity relationship 
Peptides 1-8 were investigated in an acute in vivo model in lean 
male NMRI mice (Naval Medical Research Institute, Charles 
River). The vehicle for all experiments was isotonic saline (0.9%). 
The peptides were administered twice daily subcutaneously in the 
inguinal region. The mice were given either vehicle (0.9% saline), 
Figure 3. Acute effect of peptides 3 and 7 in lean male NMRI mice. The mice were given either 0.9% saline as vehicle (□), 1.0 μmol/kg/day PYY3-36 (▲), or 1.0 
μmol/kg/day branched peptide (■) two times a day for two days, shown by an arrow, with a total of five injections. The body weights were calculated every 
morning for four days and given as mean body-weight (per cent of day zero). There were seven mice in each group (n=7). 
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Figure 2. UV CD spectra of PYY1-36, PYY3-36, peptide 3-4, and 
peptide 6-7 in aqueous buffered solution (20 μM peptide in 10 mM 
phosphate buffer). 
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PYY3-36, or peptides 1-8 in concentrations of 1.0 µmole/kg/day 
(volume of 3 mL/kg). The animals were injected a total of five 
times, starting on day 0.5 and last injection at day 2.5. The 
body-weights were recorded each morning at day 0 to 4. The 
animals had free access to food and water throughout the 
duration of the experiment.  
The peptides 1, 2, and 6 had poor effect on body-weight 
compared to PYY3-36, which correlated with the relatively good 
binding affinity to the Y1 receptor as well as the 3-4 fold reduction 
in Y2 receptor binding affinity. Also, peptide 5 showed no effect 
on body-weight, which was probably because of the relatively 
poor Y2 receptor binding affinity. Binding affinities of peptides 3 
and 4 were almost equivalent, except in Y2 receptor affinity of 
peptide 4 that was superior. However, while peptide 4 did not give 
any body-weight lowering effect, peptide 3 was efficacious (~4% 
body-weight reduction) (Figure 3). Almost identical Y receptor 
affinities were given for the isomeric pair 7 and 8, nevertheless, 
peptide 7 reduced body-weight by ~3% (Figure 3) and peptide 8 
had no effect, even though peptide 8 has slightly better binding 
affinity pattern. Peptides 3 and 4 both have the GPRRP turn motif 
and peptides 7 and 8 both have the SP turn before the additional 
amphipathic α-helix. The key difference was that the additional 
α-helix in peptides 4 and 8 was the retro-sequence (PYY31-17), 
unlike the two compounds showing body-weight reducing efficacy, 
peptides 3 and 7 (Figure 3), which had the forward sequences 
(PYY17-31). Thus, in contrast to the binding experiments the 
orientation of the additional amphipathic α-helix, i.e. forward vs. 
retro sequence, was important for in vivo efficacy. Moreover, the 
in vivo experiments generally confirm the results from the affinity 
study that the turn or spacer motif was of central importance.   
Conclusion 
In conclusion, based on the hypothesis that PYY3-36 interacts 
with the membrane prior to receptor binding, we have designed 
PYY3-36 analogs with a novel peptide architecture. An additional 
amphipathic α-helix was introduced on the Lys-4 side-chain in the 
PYY3-36 sequence. This increased the selectivity for the Y2 
receptor subtype over the Y1 receptor through a decrease in 
binding to the latter, possibly by guiding the C-terminal 
pentapeptide into a beneficial binding mode. In addition, previous 
studies had shown that N-terminal truncation of PYY3-36 had 
dramatically decreased its Y1 binding16; thus placing an additional 
helix at the N-terminus might decrease Y1 binding. The turn motif 
showed to be a switch for Y1 receptor potency without affecting 
the Y2 receptor potency. Incorporating the restricted GPRRP and 
SP turns gave high potency both in vitro and in vivo. In contrast, 
the GG and PE turns, as well as the absence of a turn in the 
sequence, gave either poor Y2 receptor affinity or relative high Y1 
receptor affinity in vitro and showed no activity in vivo. 
Introduction of an additional α-helix also provides more 
possibilities for self-assembly of these novel PYY3-36 analogs. 
The addition of an amphipathic α-helix generally leads to an 
increased degree of mean ellipticity (ME). CD indicates non or 
little disturbance of the native α-helical structure of the peptides 
and SEC indicates the peptides are monomers in PBS. Peptides 
with the retro-sequence were inactive in the in vivo experiments, 
in contrast to the structure-affinity relationship experiments which 
shown good selectivity and affinity. An increased Y receptor 
selectivity, compared to PYY3-36, led to a 3-4% reduction in 
body-weight for the peptides 3 and 7 in lean male NMRI mice. 
This demonstrates that radical re-design of the PYY3-36 
architecture can provide new agonists with nanomolar affinities 
and improved sub-type selectivity as well as in vivo efficacy. 
Experimental Section 
Materials. The organic solvents and reagents for peptide synthesis 
were all of analytical reagent grade and were obtained from Fluka, 
Advanced Chemtech, Sigma Aldrich, Chemimpex, Chemlabs or 
Spectrochem. TentaGel S Rink Amide resin was obtained from Fluka. 
Human Embryonic Kidney 293 cells (HEK293 Flp-In T-Rex), and 
pcDNA3.1 vector were purchased from Invitrogen. Dulbecco’s 
Modified Eagle’s Medium (D-MEM), fetal calf serum, penicillin-
streptomycin solution, phosphate buffered saline (PBS), sucrose, and 
99% glycerol were all obtained from Sigma-Aldrich. FuGENE 6 
transfection reagent, complete protease inhibitor cocktail tablets and 
bovine serum albumin (BSA) were purchased from Roche. 2-Amino-
2-hydroxymethyl-propane-1,3-diol (TRIS), MgCl2·6H2O, CaCl2, and 
NaCl were obtained from AppliChem GmbH. (2S,3S)-1,4-bis-
sulfanylbutane-2,3-diol (DTT) was obtained from GE Healthcare and 
radioactive labeled agonists were purchased from Phoenix 
pharmaceuticals. 96-Well filtration MultiScreen HTS, DV plates were 
obtained from Millipore.  
Peptide synthesis. The peptides were prepared by automated 
peptide synthesis on a Symphony parallel synthesizer (PTI) by 
standard solid-phase peptide synthesis (SPPS) on TentaGel S Rink 
Amide resin (0.24 mmol/g loading) with 9-fluorenylmethyloxycarbonyl 
(Fmoc) for protection of Nα-amino groups except for the N-terminal Ile 
of the main-chain, where Boc (tert-butoxycarbonyl) was used. Side-
chain protecting groups were tert-butyl (Ser, Thr, Tyr, Asp, Glu), tert-
butoxycarbonyl (Lys), 1-(4,4-dimethyl-2,6-dioxocyclohex-1-
ylidene)ethyl (Dde, for branching at Lys), 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), and trityl (Trt, for Asn, Gln, 
His). The peptides syntheses were conducted in 0.1 mmol scale. 
Nα-Fmoc amino acids (6.0 equiv) were coupled using 
diisopropylcarbodiimide (DIC) (6.0 equiv) as coupling agent and 
1-hydroxybenzotriazole (HOBt) (6.0 equiv) as additive in DMF for 120 
min. Nα-Fmoc deprotection was performed using piperidine-DMF (1:4) 
for 3 min, followed by piperidine-DMF (1:4) for 17 min. The Lys(Dde) 
residue was side-chain deprotected with 2.5% (v/v) hydrazine hydrate 
in DMF at room temperature for 15 min. The peptide amides were 
Table 3. Quantification and characterization data of PYY1-36, PYY3-36 and 
peptide 1-8. 
 ESI-MS (m/z)[a] Purity[b] 
Peptide Calcd. MS Found, [M+4H]4+ [%] 
PYY1-36 4309.8 1078.1 98 
PYY3-36 4049.5 1012.8 98 
1 5926.3 1482.4 97 
2 5926.3 1482.5 96 
3 6490.4 1623.3 96 
4 6490.4 1623.3 96 
5 6042.0 1510.6 95 
6 6111.0 1528.5 95 
7 6111.0 1528.1 96 
8 6153.0 1538.7 95 
[a] Identified by ESI-MS on a Agilent Technologies LC/MSD VL.  
[b] Quantified by RP-HPLC at 215 nm. Eluent A: 0.1% TFA in H2O. Eluent B: 
0.1% TFA in AcN. 
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released from the solid support by treatment with reagent K 
(trifluoroacetic acid (TFA)-phenol-thioanisol-1,2-ethanedithiol (EDT)-
H2O (82.5:5:5:2.5)) for 2.5 hours. The TFA solutions were 
concentrated by nitrogen flow and the compounds were precipitated 
with diethylether to yield the crude materials as white powders.  
Purification was accomplished by RP-HPLC (Agilent 1200 series) on 
a preparative column (Zorbax-Eclipse XDB-C18, 7 μm particles, 
21.2×250 mm) using the following solvent system: solvent A, water 
containing 0.1%  TFA; solvent B, acetonitrile containing 0.1% TFA. B 
gradient elution (0-2 min 5%, 2-5 min 5-25%, 5-50 min 25-60%) was 
applied at a flow rate of 20 mL min-1 and column effluent was 
monitored by UV absorbance at 220 nm.  Identification and 
quantification were carried out by LC-MS (Agilent Technologies 
LC/MSD VL) using the eluent system A-B (solvent A, water containing 
0.1% TFA; solvent B, acetonitrile containing 0.1% TFA). The eluent 
system A-B was applied on a C18 analytical column (Zorbax Eclipse 
XDB, 80 Å 5 μm 4.6×150 mm) where the B gradient elution (0-25 min: 
5-50%) was applied at a flow rate of 1.0 mL min-1. Quantification and 
characterization data are given in Table 3. 
Size exclusion chromatography. SEC was performed on an ÄKTA 
purifier equipped with a Superdex peptide HR10/30 column (GE 
healthcare) with an internal diameter of 10 mm. Packing height was 
30 cm and with an approximated column volume of 24 mL. The 
following standards dissolved in PBS (1.0 mg mL-1) were used; 
Aprotinin (6500 Da), ribonuclease A (13700 Da), carbonic anhydrase 
(29000 Da) and ovalbumin (43000 Da). As mobile phase phosphate 
buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer) 
at pH 7.4, was used. The samples were dissolved in 10 mM 
phosphate buffer at pH 7.4 to a final peptide concentration of 40 μM. 
Inject volume was 50 μL. The column effluent was monitored at 215, 
254 and 280 nm. 
Circular dichroism spectroscopy. UV CD spectra were recorded on 
a JASCO J-810 circular dichroism system using rectangular Hellma 
quartz cells with a light path of 1 mm. The peptide solutions were 
approximately 20 μM in 10 mM phosphate buffer, pH 7.4. The 
absolute concentration was determined spectroscopically (tyrosine 
absorption at 274 nm, using ε = 1420 cm−1M−1). The mean residue 
ellipticity (MRE) calculated according to Yang et al. in which the 
number n refers to the number of residues.21 The α-helicity was 
calculated according to a formula by Yang and co-workers.21 
Radioligand displacement assay. Cell culture and receptor 
expression: The SK-N-MC cells were cultured in a 1:1 mix of HAM 
F12 and Dulbecco’s Modified Eagle’s Medium (D-MEM 1885), 
containing 15% (v/v) fetal calf serum (FCS), 1% non essential amino 
acids and 1% (v/v) penicillin-streptomycin in humidified atmosphere of 
5% carbon dioxide and 95% air, at 37°C. The human embryonic 
kidney (HEK293 Flp-In T-Rex) derived cell line was cultured in 
Dulbecco’s Modified Eagle’s Medium (D-MEM), containing 10% (v/v) 
fetal calf serum (FCS) and 1% (v/v) penicillin-streptomycin. Cells were 
grown as monolayers in humidified atmosphere of 5% carbon dioxide 
and 95% air, for 48 hours at 37°C. Using serum-free D-MEM and 
FuGENE 6 transfection reagent HEK293 Flp-In T-Rex cells were 
transiently transfected by pcDNA3.1 vectors which encode either the 
human Y2 or Y4 receptor (FuGENE 6/pcDNA3.1, 3:1). The 
transfected HEK293 Flp-In T-Rex cells were set to express the 
receptors in humidified atmosphere of 5% carbon dioxide and 95% air, 
for another 48 hours at 37°C.  
Preparation of membrane fractions. The SK-N-MC and the transiently 
transfected HEK293 Flp-In T-Rex cells were washed with phosphate 
buffered saline (PBS) and homogenized in cold homogenization 
buffer (50 mM Tris (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, 1.0 mM 
DTT, complete protease inhibitor cocktail (one tablet per 50 mL 
buffer)). An equal amount of 0.6 M sucrose was added to the cell 
mixture. The homogenate was centrifuged (10,000 g, 10 min at 4°C). 
Cell pellets were washed in washing buffer (SK-N-MC cells: 50 mM 
TRIS (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 2.5 mM CaCl2, 0.2% 
(w/w) BSA fraction V. HEK293-Flp-In-T-Rex: 50 mM TRIS (pH 7.5), 
2.5 mM MgCl2, 1.0 mM CaCl2, complete protease inhibitor cocktail 
(one tablet per 50 mL buffer), 1.0% (w/w) BSA fraction V), and 
subsequently the suspensions were centrifuged (10,000 g, 10 min at 
4°C). The pellets were re-suspended in glycerol containing binding 
buffer (50 mM TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, complete 
protease inhibitor cocktail (one tablet per 50 mL buffer), 1.0% (w/w) 
BSA fraction V, 20% (v/v) glycerol) and concentration was adjusted to 
an OD600 of 1.6.   
Binding affinity. All binding experiments were performed in 96-well 
filtration MultiScreen HTS, DV plates (Millipore) and every 
concentration point was performed as triplicates. The absolute stock 
concentration of the unlabeled peptides were determined 
spectroscopically (tyrosine absorption at 274 nm, using ε = 1420 
cm−1M−1). The unlabeled peptide (25 μL) at concentrations between 
10 pM and 10 μM, cell membrane suspension (3.5 µL), binding buffer 
(61.5 µL, 50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM CaCl2, 
complete protease inhibitor cocktail (one tablet per 50 mL buffer), 
1.0% (w/w) BSA fraction V)), radioligand solution (10 µL; Y1R: 
125I-[31Leu,34Pro]-pNPY; Y2R: 125I-PYY3-36; and Y4R: 125I-PP; specific 
activity of 800-1000 Ci mmole-1). After 1-2 hours of incubation the 
assay was terminated by filtration. Finally, the membrane-receptor-
ligand complexes were washed twice in cold TRIS buffer (50 mM 
TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM CaCl2) containing 5.0% BSA 
fraction V. Bound radioactivity was determined as counts per minute 
(Wallac 1470 WizardTM Automated Gamma Counter). Binding data 
were analyzed with GraphPad Prism 5.0 (GraphPad Software, Inc. 
San Diego, CA, USA). The displacement experiments were replicated 
until the standard error of mean (S.E.M.) of –log IC50 was below 0.1 (n 
= 2-5). 
In vivo experiments. All experiments were conducted in accordance 
with internationally accepted principles for the care and use of 
laboratory animals and were approved by the Danish Committee for 
Animal Research. 
Animals. The studies were carried out in lean male NMRI mice (Naval 
Medical Research Institute, Charles River) 8-9 weeks old. Studies 
were performed in the In Vivo Pharmacology Department of 
Rheoscience A/S. Animals were kept on a 12:12-h light-dark cycle 
(lights on at 03:00 AM) in a temperature-controlled environment (22–
24°C). 
Sample preparation. Vehicle for all experiments was isotonic saline. 
Compounds were administered twice daily subcutaneously in the 
inguinal region (inject volume: 3 mL/kg; for a 30 gram mouse 0.09 
mL). The animals were given either vehicle (0.9% saline), PYY3-36 or 
peptides 1-8 in concentrations of 1.0 µmole/kg/day. 
General procedure. The animals were on the day of arrival given 
water and food for the entire experiment (standard chow; Altromin 
standard chow 1324; Petersen, Ringsted, Denmark) and transferred 
to single cages upon arrival. After 5 days body-weight was recorded 
on the morning of day 0 (7:00 AM) and the mice were randomized. In 
the afternoon of day 0 (14:30 PM) the mice are given the first injection 
and the following 1.5 days mice are injected daily (06:30 AM and 
14:30 PM) with a total of 5 injections. Body-weight was recorded daily 
in the morning immediately after injection. Last injection was at 14:30 
PM on day 2. Body-weight was also recorded on the morning of day 3 
and 4. 
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Abstract 
 Food intake and energy expenditure are homeostaticly regulated by the 
hypothalamus and brainstem by central and peripheral hunger and satiety signals, such as 
PYY3-36. PYY3-36 expresses its actions by binding to an appetite and body-weight 
controlling G-protein coupled receptor family, the so-called Y receptors. It has been 
hypothesized that PYY3-36 accumulates on the surface of the membrane prior to receptor 
activation. Based on this phenomenon we have designed a collection of PYY analogs, 
which could possess a higher affinity towards the membrane and consequently, an 
increased peptide concentration in the vicinity of the Y receptor. The N-terminus of PYY 
was exchanged with different de novo designed heptad repeat α-helices. In doing so, the 
hydrophobicity and the amphipathic nature of the ligands were increased. The results 
show increased Y2 receptor affinity and potency for a number of our novel Y2 receptor 
agonists. Additionally, the affinity and potency towards the Y1 and Y4 receptors were 
either unaffected or decreased, most likely as a result of the removal of the flexible 
N-terminal segment. These novel ligands further support the hypothesis that PYY3-36 
associates with the membrane prior to binding to the receptor. 
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Introduction 
 Food intake and energy expenditure are homeostaticly regulated by the 
hypothalamus and brainstem. Central and peripheral hunger and satiety signals, such as 
neural and hormonal messengers from the gut and adipose tissue, supply key brain 
regions with information of the current state of energy.1 However, the regulatory system 
is generally unable to cope with large amounts of high-energy foods in conjunction with 
an inactive lifestyle, resulting in a gain in body-weight.2 Even though the system, in some 
cases, has proven unable to control food intake, elements of the regulatory system might 
be the key to combat obesity.  
 The only effective treatment of morbid obesity is a gastric bypass operation, 
which often leads to 30-40% sustained weight-loss.3 In addition to mechanical factors, 
gastric bypass also leads to changes in the release of gut hormones, such as increased 
secretion of peptide YY (PYY3-36) and GLP-1.4 Full-length PYY1-36 is postprandially 
secreted by L-cells in the distal gut.5 Subsequently, the N-terminal dipeptide, Tyr-Pro, is 
cleaved off by the ubiquitously expressed enzyme, dipeptidyl peptidase IV (DPP-IV),6 
which produces the major circulating form of the hormone in both the fed and fasted 
state, PYY3-36.7 Furthermore, it has recently been shown that PYY3-36 play a role in 
energy homeostasis and has additionally been proposed as a novel class of peptide 
hormones for the treatment of obesity.8 Moreover, peripheral administration of PYY3-36 
reduces body-weight in several animal models of obesity further demonstrating that Y2 
agonists are pharmacological relevant.8,9  
PYY is a member of the PP-fold family of peptides, that also consists of 
pancreatic polypeptide (PP) and neuropeptides Y (NPY),10 which expresses their actions 
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by binding to an appetite and body-weight controlling G-protein coupled receptor family, 
the so-called Y receptors (Y1, Y2, Y4 and Y5).11 PYY1-36 is an agonist in the nanomolar 
range stimulating both the Y1 and Y2  receptors sub-types,12,13 leading to numerous 
actions especially on the gastrointestinal function.14 PYY1-36 acts through the Y1 
receptor in the CNS to stimulate appetite and promote weight gain. Conversely, the major 
blood-circulating form of PYY, the N-terminally truncated PYY3-36, binds in a lesser 
extent to the Y1 receptor, but with a high affinity to the Y2 receptor.12 Given the 
possibility that PYY3-36 analogs, when given in pharmacological doses that affects 
appetite and food intake,15 may also engage central orexigenic Y1 receptors we aimed to 
develop more selective (Y2 over Y1) PYY3-36 analogs. 
PYY1-36 consists of a C-terminal receptor-recognizing pentapeptide, subsequent 
to an amphipathic α-helix and followed by a flexible N-terminal polyproline helix. Both 
PYY1-36 and PP are back-folded in solution, which is not the case for NPY, however, 
when bound to the membrane NPY and PYY1-36 show almost identical secondary 
structures, which are in alignment with the virtually matching binding profiles towards 
the Y receptor sub-types, as well as their high degree of sequence homology.16 In 
contrast, PP is pharmacologically different from the other members of PP-fold family of 
peptides as it selectively activates the Y4 receptor. It has a different secondary structure 
in the membrane-bound state - especially in the C-terminal region.16-18 Zerbe and co-
workers have hypothesized that the PP-fold peptides bind to the Y receptors by a 
mechanism referred to as the membrane compartment model,16-18 which initially was 
proposed by Kaiser and Kezdy,19 and further developed by Schwyzer et al.20 Prior to 
binding to the receptor, the amphipathic peptide ligands associate with the membrane 
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surface and accumulate in the vicinity of the receptor. The bioactive conformations are 
induced, which leads to a reduced entropic loss upon receptor binding and activation. It is 
hypothesized that the amphipathic α-helix of the PP-fold peptides associates with the 
membrane and guide the C-terminal receptor-recognizing segment into the optimal 
conformation for receptor activation, thus the receptor-membrane associated state could 
be close to or in the bioactive conformation.17  
 We have taken advantage of the hypothesized membrane-ligand binding 
mechanism in the design of an array of new PYY analogs. The N-terminus, which is less 
important for Y2 receptor activity,11,21 was exchanged by an amphipathic α-helix to 
increase the affinity of the agonist towards the cell membrane, thus an increased 
concentration of ligand should accumulate in the vicinity of the Y receptors. The 
accumulated membrane-bound peptide is assumed to be in the receptor activating 
conformation. Additionally, we believe that an additional amphipathic α-helix can induce 
the inherent PYY α-helix in the conformation profitable for Y2 receptor activation. 
Given, that the N-terminus of PYY is not part of the construct of the novel analogs, we 
presume that the Y1 receptor will be less activated compared to the natural agonist. The 
de novo α-helical segments are sequences derived from heptad repeat peptides initially 
designed by Koksch and co-workers,22 Lazo and Downing,23 Mutter and co-workers,24 or 
Causton and Sherman25. These heptad repeat sequences were not originally designed for 
membrane binding, but for the study of self-assembly or coiled-coil systems in different 
environments.22-25 The majority of the introduced amphipathic de novo α-helix fragments 
have a neutral net charge, however, positive charged segments has also been exploited.  
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Heptad repeat (seven residues) motifs are known to be able to assemble specific 
α-helices into larger structures such as coiled coils. Adjacent heptad repeat motifs have 
been recognized in a diverse range of fibrous and globular proteins, and have the form (a-
b-c-d-e-f-g)m where about 70-75% of the a and d positions are occupied by apolar 
residues.26 Position e and g are often charged residues and position b, c, and f are 
preferably polar residues. This form of heptad repeat pattern results in α-helices which 
have 3.6 residues per turn and are amphipathic.27  
 
Materials and methods 
Materials. The organic solvents and reagents for peptide synthesis were all of 
analytical reagent grade and were obtained from Iris Biotech GmbH (Germany). 
TentaGel S Rink Amide resin was obtained from Rapp Polymere GmbH. Milli-Q 
(Millipore) water was used for RP-HPLC analyses and purifications. Human Embryonic 
Kidney 293 cells (HEK293 Flp-In T-Rex), and pcDNA3.1 vector were purchased from 
Invitrogen. Dulbecco’s Modified Eagle’s Medium (D-MEM), fetal calf serum, penicillin-
streptomycin solution, phosphate buffered saline (PBS), sucrose, and 99% glycerol were 
all obtained from Sigma-Aldrich. FuGENE 6 transfection reagent, complete protease 
inhibitor cocktail tablets and bovine serum albumin (BSA) were purchased from Roche. 
2-Amino-2-hydroxymethyl-propane-1,3-diol (TRIS), MgCl2·6H2O, CaCl2, and NaCl 
were obtained from AppliChem GmbH. (2S,3S)-1,4-bis-sulfanylbutane-2,3-diol (DTT) 
was obtained from GE Healthcare and radioactive labeled agonists were purchased from 
Phoenix pharmaceuticals. 96-Well filtration MultiScreen HTS, DV plates were obtained 
from Millipore. [3H]-myo-inositol (PT6-271) was purchased from Amersham. 
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Peptide synthesis. The peptides were prepared by automated peptide synthesis on 
a Syro II peptide synthesizer (MultiSynTech) by standard solid-phase peptide synthesis 
(SPPS) on TentaGel S Rink Amide resin with 9-fluorenylmethyloxycarbonyl (Fmoc) for 
protection of Nα-amino groups. Side-chain protecting groups were tert-butyl (Ser, Thr, 
Tyr), 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), and trityl (Trt, 
for Asn, Gln, His). Nα-Fmoc amino acids (4.0 equiv) were coupled using N-[(1H-
benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide HBTU (3.8 equiv), 1-hydroxybenzotriazole (HOBt) (3.6 
equiv), 1-hydroxy-7-azabenzotriazole (HOAt) (0.4 equiv) and N,N-diisopropylethylamine 
(DIEA) (7.8 equiv) as coupling reagents in DMF for 2 hours. Nα-Fmoc deprotection was 
performed using piperidine-DMF (2:3) for 3 min, followed by piperidine-DMF (1:4) for 
12 min. The peptides were released from the solid support by treatment of trifluoroacetic 
acid (TFA)-triethylsilane (TES)-H2O (95:2:3) for 2 × 2.5 hours. The TFA solutions were 
concentrated by nitrogen flow and the compounds were precipitated with diethylether to 
yield the crude materials as white powders. Purification was accomplished by preparative 
RP-HPLC (Dionex Ultimate 3000 system) on a preparative column (FeF Chemicals, 300 
Å 5 μm C4 particles, 2.1×200 mm) followed by a second purification on a preparative 
C18 column (FeF Chemicals, 200 Å 10 μm C18 particles, 2.1×200 mm) using the 
following solvent system: solvent A, water containing 0.1%  TFA; solvent B, acetonitrile 
containing 0.1% TFA. B gradient elution (0-50 min: 10% to 60%) was applied at a flow 
rate of 10 mL min-1 and column effluent was monitored by UV absorbance at 215 and 
254 nm simultaneously. Identification was carried out by ESI-MS (MSQ Plus Mass 
Spectrometer, Thermo). The peptides were quantified by analytical HPLC (Dionex 
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Ultimate 3000 system equipped with a PDA UV detector) using the eluent system A-B 
(solvent A, water containing 0.1% TFA; solvent B, acetonitrile containing 0.1% TFA). 
Eluent system A-B was applied on a C4 analytical column (phenomenex, Jupiter, 300 Å 5 
μm C4 particles, 3.9×150 mm) where a B gradient elution (0-14 min: 5% to 100%) was 
applied at a flow rate of 1.0 mL min-1. Quantification and characterization data are given 
in Table 1.  
Radioligand displacement assay. Cell culture and receptor expression: The SK-
N-MC cells were cultured in a 1:1 mix of HAM F12 and Dulbecco’s Modified Eagle’s 
Medium (D-MEM 1885), containing 15% (v/v) fetal calf serum (FCS), 1% non essential 
amino acids and 1% (v/v) penicillin-streptomycin in humidified atmosphere of 5% 
carbon dioxide and 95% air, at 37°C. The human embryonic kidney (HEK293 Flp-In T-
Rex) derived cell line was cultured in Dulbecco’s Modified Eagle’s Medium (D-MEM), 
containing 10% (v/v) fetal calf serum (FCS) and 1% (v/v) penicillin-streptomycin. Cells 
were grown as monolayers in humidified atmosphere of 5% carbon dioxide and 95% air, 
for 48 hours at 37°C. Using serum-free D-MEM and FuGENE6 transfection reagent 
HEK293 Flp-In T-Rex cells were transiently transfected by pcDNA3.1 vectors which 
encode either the human Y2 or Y4 receptor (FuGENE6-pcDNA3.1, 3:1). The transfected 
HEK293 Flp-In T-Rex cells were set to express the receptors in humidified atmosphere 
of 5% carbon dioxide and 95% air, for another 48 hours at 37°C.  
Preparation of membrane fractions: The SK-N-MC and the transiently transfected 
HEK293 Flp-In T-Rex cells were washed with phosphate buffered saline (PBS) and 
homogenized in cold homogenization buffer (50 mM Tris (pH 7.5), 2.5 mM MgCl2, 1.0 
mM CaCl2, 1.0 mM DTT, complete protease inhibitor cocktail (one tablet per 50 mL 
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buffer)). An equal amount of 0.6 M sucrose was added to the cell mixture. The 
homogenate was centrifuged (10,000 g, 10 min at 4°C). Cell pellets were washed in 
washing buffer (50 mM TRIS (pH 7.5), 2.5 mM MgCl2, 1.0 mM CaCl2, complete 
protease inhibitor cocktail (one tablet per 50 mL buffer), 1.0% (w/w) BSA fraction V), 
and subsequently the suspensions were centrifuged (10,000 g, 10 min at 4°C). The pellets 
were re-suspended in glycerol containing binding buffer (50 mM TRIS (pH 7.5), 2.5 mM 
MgCl2, 1.0 mM CaCl2, complete protease inhibitor cocktail (one tablet per 50 mL 
buffer), 1.0% (w/w) BSA fraction V, 20% (v/v) glycerol) and concentration was adjusted 
to an OD600 of 1.6.   
Binding affinity: All binding experiments were performed in 96-well filtration 
MultiScreen HTS, DV plates and every concentration point was performed as triplicates. 
The unlabeled peptide (25 μL) at concentrations between 10 pM and 10 μM, cell 
membrane suspension (3.5 µL), binding buffer (61.5 µL, 50 mM TRIS, pH 7.5, 2.5 mM 
MgCl2, 1.0 mM CaCl2, complete protease inhibitor cocktail (one tablet per 50 mL 
buffer), 1.0 % (w/w) BSA fraction V)), radioligand solution (10 µL; Y1R: 125I-
[31Leu,34Pro]-pNPY; Y2R: 125I-PYY3-36; and Y4R: 125I-PP; specific activity of 800-1000 
Ci/mmole) were added. After 1-2 hours of incubation the assay was terminated by 
filtration. Finally, the membrane-receptor-ligand complexes were washed twice in cold 
TRIS buffer (50 mM TRIS, pH 7.5, 2.5 mM MgCl2, 1.0 mM CaCl2). Bound radioactivity 
was determined as counts per minute (Wallac 1470 WizardTM Automated Gamma 
Counter). Binding data were analyzed with GraphPad Prism 5.0 (GraphPad Software, 
Inc. San Diego, CA, USA). The displacement experiments were replicated until the 
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standard error of mean (S.E.M.) of –log IC50 was below 0.1 (n = 2-5), except when 
different is stated. 
Functional assay. Transfections and tissue culture: COS-7 cells were grown in 
Dulbecco’s modified Eagle’s medium 1885 supplemented with 10% fetal calf serum, 2 
mM glutamine and 0.01 mg/mL gentamicin. Cells were transfected with 10 μg cDNA of 
wild type Y1 or Y2 receptors and 10 μg cDNA of a GαΔ6qi4myr28 using the calcium 
phosphate precipitation method with chloroquine addition.  The chimeric G-proteins 
allow the Gi coupled receptors to signal through the signal transduction pathways 
known for the Gq coupled receptors. Receptors from the PP fold family of peptides - 
the Y1 and Y2 receptors - were cloned from a human cDNA library and expressed in a 
pcDNA3.1 vector.  
Phosphatidylinositol turnover: One day after transfection, COS-7 cells were 
incubated for 24 hours with 5 μCi of [3H]-myo-inositol in 1 mL medium, washed twice in 
buffer, 20 mM HEPES, pH 7.4, and were subsequently incubated in 0.5 ml buffer 
supplemented with 10 mM LiCl at 37˚C for 30 min. After stimulation with various 
concentrations of PYY3-36 or the synthetic analogs for 45 min at 37˚C, cells were 
extracted with 10% ice-cold formic acid followed by incubation on ice for 30 min. The 
generated [3H]-inositol phosphate was purified on Bio-Rad AG 1-X8 anion-exchange 
resins. Determinations of each measuring point were made in duplicates. The functional 
assays were replicated at least 3 times. 
Size exclusion chromatography. SEC was performed on an ÄKTA purifier 
equipped with a Superdex Peptide HR10/30 column (GE healthcare) with an internal 
diameter of 10 mm. Packing height was 30 cm and with an approximated column volume 
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of 24 mL. The following standards dissolved in PBS (1.0 mg mL-1) were used; Aprotinin 
(6500 Da), ribonuclease A (13700 Da), Carbonic anhydrase (29000 Da) and ovalbumin 
(43000 Da). The mobile phase was phosphate buffered saline (137 mM NaCl, 2.7 mM 
KCl, 10 mM phosphate buffer) at pH 7.4. The samples were dissolved in 10 mM 
phosphate buffer at pH 7.4 to a final peptide concentration of 40 μM. Inject volume was 
50 μL. The column effluent was monitored at 215, 254 and 280 nm. 
Circular dichroism spectroscopy. UV CD spectra were recorded on a JASCO 
J-810 circular dichroism system using rectangular Hellma quartz cells with a light path of 
1 mm. The peptide solutions were approximately 20 μM in 10 mM phosphate buffer, pH 
7.4. The absolute concentration was determined spectroscopically (tyrosine absorption at 
274 nm, using ε = 1420 cm−1M−1). The mean residue ellipticity (MRE) and degree α-
helicity were calculated according to Yang et al.29 The number n refers to the number of 
residues. 
 
Results and Discussion 
Peptide synthesis. The peptides were synthesized on Rink Amide TentaGel resin 
using the Fmoc/t-Bu strategy by automated solid-phase peptide synthesis. The Nα-Fmoc-
protected amino acids were coupled using HBTU as coupling reagent, DIEA as base, and 
HOBt and HOAt as additive, in DMF. Coupling times were generally 2 × 2.5 hours. The 
peptides were side-chain deprotected and at the same time cleaved from the solid support 
by a TFA cocktail containing TES and H2O as scavengers. Finally, the peptides were 
purified by RP-HPLC and characterized by analytical HPLC and mass spectrometry. The 
final products were obtained with > 95% purity (Table 1).   
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Structure evaluation. UV CD of PYY3-36 as well as the novel Y2 agonists (20 
μM) were obtained in 10 mM phosphate buffer (pH 7.4) using a JASCO J-810 circular 
dichroism system. PYY3-36 gave a degree of α-helicity of 26%, which is in agreement 
with literature.30 The spectra acquired for peptides 1-4, 7-9, 11-14, 17, 20, and 21 
(α-helicity between 25-52%) are typical for the α-helical structure, showing characteristic 
minima at 208 nm and 222 nm (Figure 1). The spectra obtained of peptides 1, 5, 10, 15, 
and 16 (α-helicity between 8-16%) also showed typical α-helical structures, however, to a 
considerable lower extent. Peptides 6, 18, and 19 were not investigated. 
UV CD also show that substituting Leu with Trp (peptide 2 (α-helicity: 45%) and 
12 (α-helicity: 50%), respectively) slightly stabilizes the de novo α-helix, however, 
introducing Tyr instead of Lys (peptide 15 (α-helicity: 8%) and 2 (α-helicity: 45%), 
respectively) resulted in a nearly abolishment of α-helical structure (not shown). By 
exchanging the positively charged, hydrophilic Lys with the neutral, hydrophobic Tyr 
residue the ionic interactions between positive and negative charged residues of the de 
novo α-helix is reduced which consequently could lead to a destabilization of the α-helix. 
Generally, circular dichroism reveals that large reduction in α-helicity results in poor 
binding towards all the Y receptor subtypes, which is in alignment with the membrane 
compartment model for the PP-fold peptides.16-18 
Despite, the amphipathic nature and the high degree of α-helicity of the novel 
PYY3-36 analogs, size exclusion chromatography in PBS showed no self-assembly of the 
tested analogs, which could indicate a back-folding of the additional heptad repeat 
sequence onto the native amphipathic PYY α-helix resulting in a hydrophobic core 
between the two α-helix segments. Another possibility could be that the peptides are 
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highly aggregated thus unable to elute from the SEC-column due to size and interaction 
with the column-material.  
Affinity and activity evaluation. To characterize the influence of substituting the 
flexible hydrophilic N-terminus with amphipathic de novo designed α-helices, the binding 
affinity of the novel PYY3-36 analogs were tested using radioligand displacement assay 
(competition binding assay) based on membranes from SK-N-MC and HEK293 Flp-In T-
Rex cell lines expressing the human Y1, Y2 and Y4 receptor sub-types, respectively. 
125I-[31Leu,34Pro]-pNPY for Y1 receptor, 125I-hPYY3-36 for Y2 receptor and 125I-hPP for 
Y4 receptor were used as radioligands. The analogs with the highest affinity as well as 
selectivity towards the Y2 receptor were additionally analyzed for their ability to activate 
the Y1 and Y2 receptor sub-types. The signal transduction assay was based on COS-7 
cells expressing the chimeric G-protein GαΔ6qi4myr,28 and either the Y1 or Y2 receptor 
sub-type, which allows the Gi coupled receptors to signal through the signal 
transduction pathways known for the Gq coupled receptors. After incubation the 
generated [3H]-inositol phosphate was purified and measured. Binding affinities (IC50 
values) and activation potencies (EC50 values) for the PYY3-36 analogs as well as native 
PYY3-36 are summarized in Table 2. 
Structure affinity and activity relationship. The binding and signal transduction 
studies of native human PYY3-36 confirms the high potency towards the Y2 receptor 
subtype.31 PYY3-36 is, however, only moderately selective because of the additional 
engagement to the Y1 receptor (Table 2).31 Though a N-terminal truncation version of 
PYY3-36, e.g. PYY13-36 (peptide 1), leads to a high degree of Y2 receptor selectivity, 
the sub-nanomolar affinity towards the anorectic Y2 receptor also drops, which confirms 
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previous reports.13,32 Introducing an amphipathic heptad repeat sequence to PYY13-36 
retains part of the affinity towards the Y2 receptor first shown by peptide 2 - the high Y2 
receptor selectivity shown by PYY13-36 (peptide 1) was nevertheless, preserved. 
Modifying peptide 2 at the N-terminus by acetylation or lipidation did not result in altered 
Y receptor affinity or selectivity (peptides 3 and 4). Conversely, adding PYY3-9 in the 
N-terminus of peptide 2, giving peptide 5, resulted in an undesirable Y1 receptor affinity 
gain and a fivefold decrease in Y2 receptor affinity compared to peptide 2. Exchanging 
the N-terminal Tyr of peptide 2 with a hydrophobic Ala (peptide 6), slightly improved the 
Y2 receptor affinity compared to peptide 2 but, the signal transduction assay showed a 
6-fold decrease in Y2 receptor activity compared to inherent PYY3-36 (Table 2). 
Altering the stereogenic center of the amino acid residues of the turn motif by 
incorporating D-amino acids into the loop of the peptide 2 sequence (peptides 7-10) 
resulted in only minor changes in the affinity towards the Y receptors compared to 
peptide 2. This indicates that changing the geometry of this type of turn has less impact 
on the binding affinity towards the Y receptors.  
Substituting the hydrophobic Leu of the heptad repeat segment with the less 
hydrophobic Phe (peptide 11) or Trp (peptide 12) resulted in equipotency towards the Y2 
receptor subtype compared to peptide 2. Interestingly the Phe containing analog 
demonstrated a major increase in Y1 receptor affinity (eleven-fold) compared to peptide 
2. Moreover, selected Glu or Lys residues of peptide 2 were substituted with Ser, 
peptides 13 and 14, to change the isoelectric point and the net charge of the heptad repeat 
segment, only resulted in minor increases in Y2 receptor affinity towards the Y receptors 
compared to peptide 2. However, substituting the Ser of peptide 14 for Tyr (peptide 15) 
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gave poor binding affinities towards all Y receptor subtypes, which may originate from a 
destabilization of the α-helices (α-helicity: 8%). The side-chain of Ser residues can make 
specific hydrogen bonds to the carbonyl oxygen of the third or fourth residue earlier in 
the sequence, which may stabilize the α-helix.33 Furthermore, peptide 15 is more 
hydrophobic than peptide 14, which could alter the binding mode towards the membrane, 
thus also the binding conformation towards the Y receptors.  Moreover, moving the de 
novo segment further away from the native PYY α-helix (peptide 16) also destabilized 
the secondary structure of the novel Y2 receptor agonist (α-helicity: 16%) as well as 
demonstrating a poor binding towards the Y receptors.  
The affinity towards the Y2 receptor was significantly improved when the 
N-terminal α-helix of peptide 2 was exchanged by different heptad repeat sequences22-24 
(peptides 17-20). Peptides 17 and 18 differ at position c and g of the heptad repeat 
segment which are swap over - heptad repeat sequences of peptides 17 (LKELERK) and 
18 (LKKLERE) (Table 2). The binding assays show that peptide 17 and PYY3-36 have 
equivalent binding affinities towards the Y1 and Y2 receptor sub-types. Contrary, peptide 
18 resulted in a slight and significant decrease in binding affinity towards the Y2 and Y1 
receptors, respectively, consequently leading to a highly selective analog. The major 
differences in binding affinity towards the Y1 receptor were not shown by the signal 
transduction assay of peptides 17 and 18 (Table 2 and Figure 2), which, however, 
resulted in a two- to threefold increase in potency towards the Y2 receptor and only 
minor decreases towards the Y1 receptor. Interestingly, peptide 19 resulted in an 
exceptional high affinity and potency towards the Y2 receptor (fivefold increase 
compared to PYY3-36), in addition to a slight reduction in Y1 receptor potency. The high 
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affinity may originate from the high Arg and Lys content of the amphipathic heptad 
repeat α-helix sequence. The positively charged residues may have a high affinity 
towards the negatively charged phospholipid bilayer of the membrane that additionally 
pre-orientates the inherent PYY α-helix in a conformation profitable for activation of the 
Y2 receptor subtype. Moreover, binding experiments of peptide 20 showed high affinity 
towards the Y2 receptor even though the de novo designed sequence has a neutral net 
charge, however, all the positively charged Lys are clustered in the middle of the heptad 
repeat sequence, which may again lead to a local net charge that are positive. Finally, 
peptide 21 showed poor Y2 receptor affinity compared to PYY3-36 that could originate 
from an unfavorable conformation of the C-terminal helix for Y receptor binding. Peptide 
21 additionally, as the only compound of this series of PYY analogs, shows a better 
affinity towards the Y4 receptor compared to PYY3-36. 
To summarize; to our knowledge no previously reported analogs of PYY3-36 has 
shown a fivefold increase in Y2 receptor potency in addition to a fourfold increase in Y 
receptor selectivity (Y2 over Y1) compared to PYY3-36. A neutral net charge of the 
heptad repeat sequences (peptide 2-12, 14-16, and 21) generally showed low to poor Y2 
receptor affinity and significantly decreased Y1 and Y4 receptor affinity, even though the 
sequences were designed to be amphipathic of nature. The amphipathic sequences with a 
positive net charge (peptides 13, and 17-20) showed up to a fivefold increase in Y2 
receptor potency without affecting the Y1 receptor potency, consequently leading to an 
increase in Y receptor selectivity (Y2 over Y1) (Table 2). 
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Conclusion 
We have taken advantage of the phenomenon that the PP-fold peptides associate 
with the membrane prior the receptor activation, in the design of an array of novel Y2 
receptor ligands. We believe that this rational design concept for the development of 
novel PYY analogs is very unique and innovative. Our novel Y receptor ligands increase 
both Y2 receptor affinity and selectivity, as well as support the hypothesis that members 
of PP-fold family of peptides associates with the membrane prior to receptor activation. 
These preliminary results point towards that increasing the affinity towards the 
membrane enhances the potency towards the Y2 receptor subtype. Our novel PYY 
analogs give a superior Y2 affinity over Y1, which potentially could lead to an enhanced 
pharmacological effect. The Y2 receptor agonists with the highest potency have a 
positive net charge in their heptad repeat segments, which could associate with the 
phospholipid bilayer, and thereby may lead to an increased ligand accumulation in the 
vicinity of the membrane, and in this manner also the Y receptors. Finally, we established 
by circular dichroism that high degree of MRE at 220 nm is important for achieving 
potent de novo designed PYY analogs. We believe this knowledge can contribute to the 
development of more efficacious therapeutics against obesity in the future.   
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TABLES: 
Table 1. Quantification and characterization data of PYY3-36 and R1-NRYYASLRHYLNLVTRQRY-NH2 (R1-PYY18-36) analogs.  
ESI-MS (m/z)a Purityb  
Peptide N-terminal, R1 Calcd. MS Found Assigned Found Assigned (%) 
PYY3-36 H-IKPEAPGEDASPEEL- 4049.46 1012.8  [M+4H]4+ 810.2 [M+5H]5+ 98 
1 H-SPEEL- 3040.6 1041.6 [M+3H]3+ 761.4 [M+4H]4+ 98 
2         H-YEELLKKLEELLKKASPEEL- 4870.6 1219.5 [M+4H]4+ 975.8 [M+5H]5+ 99 
3 CH3(CH2)4CO-YEELLKKLEELLKKASPEEL- 4968.8 1243.0 [M+4H]4+ 994.5 [M+5H]5+ 99 
4 Ac-YEELLKKLEELLKKASPEEL- 4912.6 1228.4 [M+4H]4+ 983.0 [M+5H]5+ 99 
5 H-IKPEAPGYEELLKKLEELLKKASPEEL- 5563.4 1391.7 [M+4H]4+ 1113.6 [M+5H]5+ 99 
6                    H-AEELLKKLEELLKKASPEEL- 4778.5 1195.3 [M+4H]4+ 956.2 [M+5H]5+ 99 
7                    H-YEELLKKLEELLKKASpEEL- 4870.6 812.5 [M+6H]6+ 696.5 [M+7H]7+ 99 
8                    H-YEELLKKLEELLKKASPeEL- 4870.6 812.3 [M+6H]6+ 696.7 [M+7H]7+ 95 
9                    H-YEELLKKLEELLKKASPEeL- 4870.6 812.2 [M+6H]6+ 696.2 [M+7H]7+ 97 
10                    H-YEELLKKLEELLKKASpeEL- 4870.6 812.5 [M+6H]6+ 696.4 [M+7H]7+ 99 
11                   H-YEEFFKKLEELFKKASPEEL- 4972.6 1243.9 [M+4H]4+ 995.4  [M+5H]5+ 99 
12                H-YEEWWKKLEELWKKASPEEL- 5089.7 1273.2 [M+4H]4+ 1018.8 [M+5H]5+ 99 
13                    H-YESLLKKLSELLKKASPEEL- 4786.5 1197.4 [M+4H]4+ 958.0 [M+5H]5+ 99 
14                    H-YEELLKSLEELLKSASPEEL- 4788.4 1197.7 [M+4H]4+ 958.0 [M+5H]5+ 99 
15                    H-YEELLKYLEELLKYASPEEL- 4940.6 1235.8 [M+4H]4+ 989.0 [M+5H]5+ 99 
16          H-YEELLKKLEELLKKAGEDASPEEL- 5242.9 1311.1 [M+4H]4+ 1049.1 [M+5H]5+ 99 
17               H-YLERKLKELERKLKELSPEEL- 5111.9 1278.6 [M+4H]4+ 1023.2 [M+5H]5+ 99 
18 H-YLERELKKLERELKKLSPEEL- 5111.9 1279.2 [M+4H]4+ 1023.3 [M+5H]5+ 99 
19 H-YLKALKEALKALKEALKSPEEL- 4953.7 1239.2 [M+4H]4+ 991.6 [M+5H]5+ 99 
20 H-NLEELKKKLEELKGSPEEL- 4694.3 1174.3 [M+4H]4+ 939.8 [M+5H]5+ 99 
21 H-YLKALEEKLKALEEKLKALEEKGSPEEL- 5697.5 1425.0 [M+4H]4+ 1140.4 [M+5H]5+ 98 
a Identified by ESI-MS on a MSQ Plus Mass Spectrometer (Dionex). b Quantified by RP-HPLC at 215 nm. Eluent  system  A-B: 
Eluent A: 0.1% TFA in H2O. Eluent B: 0.1% TFA in AcN. 
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Table 2. PYY3-36a and R1-NRYYASLRHYLNLVTRQRY-NH2 (R1-PYY18-36) binding to Y receptor subtypes Y1, Y2, and Y4, in 
addition to functional Y1 and Y2 receptor evaluation of the most potent Y2R agonists.   
Binding affinity                       
assay IC50 [nM] 
Signal transduction 
assay EC50 [nM] 
Peptide N-terminal, R1 Y1R
b Y2Rc Y4Rc Y1Rd Y2Rd 
PYY3-36 H-IKPEAPGEDASPEEL- 7.8 ± 1.1 0.50 ± 0.09 255 ± 29 90 ± 12 5.6 ± 1.1 
1 H-SPEEL- >1000 36.2 ± 7.2 >1000 - - 
2         H-YEELLKKLEELLKKASPEEL- 518 ± 350 10.7 ± 2.5 >1000 - - 
3 CH3(CH2)4CO-YEELLKKLEELLKKASPEEL- >1000 9.1 ± 6.7 >1000 - - 
4 Ac-YEELLKKLEELLKKASPEEL- 794 ± 291 8.6 ± 1.8 >1000 - - 
5 H-IKPEAPGYEELLKKLEELLKKASPEEL- 230 ± 59 54.0 ± 21.4 >1000 - - 
6                    H-AEELLKKLEELLKKASPEEL- 424 ± 2 6.1 ± 1.8 >1000 141 ± 11 31.6 ± 12.5 
7                    H-YEELLKKLEELLKKASpEEL- 141 ± 8 5.5 ± 1.4 >1000 - - 
8                    H-YEELLKKLEELLKKASPeEL- >1000 29.1 ± 10.9 >1000 - - 
9                    H-YEELLKKLEELLKKASPEeL- >1000 11.8 ± 3.3 >1000 - - 
10                    H-YEELLKKLEELLKKASpeEL- 774  ± 104 12.0 ± 3.5 >1000 - - 
11                   H-YEEFFKKLEELFKKASPEEL- 48 ± 4 8.0 ± 3.5 >1000 - - 
12                H-YEEWWKKLEELWKKASPEEL- >1000 9.1 ± 6.7 >1000 - - 
13                    H-YESLLKKLSELLKKASPEEL- 239 ± 124 4.9 ± 2.7 >1000 94 ± 33 3.9 ± 2.8  
14                    H-YEELLKSLEELLKSASPEEL- 805 ± 43 4.6 ± 1.1 >1000 - - 
15                    H-YEELLKYLEELLKYASPEEL- >1000 14 ± 9e >1000 - - 
16          H-YEELLKKLEELLKKAGEDASPEEL- 340 ± 107  14.1 ± 3.4 >1000 - - 
17               H-YLERKLKELERKLKELSPEEL- 11 ± 1.4 0.9 ± 0.4 >1000 113 ± 21 2.3 ± 1.2 
18 H-YLERELKKLERELKKLSPEEL- >1000 3.2 ± 2.6 >1000 97 ± 31 3.1 ± 1.8 
19 H-YLKALKEALKALKEALKSPEEL- >1000 4.3 ± 0.5 664 ± 276 63 ± 27 1.1 ± 1.0 
20 H-NLEELKKKLEELKGSPEEL- 27 ± 0.4 2.1 ± 0.5 532 ± 354 - - 
21 H-YLKALEEKLKALEEKLKALEEKGSPEEL- 141 ± 8 36.8 ± 19.0 174 ± 40 - - 
a Native human sequences. b SK-N-MC cells expressing the Y1R. c Y2R or Y4R transfected HEK293 Flp-In T-Rex cells.           
d Y1R or Y2R and GαΔ6qi4myr transfected COS-7 cells. e log S.E.M > 0.1 
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Figure 1. UV CD spectra of PYY3-36, peptide 2, 13, and 17 in aqueous buffered solution (20 μM 
peptide in 10 mM phosphate buffer). 
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Figure 2. Functional assay. The activity of PYY3-36, peptide 17 and 18 towards the Y1 (▲) and 
Y2 (■) receptor subtypes. 
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Abstract 
Precise microwave heating has emerged as a valuable addition to solid-phase 
peptide synthesis. New methods and protocols are required to utilize this potential and 
make it a reliable technique. Here we describe a new semi-automated instrument for 
solid-phase peptide synthesis with microwave heating and report protocols for its reliable 
use. The instrument features a flow-through reaction vessel that is placed in the 
microwave instrument throughout the synthesis. Bubbling with N2 gas during the 
microwave irradiation proved important for temperature control. Washing and Fmoc 
removal steps were automated, while activated Fmoc-amino acids were added manually. 
Several linkers and resins were evaluated and protocols for synthesis of difficult 
sequences were developed. These included on-resin reductive amination of BAL handles 
under microwave heating. We believe that the instrument, as well as the protocols for its 
use, will be useful tools for peptide chemists. 
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Keywords 
Microwave-assisted solid-phase peptide synthesis, SPPS, difficult sequences, 
PYY, LysM domain, ortho backbone amide linker 
 
Introduction 
Solid-phase peptide synthesis (SPPS) is still often faced with difficulties in the 
assembly of long and so-called difficult sequences due to incomplete reactions, possibly 
caused by aggregation and sterical hindrance. These problems have only partly been 
solved by new coupling reagents and solid supports. Precise microwave heating has 
emerged as one new, additional parameter for SPPS.1-6 Combining SPPS with precise 
microwave heating has the potential to enable syntheses of long and/or difficult 
sequences and to improve purity. 
During the synthesis of difficult sequences the peptide chain most likely becomes 
partially inaccessible typically due to the formation of secondary structures, especially of 
β-sheets.7 Methods to suppress intra-molecular aggregation have been described and 
include pseudo-prolines,7 solvent composition,8 and chaotropic salts,9,10 however, the 
utility is limited and the efficiency is variable. Inter-molecular aggregation could lead to a 
poor solvation of the peptidyl-polymer, but it is less pronounced with low-loading resins. 
Heating is likely to reduce both the inter- and intra-molecular derived aggregation and 
thereby to decrease the reaction time and improve the coupling efficiency of bulky and β-
branched amino acids, as well as Nα-deprotection of sterically hindered peptidyl-
polymers. Kappe et al. have recently probed microwave-assisted SPPS by comparing it 
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with oil bath-heating SPPS and concluded that the effect was of thermal nature.11 Non-
thermal effects were absent, which contradicts some previous suggestions.12,13 
Microwave irradiation is an advantageous tool in peptide chemistry because of the rapid 
and precise elevation of the temperature, and the efficient temperature control during the 
synthesis.  
In this paper a new, flexible semi-automated instrument for the application of 
precise microwave heating in solid-phase peptide synthesis is presented. It combines a 
slightly modified Biotage Initiator microwave instrument, with a custom-modified semi-
automated peptide synthesizer from MultiSynTech (Figure S1, Supporting Information). 
A specially made flow-through reaction vessel is placed in the microwave oven for the 
duration of the synthesis (Figure S2, Supporting Information). Mixing is achieved by 
nitrogen bubbling and is necessary to reach a homogenous heat distribution in the reactor 
vessel,4 as magnetic stirring is problematic during solid-phase synthesis. The washing 
steps are automated, though the activated amino acid derivatives have to be added 
manually. 
Protocols were optimized for both Nα-deprotection and for peptide coupling 
reactions. The external conditions, temperature and time, for Fmoc removal were first 
studied on Fmoc-Rink polystyrene resin (PS) (1) and the optimal conditions were further 
investigated on a resin-bound Fmoc protected 37-mer, 
Fmoc-VATTLYENLTNWNIVQASNPGVNPYLLPERVKVVFPL-Rink-TG (2), derived from 
the Nod-factor receptor 5 (Nfr5), LysM2 domain (Lotus japonicus sequence).14  
Coupling conditions, temperature and time, were optimized using decapeptide 3 
(Table 1), which Carpino and co-workers have reported to be a very difficult sequence,15 
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and originates from the C-terminus of the MuLV CTL epitope.16 The optimized protocol 
has been utilized to synthesize the following peptides: Peptide hormone PYY1-3617 
(Table 1, peptide 4), different regions of the Nfr5, LysM2 domain (Lotus japonicus 
sequence) (Table 1, peptides 5 and 6),14 and finally a glycopeptide aldehyde (Table 1, 
peptide 7). 
 
Results and discussion 
Microwave-assisted Fmoc removal. As a model system for Fmoc removal the 
high-loading (0.71 mmol/g) Fmoc-Rink PS (1) was chosen, as it in our hands required 
long reaction times at room temperature to be fully deprotected. The Rink Amide PS was 
deprotected by piperidine-DMF (1:4) using variable temperatures (RT, 60°C, 80°C) 
obtained by microwave irradiation and reaction times (2-15 min). After initial Fmoc 
removal the residual loading was determined by a loading test. Residual loading after Nα-
deprotection at RT for 2 min was 0.99 μmol per gram resin, however residual loading 
after Nα-deprotection at 60°C for 2 min was merely 0.13 μmol per gram resin (Table 2). 
The difference is noteworthy when synthesizing long and difficult sequences because the 
Nα-group becomes more hindered as the peptidyl-resin chain grows. The results were 
integrated in an optimized Nα-deprotection protocol: piperidine-DMF (1:4) for 1 min at 
RT followed by piperidine-DMF (1:4) for 2 min at 60°C. The protocol was verified on 
the Nα-deprotection of peptidyl-resin 2, which is the C-terminal 37 residue segment of the 
LysM2 domain. After Nα-deprotection the residual loading was analyzed by a loading test 
and was determined to be < 0.0005 mmol/g (Figure 1.B). The protocol has been used in 
all the following microwave-assisted experiments including the coupling optimization, 
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except the Nα-deprotection of aspartic acid, which was deprotected without the use of 
microwave irradiation to avoid any risk of epimerization. 
Microwave-assisted amino acid coupling optimization. The decapeptide 
sequence 3 derived from the MuLV CTL epitope (26 amino acids) was first reported as a 
difficult sequence by Jung and Redemann, who showed major deletion peptides within 
the first nine amino acid coupling steps.16 As a difficult sequence, peptide 3 was chosen 
to determine the optimal coupling conditions (temperature and time) for the semi-
automated microwave-assisted peptide synthesizer (SAMPS) using HBTU, HOBt, and 
DIPEA as coupling reagents. The coupling temperature was RT, 60°C or 80°C and the 
coupling time 2 min, 5 min or 10 min. On a fully automated synthesizer (Syro II, 
MultiSynTech) two control syntheses were additionally performed with coupling times of 
45 min and 2×150 min at RT. All the coupling conditions were analyzed by LC-MS and 
the efficiency was measured by the percentage of peak area of peptide 3. Coupling at RT 
for 2 min gave rise to a poor purity of 6% and the major deletion peptides were des-Phe 
and des-(Phe Thr) (10), des-(Trp Thr) (12) and des-(Trp Phe) (13). Peptide couplings 
performed at 60°C for 2 min improved the purity of peptide 3 considerably to 20%, 
however, elevating the temperature to 80°C for 2 min only increased the efficiency by an 
additional few per cent to 24% (Figure 2). Prolonging the reaction time from 2 min to 10 
min at 60°C improved the purity of the final, crude peptide from 20% to 30% and the 
latter is compatible with conventional peptide synthesis at RT for 45 min (32%). 
Interestingly, a twofold increase in purity was observed when the reaction time was 
extended from 2 min to 10 min at 80°C, from 24% to 44%, and approximately equaled 
conventional peptide synthesis for 2×150 min at RT.  
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 Based on comparison with reported literature data on epimers15 our LC-MS 
analysis did not show any epimer formation of peptide 3. Carpino et al. did however 
observe the D-Ser epimer of peptide 3 as byproduct during their synthesis, even at RT, 
which probably can be explained by the absence of additives in the coupling mixture.15 
To summarize, these experiments show that microwave-assisted peptide coupling 
at 80°C for 10 min performs equal to double couplings for 150 min at RT. No 
epimerization was observed in any of the used protocols, as detected by the absence of 
additional peaks with identical masses. Peptide 3 is indeed a very difficult sequence and 
the optimal performance describe in literature, to our knowledge, provides a purity of 
49%, which was achieved using Nα-Bsmoc protection, HATU and DIPEA system with 7 
min preactivation, coupling times of 30 min and 15 min deblocking.15 We believe that 
less aggregating and sterically unhindered peptides can easily be synthesized using 
couplings at 80°C for only 2 min. This reduces the synthesis times significantly and 
provides a higher peptide turnover. 
 
Application to other sequences 
Peptide YY. PYY1-36, 4, is a 36 amino acid long peptide hormone involved in 
the regulation of food intake. It consists of a C-terminal α-helix and a N-terminal poly-
proline helix.17 PYY1-36 was synthesized on the SAMPS using the optimized protocol 
(10 min at 80°C). LC-MS showed a crude purity of 41% (data not shown) which 
demonstrates that microwave-assisted synthesis can potentially decrease the overall 
synthesis time of PYY1-36 considerably.   
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Nfr5 receptor peptides. In an ongoing study of Nfr5, difficulties during synthesis 
of a variety of analogs of the LysM2 domain were observed. Especially the synthesis of 
the C-terminal and the N-terminal regions were problematic, presumably due to 
formation of β-sheet like aggregates. LysM domains consist of two α-helices which are 
situated alongside a two-stranded anti-parallel β-sheet (βααβ structure) and has been 
identified in Nfr5 by sequence alignment of the crystal structure with the LysM domain 
of Bacillus subtilis ykuD.18 
The 11-mer 5 derives from the C-terminus of the LysM2 domain and consists of 
several β-branched and bulky amino acid residues resulting in sterical hindrance during 
peptide chain assembly. Nevertheless peptide 5, which is a very difficult sequence to 
synthesize, was prepared in an acceptable purity (48%) using the SAMPS (Figure 3).  
Furthermore, it is also difficult to synthesize the N-terminal 11-mer region of the 
LysM2 domain (residue 42-52) hence the SAMPS was used to synthesize this region. The 
first 41 amino acid were coupled using automated SPPS with coupling times of 2×150 
min at RT (the underlined part of entry 6, Table 2) and residue 42-52 were coupled using 
the optimized protocol for the SAMPS (80°C for 10 min). The microwave heating was a 
prerequisite for obtaining this protein segment after HPLC purification. However, it was 
difficult to estimate the crude purity due to close-lying peaks. 
Glyco-peptide aldehyde. The α-GalNAc moiety is a Tn cancer antigen which is 
recognized by a variety of lectins e.g. macrophage galactose lectin (MCL),19 
consequently cancer-associated glycopeptides and proteins represent a potential target for 
immunodiagnostics and therapeutics.20 We have previously reported a method for peptide 
coupling with microwave heating in a sealed container. This also worked particularly 
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well in the reductive amination of the ortho backbone amide linker (o-BAL) on TentaGel 
polymer.5 For the synthesis of glycopeptide aldehyde 7 by SAMPS in an open vessel, 
methanol was substituted for DMF in the reductive amination. The subsequent acylation 
of the secondary amine was performed in DMF-DCE (1:9) at 60°C, as the latter has a b.p. 
of 83°C (Scheme 1). 
Glycopeptide aldehyde 7 was subsequently synthesized using the optimized 
SAMPS protocol (coupling at 80°C for 2 min). After cleavage from the o-BAL 
functionalized TG resin four major peaks appeared in the analytical RP-HPLC 
chromatogram, however, by LC-MS it is conclusive that all the major peaks were 
glycopeptide 7 derivatives. Peak 18 is the fully acetylated version of peptide 7, peak 17 
and 19 are versions where one acetyl group has been lost, and peak 16 is a version where 
two acetyl groups has been lost (Figure 4.A). The partial O-deacetylation could possibly 
be due to the activation of DIPEA at elevated temperature, however Matsushita et al. 
does not report any problems during microwave-assisted synthesis of glycopeptides at 
50°C.2 These findings indicate that coupling glyco-amino acids at 80°C, can cause partial 
deacetylation of the glycan, but this may not be a major problem. Treating the peptide 
mixture with 0.1 M methoxide (NaOMe, pH 10) completely deprotected the glycan 
hydroxyl groups to yield the O-linked N-acetylgalactoseamine peptide aldehyde 7. The 
overall purity of glycopeptide 7 was 92% (Figure 4.B). 
 
Conclusion 
The semi-automated synthesizer (SAMPS) provides a flexible platform for 
peptide synthesis and different types of on-resin chemistry such as anchoring of o-BAL. 
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Several types of resins, with different functionalities were tested successfully. A 
systematic study of temperature and time showed that the reaction time for Fmoc removal 
can in most cases be reduced to 2 min at 60°C and the coupling time could be reduced to 
2-10 min at 80°C. Using the optimized protocol for the semi-automated microwave 
assisted peptide synthesizer numerous peptides was synthesized. The peptides were 
completed faster than conventionally and in addition some were made in a significantly 
higher purity. 
 
Materials and methods 
General experimental. Materials were obtained from commercial suppliers 
(Sigma-Aldrich, Iris Biotech GmbH, Novabiochem, Sussex Research, Varian (Polymer 
laboratory). Milli-Q (Millipore) water was used for LC-MS analysis. The peptides were 
synthesized on either TentaGel S Rink Amide resin (loading 0.24 mmol/g), polystyrene 
Rink Amide resin (loading 0.71 mmol/g) or TentaGel S resin (loading 0.26 mmol/g), with 
9-fluorenylmethyloxycarbonyl (Fmoc) for protection of Nα-amino groups. Side-chain 
protecting groups were tert-butyl (Ser, Thr, Tyr), 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), and trityl (Trt, for Asn, Gln, His). Peptides 
prepared on the semi-automated solid-phase microwave-assisted peptide synthesizer were 
prepared using Nα-Fmoc amino acids (4.0 equiv, 0.20 mol/L) which were coupled using 
N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide (HBTU) (3.8 equiv, 0.19 mol/L), 1-hydroxybenzotriazole 
(HOBt) (4.0 equiv, 0.20 mol/L) and N,N-diisopropylethylamine (DIEA) (7.8 equiv, 0.39 
mol/L) as coupling agents in DMF, except His which was coupled in NMP. Nα-Fmoc 
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deprotection was performed using piperidine-DMF (1:4). Control peptides were prepared 
conventionally on a fully automated Syro II peptide synthesizer (MultiSynTech) using a 
similar protocol except that a 9:1 mixture of HOBt-HOAt (HOAt; 1-hydroxy-7-
azabenzotriazole) was used as additive (4.0 equiv). Nα-Fmoc deprotection was performed 
using piperidine-DMF (2:3) for 3 min, followed by piperidine-DMF (1:4) for 12 min. All 
peptides were cleaved from the solid support by treatment with trifluoroacetic acid 
(TFA)-triethylsilane (TES)-H2O (95:2:3) for 2 hours, except the glycopeptide aldehyde 
which was released with by TFA-H2O (95:5). The TFA mixtures were concentrated by 
nitrogen flow and the compounds were precipitated with diethylether to yield the crude 
materials as white powders. Quantification was performed by LC-MS (Dionex Ultimate 
3000 system equipped with PDA) on an analytical C4 column (phenomenex, Jupiter, 300 
Å 5 μm particles, 3.9×150 mm) or on a C18 column (phenomenex, Germini, 110 Å 3 μm 
particles, 4.6×50 mm). The following solvent system was used: solvent A, water 
containing 0.1% formic acid; solvent B, acetonitrile containing 0.1% formic acid. 
Identification was carried out by ESI-MS (MSQ Plus Mass Spectrometer, Thermo). 
The reaction-time for all microwave-assisted reactions was for technical reasons 
extended by 1 min (+1 min) beyond the time of heating (Supporting Information). Thus, 
2 min at 60°C means 2 min at 60°C plus 1 min with no irradiation giving a total of 3 min 
reaction time, however, only two minutes of heating. 
Amine deprotection, Fmoc-Rink Amide PS.  Fmoc-Rink Amide PS resin  with 
an initial loading of 0.71 mmol/g was deprotected by treatment with piperidine-DMF 
(1:4) using various reaction times (2 min, 5 min, 10 min, 15 min) and temperatures (RT, 
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60°C, 80°C). The resin was washed 3 times with DMF and the residual loading was 
determined by a loading test on 35-45 mg of resin (Table 3).21 
Amine deprotection, LysM2 domain (37 residues). Peptide 2 was synthesized 
by conventional SPPS at RT on a fully automated peptide synthesizer. The peptide was 
synthesized on TentaGel Rink amide resin (loading 0.18 mmol/g) with coupling times of 
2×150 min and Nα-deprotection with piperidine-DMF (2:3) for 3 min followed by 
piperidine-DMF (1:4) for 12 min, and finally 16 min with piperidine-DMF (1:4). 
Released peptide 2 was analyzed by LC-MS (C18 column) both before (Figure 1.A) and 
after (Figure 1.B) the final Nα-deprotection via B gradient elution (0-8 min: 5% to 38%, 
8-10 min: 100%, 10-11 min: 100%) with an applied flow rate of 1.0 mL min-1. The 
loading of peptide 2 was determined by loading test: 0.044 mmol/g, and the residual 
loading after Nα-deprotection of peptidyl-resin 2 was determined by an additional loading 
test: < 0.0005 mmol/g. ESI-MS of released Fmoc protected peptide 2, calculated average 
isotopic composition for C209H313N49O55, 4391.3 Da. Found. m/z 1464.9 [M+3H]3+, 
1099.0 [M+4H]4+. ESI-MS of Fmoc deprotected peptide 2, calculated average isotopic 
composition for C194H303N49O53, 4169.4 Da. Found: m/z 1390.9 [M+3H]3+, 1043.4 
[M+4H]4+. 
Coupling optimization, peptide 3. Microwave-assisted amino acid coupling 
optimization was conducted on Rink amide PS resin (loading 0.71 mmol/g) using various 
amino acid coupling temperatures (RT, 60°C, 80°C) and times (2 min, 5 min, 10 min). 
Fmoc removal was carried out by treatment with piperidine-DMF (1:4) at RT followed 
by 2 min at 60°C. After cleavage, the crude reaction mixtures were analyzed by LC-MS 
(C18 column) via B gradient elution (0-5 min: 5% to 37%, 5-8.5 min: 37%, 8.5-9.5 min: 
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37%-100%, 9.5-10 min: 100%) with an applied flow rate of 1.0 mL min-1. Purity: 6% 
(RT, coupling time 2 min), 20% (60°C, 2 min), 30% (60°C, 10 min), 24% (80°C, 2 min), 
33% (80°C, 5 min), 44% (80°C, 2 min). ESI-MS (80°C, 2 min), calculated monoisotopic 
composition for C58H90N12O14S, 1210.6 Da. Found: m/z 1211.9 [M+H]+. 
Control peptides were synthesized conventionally at RT on Rink amide PS resin 
(loading 0.71 mmol/g) using the general protocol for automated peptide synthesis with 
amino acid coupling times of 45 min and 2×150 min. The crude mixture was analyzed by 
LC-MS (C18 column) via B gradient elution (0-5 min: 5% to 37%, 5-8.5 min: 37%, 8.5-
9.5 min: 37%-100%, 9.5-10 min: 100%) with an applied flow rate of 1.0 mL min-1. 
Purity: 32% (RT, coupling time 45 min), 43% (RT, 2×150 min). ESI-MS, calculated 
monoisotopic composition for C58H90N12O14S, 1210.6 Da. Found: m/z 1211.6 [M+H]+. 
PYY1-36, peptide 4. Microwave-assisted synthesis was performed on TentaGel 
Rink amide resin (loading 0.24 mmol/g) using the optimized SAMPS protocol: coupling 
times of 10 min at 80°C and Fmoc removal by treatment with piperidine-DMF (1:4) for 1 
min, without heating, followed by 2 min at 60°C. The crude product was analyzed by 
LC-MS (C4 column) via B gradient elution (0-14 min: 5% to 100%) with an applied flow 
rate of 1.0 mL min-1. Purity 41%, ESI-MS, calculated average isotopic composition for 
C194H295N55O57, 4309.2 Da. Found: m/z 1437.9 [M+3H]3+, 1078.3 [M+4H]4+, 863.0 
[M+5H]5+, 719.3 [M+6H]6+, 616.7 [M+7H]7+. 
C-terminal LysM2 domain, peptide 5. Synthesized on TentaGel Rink amide 
resin (loading 0.24 mmol/g) using the optimized SAMPS protocol: coupling times of 10 
min at 80°C and Fmoc elimination by treatment with piperidine-DMF (1:4) for 1 min, 
without heating, followed by 2 min at 60°C. The crude product was analyzed by LC-MS 
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(C18 column) via B gradient elution (0-8 min: 5% to 38%, 8-10 min: 38% to 100%) with 
an applied flow rate of 1.0 mL min-1. Purity 48%, ESI-MS, calculated average isotopic 
composition for C63H105N15O14, 1294.8 Da. Found: m/z 1295.8 [M+H]+, 648.3 [M+2H]2+, 
432.8 [M+3H]3+. 
N-terminal LysM2 domain, peptide 6. Synthesized on TentaGel Rink amide 
resin (loading 0.24 mmol/g). The first 41 amino acid couplings were conducted 
conventionally using the general protocol for automated peptide synthesis with coupling 
times of 2×150 min, however, the Nα-deprotection was performed with piperidine-DMF 
(2:3) for 3 min followed by piperidine-DMF (1:4) for 12 min, and finally 16 min with 
piperidine-DMF (1:4). The coupling of the final 11 C-terminal amino acids were 
completed using the optimized protocol for the SAMPS: coupling times of 10 min at 
80°C and Fmoc elimination by treatment of piperidine-DMF (1:4) for 1 min, no heat, 
followed by 2 min at 60°C. The product was analyzed by LC-MS (C18 column) via B 
gradient elution (0-3 min: 5% to 37%, 3-8 min: 37% to 38%, 8-11 min: 38% to 100%) 
with an applied flow rate of 1.0 mL min-1. ESI-MS, calculated average isotopic 
composition for C272H411N67O81, 5916.0 Da. Found: m/z 1479.6 [M+4H]4+, 1183.8 
[M+5H]5+. 
Ortho backbone amide linker (o-BAL). Anchoring (double coupling): The 
TentaGel S resin (loading 0.26 mmol/g) was washed with NMP. 5-(2-Formyl-3,5-
dimethoxyphenoxy)pentanoic acid (4.0 equiv), HBTU (3.8 equiv), HOBt (4.0 equiv), and 
DIEA (7.8 equiv) in DMF were added and reacted by microwave heating at 60°C for 10 
min. The resin was washed (3×DMF). Reductive amination (performed twice): 
Aminoacetaldehyde-dimethylacetal 99% (10 equiv) and NaBH3CN (10 equiv) were 
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suspended in AcOH–DMF (1:99), added to the o-BAL-resin, and heated by microwave 
irradiation at 60°C for 10 min. The resin was washed (3×DMF). Symmetrical anhydride 
(performed twice): Fmoc-Gly-OH (10 equiv) and DIC (5 equiv) were suspended in 1,2-
dichlorothane (DCE) in DMF (10:1) and pre-activated for 10 min. The activated amino 
acid residue was added to the resin and heated by microwave irradiation at 60°C for 10 
min. The resin was washed (3×DMF). 
Glycopeptide aldehyde 7. Synthesized on the previously prepared o-BAL 
TentaGel resin using the optimized SAMPS protocol: coupling times of 10 min at 80°C 
and Fmoc removal by treatment with piperidine-DMF (1:4) for 1 min, without heating, 
followed by 2 min at 60°C. The glycan hydroxyl groups were deacetylated on-resin using 
0.1 M methoxide (NaOMe, pH 10) for 230 min to yield the O-linked N-
acetylgalactoseamine peptide aldehyde 7. The product was analyzed by LC-MS (C18 
column) via B gradient elution (0-8 min: 5% to 38%, 8-10 min: 38% to 100%) with an 
applied flow rate of 1.0 mL min-1. Purity: 92%. ESI-MS, calculated monoisotopic 
composition for C35H43N5O14, 757.3 Da. Found: m/z 391.1 [M+Na+H]2+, 261.1 
[M+Na+2H]3+. 
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Table 1. Peptide sequences synthesized on the SAMPS. 
No Sequencea 
3 H-WFTTLISTIM-NH2 
4 H-YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
5 H-LPERVKVVFPL-NH2 
6 Ac-NATSYQIQLGDSYDFVATTLYENLTNWNIVQASNPGVNPYLLPERVKVVFPL-NH2 
7 Fmoc-S(GalNAc)EGG-H 
a Underlined sequences were synthesized conventionally.   
 
 
Table 2. Residual loading [μmole/g] after deprotection 
of Fmoc-Rink-PS resin at various reaction conditions.a  
Reaction time Temperature [°C]b 
 RT 60 80 
2 min 0.99 0.13 0.08 
5 min 0.08 0.20 0.13 
10 min 0.05 0.07 0.12 
15 min 0.03 0.08 ND 
a Loading determined by UV at 301 nm.21 b Obtained by 
microwave irradiation. 
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6.25 7.00 8.00 9.00 10.00 min
A
B
Loading:
< 0.00005 mmol/g
Residual loading:
0.045 mmol/g
 
Figure 1. The Nα-deprotection of peptidyl-resin 2 using microwave-assisted heating was 
evaluated by HPLC. Before (A, Fmoc LysM2 37-mer resin) and after (B, LysM2 37-mer resin) 
Fmoc removal, the peptides were released from the solid support and subsequently analyzed by 
LC-MS. Additionally, loading tests21 were carried out both before and after the Nα-deprotection to 
determine the performance of the microwave assisted Fmoc removal. The side peaks at 9.6 min 
(A) and 7.8 min (B) results from a deletion peptide. 
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Figure 2.  HPLC chromatograms of coupling optimization experiments. The coupling conditions 
are shown at left and the purity of peptide 3 is given in the right side of each chromatogram. 3 (H-
WFTTLISTIM-NH2), des-(Thr) (8), des-(Thr Thr) (9), des-(Phe) and des-(Phe Thr) (10), des-(Trp) 
(11), des-(Trp Thr) (12), des-(Trp Phe) (13), des-(Trp Phe Thr) (14), and des-(Trp Ile) (15). 
Conventional peptide synthesis (*). 
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80°C, 10min
Coupling conditions:                                     Purity of peptide 5:
48%5
3.00  
Figure 3. Analytical RP-HPLC chromatogram of the C-terminal 11-mer (5) of the LysM2 domain 
synthesized on the SAMPS. 
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Figure 4. Analytical RP-HPLC chromatogram of the glycopeptide 7, before (A) and after (B) 
deacetylation. Glycopeptide 7 fully acetylated (18), loss of one acetyl group (17 and 19) and loss 
of two acetyl groups (16).  
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Scheme 1. Modified SAMPS protocol for preparing o-BAL TG. 
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Figure S1. Semi-automated microwave-assisted peptide synthesizer (SAMPS). The two parts of 
the SAMPS do not communicate with each other, thus the microwave heating program on the 
Biotage Initiator has to be started manually each time heating is needed. The Initiator was slightly 
customized: the `blast-box´ underneath the reaction chamber was removed to allow suction in the 
bottom of the reaction vial, and the Initiator was operated in the ‘service mode’ (programmed to 
keep the lid open during heating). The amino acids is added manually thus the SAMPS program 
starts with the coupling. The washing and Nα-deprotetion is fully automated by the modified 
MultiSynTech SAP. The SAP module was modified by removing the original reaction flask and 
substituting magnetic stirring with nitrogen bubbling for mixing. A cycle consits of (1) coupling 
(microwave irradiation started manually), (2) drain, (3) wash, (4) Nα-deprotection (microwave 
irradiation started manually), (5) drain, and (6) wash. To avoid microwave irradiation on non-
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solvated resin after coupling and Nα-deprotection steps (the microwave irradiation was started 
manually while the solvents were added automatic which may give a time gap between the two 
parallel running programs) the SAP unit was programmed to react one more minute than the 
Initiator heated (+1 min). 
            
 
Figure S2. The custom-made, flow reactor vessels (10–20 mL and 2-5 mL) for the (SAMPS).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
